Vol. 16 Issue 4 (2023)

VSKM 2023 N 4

PDF download Download the whole Issue

ORIGINAL RESEARCH

Interleukin-6 – marker of subclinical inflammation in very elderly patients and centenarians with coronary artery disease Dvoretski L.I. (Russia, Moscow), Topolyanskaya S.V.(Russia, Moscow), Mаmchich D.S. (Russia, Moscow),Eliseeva T.A. (Russia, Moscow), Turna O.I. (Russia, Moscow), Romanova M.A. (Russia, Moscow), Vakulenko O.N. (Russia, Moscow), Bubman L.I. (Russia, Moscow),Vasilieva Y.Y. (Russia, Moscow), Lytkina K.A. (Russia, Moscow), Melkonyan G.G. (Russia, Moscow), Ratchina S.A. (Russia, Moscow) P.7

Changes in rheological properties of blood in patients with rhinosinusitis after coronavirus infection Ismoilov I.I. (Yashnabad, Tashkent), Shamsiev D.F.(Yashnabad, Tashkent), Vohidov U.N. (Yashnabad, Tashkent) P.16

Predicting the risk of adverse outcome among patients with COVID 19 hospitalized in an infectious disease hospital Kalashnikov E.S. (Russia, Astrakhan), Serdyukov A. G.(Russia, Astrakhan), Polunina E. A. (Russia, Astrakhan) P.21

Сlinical and laboratory characteristics of female patients of outpatient lipidologist Kim Z.F. (Russia, Kazan), Galyvich A.S. (Russia, Kazan),Sadykova D.I. (Russia, Kazan), Nurieva L.M. (Russia, Kazan) P.27

Features of risk factors for the development of cardiovascular complications in children with obesity Oleynik O.A. (Russia, Tomsk), Samoylova Y.G. (Russia,Tomsk), Matveeva M. V. (Russia, Tomsk), Podchinenova D. V. (Russia, Tomsk), Vorozhtsova I.N. (Russia, Tomsk),Kovarenko M. A.(Russia, Tomsk), Zakharchuk P. I. (Russia,Tomsk), Shuliko L. M. (Russia, Tomsk), Filimonov A.E. (Russia, Tomsk) P.37

The hypotensive therapy impact on hemodynamic parameters in patients with hypertension combined with rheumatoid arthritis Samorodskaya N.A. (Russia, Krasnodar), Eliseeva L. N.(Russia, Krasnodar), Khuako M.Sh. (Russia, Krasnodar) P.49

Evaluation of the incidence of brucellosis in children in conditions of intensification of individual livestock breeding Taghi-Zadeh T. G. (Azerbaijan, Baku) P.58

Vitamin D in various age related pathology in centenarians and very elderly patients with coronary artery disease Topolyanskaya S.V. (Russia, Moscow), Mаmchich D.S.(Russia, Moscow), Eliseeva T.A. (Russia, Moscow), Turna O.I. (Russia, Moscow), Romanova M.A. (Russia, Moscow), Vakulenko O.N. (Russia, Moscow), Bubman L.I. (Russia, Moscow), Koshurnikov D.S. (Russia, Moscow),Lytkina K.A. (Russia, Moscow), Melkonyan G.G. (Russia, Moscow), Vakoluk R.M. (Russia, Moscow), Ratchina S.A.(Russia, Moscow), Dvoretski L.I. (Russia, Moscow) P.63

Spa and resort possibilities in reproductive health recovery in patients with early gestational losses Yavorskaya S.D.(Russia, Barnaul), Remneva O.V. (Russia,Barnaul), Chernova A.E. (Russia, Barnaul), Dmitrienko K.V.(Russia, Barnaul), Petrov A. V. (Russia, Barnaul), Grebtsov I. V. (Russia, Barnaul) P.71

REVIEWS

On the risks of malignisation of ovarian endometriomas Gabidullina R.I. (Russia, Kazan), Minnullina F. F. (Russia, Kazan), Akhmetova D.I. (Russia, Kazan), Zaripova A.Sh.(Russia, Kazan), Zidihanova K. I. (Russia, Kazan), Root D.A.(Russia, Kazan) P.78

Predictors of coronary ins tent restenosis Enikeeva A. M. (Russia, Ufa), Gazizova L.Y. (Russia, Ufa),Gareeva D. F. (Russia, Ufa), Rakhimova R. F. (Russia, Ufa),Amineva A. M. (Russia, Ufa), Buzaev I. V. (Russia, Ufa),Zagidullin N.Sh. (Russia, Ufa) P.83

Mechanisms of thromboi nflammation in patients with systemic lupus erythematosus Ismagilova R. R. (Russia, Kazan), Maksudova A.N. (Russia, Kazan), Zubairova L.D. (Russia, Kazan), Nabiullina R.M. (Russia, Kazan) P.90

Prospects for the search and development of new original pharmaceutical substances derivatives of usninic acid extracted from lichens (review) Krylov I. Al. (Russia, Arkhangelsk), Sherstennikov N.V. (Russia, Arkhangelsk), Kubasova E. D. (Russia,Arkhangelsk), Korelskaya G.V. (Russia, Arkhangelsk),Kubasov R.V. (Russia, Arkhangelsk), Grzybowski A.M.(Russia, Arkhangelsk), Lenina J. Al. (Russia, Arkhangelsk),Karaman S.Al. (Russia, Arkhangelsk) P.97

Hypertriglyceridemia and atherosclerotic cardiovascular diseases Nurieva L.M. (Russia, Kazan), Kim Z.F. (Russia, Kazan),Galyvich A.S. (Russia, Kazan), Sadykova D.I. (Russia, Kazan) P.104

FROM PRACTICAL EXPERIENCE

Correction of fifth toe deformity of the foot Leonova S.N. (Russia, Irkutsk), Usoltsev I. V. (Russia,Irkutsk), Kosareva M. A. (Russia, Irkutsk) P.111

A clinical case of aortic coarctation in a child complicated by ischemic stroke Sagitova G.R. (Russia, Astrakhan), Tkachev I.V. (Russia,Astrakhan), Antonova A.A. (Russia, Astrakhan), Davydova O.V. (Russia, Astrakhan) P.118

HEALTH ORGANIZATION

Stages of rehabilitation for women after early reproductive loss Aleshkina O.S. (Russia, Ryazan), Konovalov O.E. (Russia,Moscow), Shulayev A.V. (Russia, Kazan), Pristupa E.M.(Russia, Ryazan), Breusov A.V. (Russia, Moscow) P.124

Satisfaction with the work of general practitioners and surgeons in public and private medical organizations Shukurov M.R. (Russia, Moscow), Konovalov O.E. (Russia,Moscow) Shulaev A.V. (Russia, Kazan) P.132

HISTORY OF MEDICINE

To the 225th anniversary of the prominent russian internist karl karlovich seidlitz Egorysheva I.V. (Russia, Moscow), Morozov A.V. (Russia, Moscow) P.138

___

ORIGINAL RESEARCH

UDC: 616-053.9

DOI: 10.20969/VSKM.2023.16(4).7-15

PDF download INTERLEUKIN-6 – MARKER OF SUBCLINICAL INFLAMMATION IN VERY ELDERLY PATIENTS AND CENTENARIANS WITH CORONARY ARTERY DISEASE

DVORETSKI LEONID I., ORCID ID: 0000-0003-3186-0102; D. Med. Sci., Professor, Department of Advanced Internal Medicine N2, First Moscow State Medical University, Russia, 119991, Moscow, Trubetskaya str., 8/2; e-mail: dvoretski@mail.ru

TOPOLYANSKAYA SVETLANA V., ORCID ID: 0000-0002-4131-8432; C. Med. Sci., Associate professor, Department of Advanced Internal Medicine N2, First Moscow State Medical University, Russia, 119991, Moscow, Trubetskaya str., 8/2; therapist of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, tel.: +7 (495) 609-14-00, e-mail: sshekshina@yandex.ru

MАMCHICH DARYA S., ORCID ID: 0000-0003-3331-4033; student, First Moscow State Medical University, Russia, 119991, Moscow, Trubetskaya str., 8/2; e-mail: dasha.mamchich@gmail.com

ELISEEVA TATYANA A., ORCID ID: 0000-0002-6921-0589; geriatrician of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: eliseet@yandex.ru

TURNA OLGA I., ORCID ID: 0000-0002-2933-7550; geriatrician of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: olga1414@mail.ru

ROMANOVA MARGARITA A., ORCID ID: 0000-0001-5351-1996; the head of 13 geriatric department of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: mur1-3@mail.ru

VAKULENKO OLGA N., ORCID ID: 0000-0002-4139-5075; the head of 6 geriatric department of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: onv.62@mail.ru

BUBMAN LEONID I., ORCID ID: 0000-0002-4195-3188; the head of 7 surgery department of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: bubmanleo@gmail.com

VASILIEVA YULIA Y., ORCID ID: 0000-0001-7977-5009; doctor of clinical laboratory diagnostics of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: juliavas07@mail.ru

LYTKINA KARINA A., ORCID ID: 0000-0001-9647-7492; C. Med. Sci., Deputy Chief Physician of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, tel.: +7 (495) 474-99-10, e-mail: lytkina.k@mail.ru

MELKONYAN GEORGYI G., ORCID ID: 0000-0002-4021-5044; D. Med. Sci., Chief Physician of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: gvv3@zdrav.mos.ru

RATCHINA SVETLANA A., ORCID ID: 0000-0002-3329-7846; D. Med. Sci., Professor, the head of Department of Advanced Internal Medicine N2, First Moscow State Medical University, Russia, 119991, Moscow, Trubetskaya str., 8/2; e-mail: svetlana.ratchina@antibiotic.ru

Abstract. Introduction. Interleukin-6 is a cytokine involved in the regulation of immune reactions, in the processes of hematopoiesis and in ammation. Levels of interleukin-6 in the blood correlate with the development of senile asthenia.Aim. The study aim was to determine the blood concentration of interleukin-6 and to evaluate the relationship of this cytokine with a number of pathological conditions in very old and centenarians with coronary artery disease. Material and Methods. 128 patients were enrolled in the cross-sectional study of interleukin-6 in very elderly patients and centenarians with coronary artery disease: 94 with coronary artery disease – in the study group, 34 without coronary artery disease – in the control group. The mean age of study patient was 88.3+5.3 years (76 to 98 years). Serum interleukin-6 concentrations (N<7.0 pg/ml) were determined by enzyme-linked immunosorbent assay. Results and discussion. Elevated interleukin-6 levels were found in 45.3% of patients. Mean interleukin-6 concentration was 8.2+6.3 (1.5-36.2) pg/ml. In patients with coronary artery disease mean interleukin-6 concentration reached 9.0 pg/ ml, in the control group – 5.8 pg/ml (p=0.001). Signi cantly higher interleukin-6 levels were found in patients with heart failure – 11.2 and 6.6 pg/ml, respectively (p=0.00005). Among patients with hyperuricemia mean interleukin-6 values reached 10.8+4.8 pg/ml. Positive correlations were found between interleukin-6 level and leukocytes count (r=0.29; p=0.002), neutrophils count (r=0.37; p=0.00002) and tumor necrosis factor-α (r=0.39; p=0.007). In patients with elevated interleukin-6 level lower Barthel index (70.7 and 80.7, respectively, р=0.003) and IADL scale (3.4 and 5.0, respectively, р=0.0002) values were observed. Conclusion. In patients with chronic coronary artery disease in very old age and centenarians an increase level of interleukin-6 is often found. Higher levels of interleukin-6 are associated primarily with heart failure and hyperuricemia.

Key words: interleukin-6, coronary artery disease, very elderly, centenarians.

For reference: Dvoretski LI, TTopolyanskaya SV, Mamchich DS, et al. Interleukin-6 – marker of subclinical in ammation in very elderly patients and centenarians with coronary artery disease. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 7-15. DOI: 10.20969/VSKM.2023.16(4).7-15.

References

  1. Tanaka T, Narazaki M, Kishimoto T. Il-6 in in ammation, Immunity, And disease. Cold Spring Harbor Perspectives in Biology. 2014; 6(10): P.a016295. DOI: 10.1101/ cshperspect.a016295

  2. Maggio M, Guralnik J.M, Longo DL, et al. Interleukin-6 in Aging and Chronic Disease: A Magni cent Pathway. J Gerontol A Biol Sci Med Sci. 2006; 61(6): 575–584. DOI: 10.1093/gerona/61.6.575

  3. Minciullo PL, Catalano A, Mandra no G, et al. In ammaging and Anti-In ammaging: The Role of Cytokines in Extreme Longevity. Archivum Immunologiae et Therapiae Experimentalis. 2016; 64(2): 111–126. DOI: 10.1007/s00005-015-0377-3

4. Bruunsgaard H., Ladelund S., Pedersen A.N., et al. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clinical and Experimental Immunology. 2003; 132(1): 24–31. DOI: 10.1046/j.1365-2249.2003.02137.x

5. Giovannini S, Onder G, Liperoti R, et al. Interleukin-6, C-reactive protein, and tumor necrosis factor-alpha as predictors of mortality in frail, community-living elderly individuals. J American Geriatrics Society. 2011; 59(9): 1679-1685. DOI: 10.1111/j.1532-5415.2011.03570.x

6. Su D, Li Z, Li X, et al. Association between Serum Interleukin-6 Concentration and Mortality in Patients with Coronary Artery Disease. Mediators of In ammation. 2013; 2013:726178. DOI:10.1155/2013/726178

7. Li H, Liu W, Xie J. Circulating interleukin-6 levels and cardiovascular and all-cause mortality in the elderly population: A meta-analysis. Arch Gerontol Geriatr. 2017; 73:257-262. DOI: 10.1016/j.archger.2017.08.007

8. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review. PLoS Medicine. 2008; 5(4): e78. DOI: 10.1371/journal.pmed.0050078

9. Saremi A, Anderson RJ, Luo P, et al. Association between IL-6 and the extent of coronary atherosclerosis in the veterans a airs diabetes trial (VADT). Atherosclerosis. 2009; 203(2): 610–614. DOI: 10.1016/j. atherosclerosis.2008.07.031

10. Tehrani DM, Gardin JM, Yanez D., et al. Impact of in ammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: Cardiovascular Health Study. Atherosclerosis. 2013; 231(2): 246-251. DOI: 10.1016/j. atherosclerosis.2013.08.036

11. Leng S, Xue QL, Huang Y, et al. Total and di erential white blood cell counts and their associations with circulating interleukin–6 levels in community–dwelling older women. J Gerontology, Series A Biological Sciences and Medical Sciences. 2005; 60(2): 153-157. DOI: 10.1093/gerona/60.2.195

12. Mauer J, Denson JL, Brüning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 2015; 36(2): 92-101. DOI: 10.1016/j.it.2014.12.008

13. Shinohara T, Takahashi N, Okada N, et al. Interleukin-6 as an Independent Predictor of Future Cardiovascular Events in Patients with Type-2 Diabetes without Structural Heart Disease. J Clin Exp Cardiology. 2012; 3(9): 209. DOI:10.4172/2155-9880.1000209

14. Morley JE, Baumgartner RN. Cytokine-Related Aging Process. J Gerontol A Biol Sci Med Sci. 2004; 59(9):M924-929. DOI: 10.1093/gerona/59.9.m924

15. Cesari M, Penninx BWJH, Pahor M, et al. In ammatory Markers and Physical Performance in Older Persons: The InCHIANTI Study. Js of Gerontology Series A: Biological Sciences and Medical Sciences. 2004; 59(3): 242-248. DOI: 10.1093/gerona/59.3.m242

16. Ferrari SL, Karasik D, Liu J, et al. Interactions of interleukin-6 promoter polymorphisms with dietary and lifestyle factors and their association with bone mass in men and women from the Framingham osteoporosis study. J Bone Mineral Research. 2004; 19(4): 552-559. DOI: 10.1359/JBMR.040103

17. Puzianowska-Kuźnicka M, Owczarz M, Wieczorowska-Tobis K, et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: The PolSenior study. Immunity and Ageing. 2016; 13:21. DOI: 10.1186/
s12979-016-0076-x

18. Kaptoge S, Seshasai SRK, Gao P, et al. In ammatory cytokines and risk of coronary heart disease: New prospective study and updated meta-analysis. Eur Heart J. 2014; 35(9): 578-589. DOI: 10.1093/eurheartj/eht367

19. Vasan RS, Sullivan LM, Roubeno R, et al. In ammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation. 2003; 107(11): 1486-1491. DOI: 10.1161/01.cir.0000057810.48709.f6

20. Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, et al. The clinical signi cance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Failure. 2019; 21(8): 965-973. DOI: 10.1002/ejhf.1482

21. Su J-H, Luo M-Y, Liang N, et al. Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases. Frontiers in Pharmacology. 2021; 12:745061. DOI:10.3389/ fphar.2021.745061

22. Wu N, Xu B, Xiang Y, et al. Association of in ammatory factors with occurrence and recurrence of atrial brillation: A meta-analysis. Int J Cardiology. 2013; 169(1): 62–72. DOI: 10.1016/j.ijcard.2013.08.078

23. Zheng N, Shi X, Chen X, Lv W. Associations Between In ammatory Markers, Hemostatic Markers, and Microvascular Complications in 182 Chinese Patients With Type 2 Diabetes Mellitus. Laboratory Medicine. 2015; 46(3): 214-220. DOI: 10.1309/LMF8R2KSTOW3FLKD

24. Liu C, Feng X, Li Q, et al. Adiponectin, TNF-α and in ammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine. 2016; 86: 100–109. DOI: 10.1016/j.cyto.2016.06.028

25. Lyngdoh T, Marques-Vidal P, Paccaud F, et al. Elevated serum uric acid is associated with high circulating in ammatory cytokines in the population-based colaus study. PLoS ONE. 2011; 6(5): e19901. DOI: 10.1371/ journal.pone.0019901

26. Amdur RL, Feldman HI, Gupta J, et al. In ammation and progression of CKD: The CRIC study. Clin J Am Society Nephrology. 2016; 11(9): 1546–1556. DOI: 10.2215/ CJN.13121215

27. MacCiò A, Madeddu C. Management of Anemia of in ammation in the elderly. Anemia. 2012; 2012: 563251. DOI: 10.1155/2012/563251

 

UDC: 616.98-036-07-08:616.36-008.64

DOI: 10.20969/VSKM.2023.16(4).16-20

PDF download CHANGES IN RHEOLOGICAL PROPERTIES OF BLOOD IN PATIENTS WITH RHINOSINUSITIS AFTER CORONAVIRUS INFECTION

ISMOILOV ISKANDAR IBRAGIMOVICH, ORCID ID: 0000-0002-7431-5852; Assistant of Department of Otorhinolaryngology «Tashkent State Dental Institute», Uzbekistan, 100047, Tashkent, Yashnabad district, Maxtumquli street, 103, e-mail: bonusha-uz@list.ru

SHAMSIEV DJAHONGIR FAZLITDINOVICH, ORCID ID: 0000-0003-2931-4946; D.Med.Sci., Prof., Head of Department of Otorhinolaryngology «Tashkent State Dental Institute», Uzbekistan, 100047, Tashkent, Yashnabad district, Maxtumquli street,103, e-mail: dfshamsiev@mail.ru

VOHIDOV ULUGBEK NURIDINOVICH, ORCID ID: 0000-0002-4237-4735; D.Med.Sci., Prof. of Department of Otorhinolaryngology «Tashkent State Dental Institute», Uzbekistan, 100047, Tashkent, Yashnabad district, Maxtumquli street, 103, e-mail: dr_ulugbek@list.ru

Abstract. Introduction. The study of the pathogenesis of purulent-in ammatory diseases of the nose and paranasal sinuses is impossible without a comprehensive analysis of various factors of homeostasis and, above all, the state of microcirculation, which largely depends on the rheological properties of blood Under the law common to all forms of uid movement, as the viscosity of the medium increases, the speed of movement decreases, and the energy costs for its movement increase. Consequently, the deterioration of the rheological properties of blood and microcirculation are directly related. Violation of microcirculation always signi cantly a ects the development of pathological processes. The aim of the study rheological properties of blood in patients with rhinosinusitis after coronavirus infection. Materials and methods. The studying the rheological properties of blood in 55 patients with rhinosinusitis after coronavirus infection are presented. The following main indicators were determined in patients: blood viscosity, erythrocyte aggregation coe cient, degree of deformability of erythrocytes, average volume of one erythrocyte, hematocrit, brinogen, morphological properties of erythrocytes. Results and discussion. In all examined patients with rhinosinusitis after coronavirus infection, the rheological properties of blood are sharply impaired. The severity of violations of the rheological properties of blood depended not only on the type of disease, but on its severity and the degree of intoxication of the body. A change in blood viscosity was detected in all examined patients. Blood viscosity indices increased sharply in proportion to the severity and prevalence of the in ammatory process and the severity of destructive changes in the a ected organs. Conclusion. The analysis of the conducted studies shows that one of the main manifestations of a violation of the rheological properties of blood in rhinosinusitis after coronavirus infection is intravascular aggregation of erythrocytes, as well as a violation of the ability of erythrocytes to reversible deformation.

Keywords: acute rhinosinusitis, coronavirus infection, blood rheology, microcirculation

For reference: Ismоilov II, Shamsiev DF, Vohidov UN. Change of rheological properties of blood in patients with rhinosinusitis after coronavirus infection/I.I. Ismailov. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 16-20. DOI: 10.20969/VSKM.2023.16(4).16-20.

References

  1. Асманов А.И., Пивнева Н.Д. Острые синуситы: современные подходы к диагностике и лечению // Практика педиатра. – 2016. – No4. – С. 28-37. [Asmanov AI, Pivneva ND. Ostryi sinusity: sovremennye podxody k diagnostike i lecheniyu [Acute sinusitis: modern approaches to diagnosis and treatment]. Praktika pediatra [Pediatrician practice]. 2016; 4: 28 – 37. (In Russ.)].

  2. Матвиенко О.Ю., Корсакова Н.Е., Лернер А.А. и др. Состояние плазменного звена гемостаза у пациентов с коронавирусной инфекцией, вызванной вирусом SARS-CоV-2 // Тромбоз, гемостаз и реология. – 2020. – No4. – С. 88-91. [Matviynko OYu, Korsakova NE, Lerner AA. Sostoyanie plazmennogo zvnea u pasientov s koronavirusnoy infeksiye, vyzvannoy virusim SARS-CоV-2 [The state of the plasma hemostasis link in patients with coronavirus infection caused by the SARS-CoM2 virus]. Tromboz, gemostaz i reologiya [Thrombosis, hemostasis and rheology.]. 2020; 4: 88 – 91. (In Russ.)].

  3. Шамсиев Д. Ф., Вохидов У. Н., Каримов О. М. Современный взгляд на диагностику и лечение хронических воспалительных заболеваний носа и околоносовых пазух //Молодой ученый. – 2018. – No. 5. – С. 84-88. [Shamsiyev DF, Vohidov UN, Karimov OM. Sovrimenniy vzglyad na diagnostiku i lecheniye xronicheskix vospalitelnix abolevaniy nosa i okolonosovix pazux [A modern view on the diagnosis and treatment of chronic in ammatory diseases of the nose and paranasal sinuses]. Molodoy ucheniy [A young scientist.]. 2018; 5: 84 – 88. (In Russ.)].

  4. Шамсиев Д.Ф. Морфологические изменения покровного эпителия полости носа при хроническом воспалении // Стоматология. Среднеазиатский научно-практический журнал. – 2005. – No1-2. – С. 51-53. [Shamsiyev DF. Morfologicheskie izmeneniya pokrovnogo epiteliya polosti nosa pri xronicheskom vospalenii [Morphological changes of the integumentary epithelium of the nasal cavity in chronic in ammation]. Stomatologiya. Sredneaziatskij nauchno-prakticheskij zhurnal [Densitry. Central Asian Scienti c and Practical Journal]. 2005;1-2:51–53. (In Russ.)].

  5. Шамсиев Д.Ф. Состояние покровного эпителия воспалительных полипов носа // «Российская ринология» научно-практический журнал. – 2005. – No2. – Стр.37. [Shamsiyev DF.Sostoyanie pokrovnogo epiteliya vospalitelnix polipov nosa [Condition of the integumentary epithelium of in ammatory nasal polyps]. Rossiyskaya rinologiya [Russian Rhinology]. 2005; 2: 37. (In Russ.)].

  6. Явелов И.С., Драпкина О.М. COVID-19: состояние системы гемостаза и особенности антитромботической терапии. // Кардиоваскулярная терапия и профилактика. – 2020. – Т. 19, No3. – С. 2571. [Yavelov IS, Drapkina OM. COVID-19: sostoyanie systemy gemostaza i osobennosti antitromboticheskoy systemi [COVID-19: the state of the hemostasis system and features of antithrombotic therapy]. Kardiovaskulyarnaya terapiya i pro laktika [Cardiovascular therapy and prevention]. 2020; 19:2: 2571. (In Russ.)].

  7. Blanco, C. H., Stein, J. B., Barinsky, G. L. et al. (2020). Management of complicated pediatric rhinosinusitis in the COVID-19 era. American Journal of Otolaryngology, 41(6), 102746. DOI: 10.1016/j.amjoto.2020.102746

  8. Djuraev JA, & Khasanov US. (2021). Results of Frequency Analysis Distribution of Polymorphism Rs1800895 592c> A In Il10 Gene among Patients with Chronic Polypoid Rhinosinusitis. International Journal Of Medical Science And Clinical Research Studies, 1(6), 129-134. DOI: 10.5935/0946-5448.20210032

  9. Inakov SA, Mamatkulov BB, Kosimova K, et al. (2020). Social and Demographic Characteristics of Elderly and their Lifestyle in Developing Countries: On the Example of Uzbekistan. Indian Journal of Forensic Medicine & Toxicology, 14(4), 7418-7425. DOI: 10.37506/ijfmt. v14i4.12821

  10. Khasanov SA, Asrorov AA, Vokhidov UN. (2006). Prevalence of chronic family tonsillitis and its prevention. Vestnik otorinolaringologii, (4), 38-40. DOI: 17152473

  11. Klimek L, Jutel M, Bousquet J, et al. (2021). Management of patients with chronic rhinosinusitis during the COVID-19 pandemic—An EAACI position paper. Allergy, 76(3), 677-688. DOI: 10.1111/all.14629

  12. Vokhidov N, Nuriddinov K, & Vokhidov U. (2020). Features of surgical and postoperative medicamental treatment of chronic polypoid rhinosinusitis. International Journal of Pharmaceutical Research, 12(3), 4863-4865. DOI: 10.1186/1939-4551-7-25

  13. Vokhidov UN, Shernazarov ON, Yakubdjanov DD, et al. (2021). Paralytic Stenosis of the Larynx: Patients Surgical Overview. International Journal of Health Sciences, 5(3), 386-392. DOI: 10.53730/ijhs.v5n3.1680

  14. Wang H, Song J, Pan L, et al. (2020). The characterization of chronic rhinosinusitis in hospitalized patients with COVID-19. The Journal of Allergy and Clinical Immunology: In Practice, 8(10), 3597-3599. DOI: 10.1016/j.jaip.2020.09.013

 

UDC:616.988-036.3:616-06

DOI: 10.20969/VSKM.2023.16(4).21-26

PDF download PREDICTING THE RISK OF ADVERSE OUTCOME AMONG PATIENTS WITH COVID-19 HOSPITALIZED IN AN INFECTIOUS DISEASE HOSPITAL

KALASHNIKOV EVGENY S., ORCID ID: 0000-0002-8699-9905, Assistant Professor of the department of Public Health with a Postgraduate Course, Astrakhan State Medical University, Astrakhan, 414000, Russia, Astrakhan, Bakinskaya str. 121, e-mail: Drevgeniy@mail.ru

SERDYUKOV ANATOLY G., ORCID ID: 0000-0001-8304-0048, D. Med. Sci., Professor, Head of the Department of Public Health with a Postgraduate Course, Astrakhan State Medical University, Astrakhan, 414000, Russia, Astrakhan, Bakinskaya str. 121, e-mail: agma@astranet.ru

POLUNINA EKATERINA A., ORCID ID: 0000-0002-3679-432X, D. Med. Sci., Associate Professor of the Internal Medicine Department of Pediatric Department, Astrakhan State Medical University, Astrakhan, 414000, Russia, Astrakhan, Bakinskaya str. 121, e-mail: gilti2@yandex.ru

Abstract. Introduction. The identi cation of predictors of mortality in COVID-19 remains one of the primary directions among all studies devoted to this topic. The search and selection of the most sensitive prognostic tools is the basis for improving the prognosis in patients with COVID-19 and for the proper allocation of health resources. Aim. The aim is to develop a prognostic model for assessing the risk of an adverse outcome in the rst two days in patients with COVID-19 hospitalized in an infectious diseases hospital. Material and Methods: the clinical and anamnestic data of 148 patients with an unfavorable (fatal) outcome in the rst two days after hospitalization and 364 patients with a favorable outcome up to 10 bed days were analyzed. Statistical analysis was carried out using the StatTech v. 2.8.8 program (developed by Stattech OOO, Russia). Results and discussion. According to the results of our study, the following predictors were included in the prognostic model: age, male gender, degree of respiratory failure, type 2 diabetes mellitus, obesity, arterial hypertension and coronary heart disease. Under the in uence of a set of predictors, the risk of an unfavorable outcome in patients with COVID-19 increased in male patients by 1.1 times, with an increase in age by 1 year by 1.1 times, in the presence of grade 2 respiratory failure by 5.9 times, grade 3 respiratory failure by 17.4 times, type 2 diabetes by 1.1 times, obesity by 1.4 times, arterial hypertension by 1.8 times, coronary heart disease by 3.7 times.Conclusion. The obtained prognostic model for assessing the risk of an adverse outcome in patients with COVID-19 has good prognostic abilities, its sensitivity and speci city were 76.5% and 77.8%, respectively. The resulting model can help optimize the prediction of outcome in hospitalized patients with COVID-19.

Key words: COVID-19, prognosis, comorbid pathology, unfavorable outcome.

For reference: Kalashnikov ES, Serdyukov AG, Polunina EA. Predicting the risk of adverse outcome among patients with covid-19 hospitalized in an infectious disease hospital. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 21-26. DOI: 10.20969/VSKM.2023.16(4).21-26.

References

Литература

  1. Khan M, Adil SF, Alkhathlan HZ, et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. Molecules. 2020; 26 (1): 39. DOI: 10.3390/molecules26010039

  2. Башкина О.А., Вязовая И.В., Сергиенко Д.Ф. Детский мультисистемный воспалительный синдром, ассоциированный с COVID-19: клинический случай // Фарматека. – 2022. – Т. 29, No 9. – С.104-107. [Bashkina OA, Vyazovaya IV, Sergienko DF. Detskij mul’tisistemnyj vospalitel’nyj sindrom, associirovannyj s COVID-19: klinicheskij sluchaj [Pediatric in ammatory multisystem syndrome associated with covid-19: a clinical case]. Farmateka [Farmateka]. 2022; 29 (9): 104-107. (In Russ.)]. DOI: 10.18565/pharmateca.2022.9.104-107

  3. Канорский С.Г. COVID-19 и сердце: прямое и косвенное влияние // Кубанский научный медицинский вестник. – 2021. – Т. 28, No 1. – С.16-31. [Kanorskij SG. COVID-19 i serdce: pryamoe i kosvennoe vliyanie [COVID-19 and the heart: direct and indirect impact]. Kubanskij nauchnyj medicinskij vestnik [Kuban Scienti c Mediacal Bulletin]. 2021; 28 (1): 16-31. (In Russ.)]. DOI: 10.25207/1608-6228-2021-28-1

  4. Tretter F, McIntyre-Mills JJ, Smith GR. Toward a big picture of COVID-19. Pharmacol Res Perspect. 2022; 10 (5):e00996. DOI: 10.1002/prp2.996

  5. Кузовлев А.Н., Ермохина Л.В., Мельникова Н.С., и др. Номограмма для прогнозирования госпитальной летальности у пациентов с COVID-19, находившихся в отделении реанимации и интенсивной терапии // Вестник анестезиологии и реаниматологии. – 2022. – Т. 19, No 1. – С.6-17. [Kuzovlev AN, Ermohina LV, Mel’nikova NS, et al. Nomogramma dlya prognozirovaniya gospital’noj letal’nosti u pacientov s COVID-19, nahodivshihsya v otdelenii reanimacii i intensivnoj terapii [Nomogram for Predicting Hospital Mortality in Patients with COVID-19 Admitted to the Intensive Care Unit.]. Vestnik anesteziologii i reanimatologii [Messenger of ANESTHESIOLOGY AND RESUSCITATION]. 2021; 28 (1): 16-31. (In Russ.)]. DOI: 10.21292/2078-5658-2022-19-1-6-17

  6. Цветков В.В., Токин И.И., Лиознов Д.А., и др. Прогнозирование длительности стационарного лечения пациентов с COVID-19 // Медицинский совет. – 2020. – Т. 17. -82–90. [Cvetkov VV, Tokin II, Lioznov DA, et al. Prognozirovanie dlitel’nosti stacionarnogo lecheniya pacientov s COVID-19 [Predicting the duration of inpatient treatment for COVID-19 patients]. Medicinskij sovet [Medical council]. 2021; 28 (1): 16-31. (In Russ.)]. DOI: 10.21518/2079-701X-2020-17-82-90

  7. Глыбочко П.В., Фомин В.В., Моисеев С.В. и др. Исходы у больных с тяжелым течением COVID19, госпитализированных для респираторной поддержки в отделения реанимации и интенсивной терапии // Клиническая фармакология и терапия. – 2020. – Т. 29, No 3. – С. 25-36. [Glybochko PV, Fomin VV, Moiseev SV, et al. Iskhody u bol’nyh s tyazhelym techeniem COVID19, gospitalizirovannyh dlya respiratornoj podderzhki v otdeleniya reanimacii i intensivnoj terapii [Clinical outcomes of patients with COVID-19 admitted for respiratory support to the intensive care units]. Klin farmakologiya i terapiya [Clinical pharmacology and therapy]. 2021; 28 (1): 16-31. (In Russ.)]. DOI: 10.32756/0869-5490-2020-3-25-36

  8. Anghel L, Tudurachi BS, Leonte A, et al. The Challenge of High Coronary Thrombotic Events in Patients with ST-Segment Elevation Myocardial Infarction and COVID-19. J Clin Med. 2022; 11 (21): 6542. DOI: 10.3390/jcm11216542

  9. Shang W, Dong J, Ren Y, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020; 92 (10): 2188-2192. DOI: 10.1002/ jmv.26031

  10. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. J ClinEndocrinolMetab. 2020; 105(8): dgaa346. DOI: 10.1210/clinem/dgaa346

  11. Стулова М.В., Кудряшева И.А., Полунина О.С., и др. Сравнительный клинико-лабораторный анализ COVID-19 ассоциированной пневмонии с внебольничной пневмонией бактериальной этиологии // Современные проблемы науки и образования. – 2020. - No3. – С. 134. [Stulova MV, Kudryasheva IA, Polunina OS, et al. Sravnitel’nyj kliniko-laboratornyj analiz COVID-19 associirovannoj pnevmonii s vnebol’nichnoj pnevmoniej bakterial’noj etiologii [Comparative clinical and laboratory analysis of covid-19 associated pneumonia with community-acquired pneumonia, bacterial etiology]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education]. 2021; 28 (1): 16-31. (In Russ.)].

  12. Сокологорский С.В., Овечкин А.М., Хапов И.В., и др. Факторы риска и методы прогнозирования клинического исхода COVID-19 (обзор) // Общая реаниматология. – 2022. – Т. 18, No1. - 31–38. [Sokologorskij SV, Ovechkin AM, Hapov IV, et al. Faktory riska i metody prognozirovaniya klinicheskogo iskhoda COVID-19 (obzor) [Risk Factors of Severe Disease and Methods for Clinical Outcome Prediction in Patients with COVID-19 (Review)]. Obshchaya reanimatologiya [General reanimatology]. 2021; 28 (1): 16-31. (In Russ.)]. DOI: 10.15360/1813-9779-2022-1-31-38

  13. Хайруллина Г.Р., Шукруллоев Н.Р., Дружкова Е.Б., и др. Беременность и COVID-19. Перинатальные исходы // Вестник современной клинической медицины. – 2022. – Т. 15, вып. 6. – С.109–116. [Hajrullina GR, Shukrulloev NR, Druzhkova EB, et al. Beremennost’ i COVID-19. Perinatal’nye iskhody [Pregnancy and COVID-19. perinatal outcomes]. Vestnik sovremennoj klinicheskoj mediciny [The Bulletin of Contemporary Clinical Medicine]. 2022; 15 (6): 109-116. (In Russ.)]. DOI: 10.20969/VSKM.2022.15(6).109-116

  14. Liang W, Liang H, Ou L, et al; China Medical Treatment Expert Group for COVID-19. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA InternMed. 2020;180 (8): 1081-1089. DOI: 10.1001/jamainternmed.2020.2033

  15. Tjendra Y, Al Mana AF, Espejo AP, et al. Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers. Arch Pathol Lab Med. 2020; 144 (12): 1465-1474. DOI: 10.5858/arpa.2020-0471-SA

  16. Хромушин В.А., Грачев Р.В., Борисова О.Н., и др. Анализ смертности населения Тульской области при хронической ишемической болезни сердца с COVID-19 в 2020-2021 годах // Вестник новых медицинских технологий. Электронное издание. - 2022. – Т. 16, No 1. С. 49-54. [Hromushin VA, Grachev RV, Borisova ON, et al. Analiz smertnosti naseleniya Tul’skoj oblasti pri hronicheskoj ishemicheskoj bolezni serdca s COVID-19 v 2020-2021 godah [Analysis of mortality of the population of the tula region at chronic coronary heart disease with COVID-19 in 2020-2021]. Vestnik novyh medicinskih tekhnologij. Elektronnoe izdanie [JOURNAL OF NEW MEDICAL TECHNOLOGIES, eEdition]. 2021; 28 (1): 16-31. (In Russ.)]. DOI: 10.24412/2075-4094-2022-1-1-7

  17. Yang TC, Emily Choi SW, Sun F. COVID-19 cases in US counties: roles of racial/ethnic density and residential segregation. EthnHealth. 2021; 26 (1): 11-21. DOI: 10.1080/13557858.2020.1830036

  18. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. N Engl J Med. 2020; 382 (26): 2534-2543. DOI: 10.1056/NEJMsa2011686

 

UDC 616.153.922-056.7-07:314.14

DOI: 10.20969/VSKM.2023.16(4).27-36

PDF download СLINICAL AND LABORATORY CHARACTERISTICS OF FEMALE PATIENTS OF OUTPATIENT LIPIDOLOGIST

KIM ZULFIYA F., ORCID ID: 0000-0003-4240-3329; C. Med. Sci., Deputy Head physician on medical a airs of City Clinical Hospital No. 7, Kazan, Russia; Chief freelance cardiologist of the Ministry of Health of Republic of Tatarstan; associate professor of the Department of internal medicine No 2 of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, e-mail: profz@yandex.ru

GALYVICH ALBERT S., ORCID ID: 0000-0002-4510-6197; D. Med. Sci., professor, the Head of the Department of cardiology of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49; Chief freelance cardiologist of the Ministry of Health of the Russian Federation in the Volga Federal District, e-mail: agalyavich@mail.ru

SADYKOVA DINARA I., ORCID ID: 0000-0002-6662-3548, D. Med. Sci., professor, the Head of the Department of hospital pediatrics of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49; pediatric cardiologist; chief freelance pediatric specialist cardiologist of the Ministry of Health of the Russian Federation in the Volga Federal District and RT, e-mail: sadykovadi@mail.ru

NURIEVA LUIZA M., ORCID ID: 0000-0002-1762-9492; cardiologist of the cardiology department No. 1 of City Clinical Hospital No. 7, Kazan, Russia, e-mail: nurievaluiza@list.ru

Abstract. Introduction. Lipid metabolism disorders are one of the most important factors contributing signi cantly to the probability of developing cardiovascular diseases, death from coronary heart disease and mortality of the population.Aim. To identify the features of anamnestic, clinical and laboratory parameters in female patients of the lipid cabinet and to determine the frequency of detection of familial hypercholesterolemia in them. Material and methods. The study included 777 female patients of the outpatient appointment of a doctor of the lipid cabinet. The examination of patients with dyslipidemia included an examination by a cardiologist-lipidologist (with the calculation of the risk of cardiovascular complications on the Systemic COronary Risk Evaluation scale, the probability of familial hypercholesterolemia on the British Simon Broom scale and the criteria of the Dutch lipid clinics. Results and discussion. The total number of 777 patients were 63% of the total number of patients in the lipid cabinet; aged 19-90 years old, average age 58.49±9.48. The average level of total cholesterol was 7.74±1.98 mmol/l, low-density lipoprotein cholesterol 4.84±1.4 mmol/l, high-density lipoprotein cholesterol 1.46±0.44 mmol/l, triglycerides 1.61±1.42 mmol/l, non-high-density lipoprotein cholesterol 6.32±1.97 mmol/l. In 23% of patients, lipid metabolism disorders are secondary. Atherosclerosis of brachiocephalic arteries was diagnosed in 68.4% of patients, hypertension was in 41.4%. 15.1% of patients were diagnosed with atherosclerotic cardiovascular disease. Conclusions. The most signi cant for the development of atherosclerotic cardiovascular disease in women with lipid metabolism disorders were body mass index, burdened family history, duration of menopause and level of physical activity. Smoking, diabetes mellitus, hypertension, external signs of dyslipidemia were not associated with atherosclerotic cardiovascular diseases.

Keywords: lipid metabolism disorders, dyslipidemia, familial hypercholesterolemia, cardiovascular diseases, atherosclerosis.

For reference: Kim ZF, Galyavich AS, Sadykova DI, Nurieva LM. Clinical and laboratory characteristics of female patients of outpatient lipidologist. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 27-36. DOI: 10.20969/VSKM.2023.16(4).27-36.

References

  1. Метельская В.А., Шальнова С.А., Деев А.Д. и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ) // Профилактическая Медицина. – 2016. – No 19(1). – С.15-23. [Metelskaya VA, Shalnova SA, Deev AD, et al. Analiz rasprostranennosti pokazatelej, harakterizuyushchih aterogennost’ spektra lipoproteinov, u zhitelej Rossijskoj Federacii (po dannym issledovaniya ESSE-RF) [Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study)]. Pro lakticheskaya Meditsina [Preventive Medicine]. 2016;19(1):15-23. (In Russ.)]. DOI: 10.17116/profmed201619115-23

  2. Блохина А.В., Ершова А.И., Мешков А.Н., и др. Липидная клиника как эффективная модель профилактической медицины // Рациональная Фармакотерапия в Кардиологии. – 2021. –No.17(1). – С.4-10. [Blokhina AV, Ershova AI, Meshkov AN, et al. Lipidnaya klinika kak e ektivnaya model’ pro lakticheskoj mediciny [Lipid Clinic is an E cacious Model of Preventive Medicine]. Racional’naya Farmakoterapiya v Kardiologii [Rational Pharmacotherapy in Cardiology]. 2021;17(1):4-10. (In Russ.)]. DOI: 10.20996/1819-6446-2021-01-02

  3. Huang Y, Gao L, Xie X, Tan SC. Epidemiology of dyslipidemia in Chinese adults: metaanalysis of prevalence, awareness, treatment, and control. Popul Health Metr. 2014;12(1):28. DOI: 10.1186/s12963-014-0028-7

  4. Баланова Ю.А., Концевая А.В., Шальнова С.А., и др. Распространенность поведенческих факторов риска сердечно-сосудистых заболеваний в российской популяции по результатам исследования ЭССЕ-РФ // Профилактическая медицина. – 2014. –No. 17(5). –С.42-52. [Balanova IuA, Kontsevaia AV, Shalnova SA, et al. Rasprostranennost’ povedencheskih faktorov riska serdechno-sosudistyh zabolevanij v rossijskoj populyacii po rezul’tatam issledovaniya ESSE-RF [Prevalence of behavioral risk factors for cardiovascular disease in the Russian population: Results of the ESSE-RF epidemiological study]. Pro lakticheskaya Meditsina [Preventive Medicine]. 2014;17(5):42-52. (In Russ.)].

  5. Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003— 2006. J Clin Lipidol. 2012;6(4):325-330. DOI: 10.1016/j. jacl.2012.05.002

  6. Huang Y, Gao L, Xie X, Tan SC. Epidemiology of dyslipidemia in Chinese adults: metaanalysis of prevalence, awareness, treatment, and control. Popul Health Metr. 2014;12(1):28. DOI: 10.1186/s12963-014-0028-7

  7. Gupta R, Rao RS, Misra A, Sharma SK. Recent trends in epidemiology of dyslipidemias in India. Indian Heart J. 2017;69(3):382-392. DOI: 10.1016/j.ihj.2017.02.020

  8. The Human Genome Variation Society. https://www. hgvs.org 

  9. ClinVar. https://www.ncbi.nlm.nih.gov/clinvar

  10. Гринштейн Ю.И., Шабалин В.В., Руф Р.Р., и др. Распространенность дислипидемии среди населения крупного региона Восточной Сибири и взаимосвязь с социодемографическими и поведенческими факторами. Профилактичексая медицина. – 2018. – No. 21(5). - С.63 69. [Grinshtein YuI, Shabalin VV, Ruf RR, Petrova MM, et al. Rasprostranennost’ dislipidemii sredi naseleniya krupnogo regiona Vostochnoj Sibiri i vzaimosvyaz’ s sociodemogra cheskimi i povedencheskimi faktorami [Prevalence of dyslipidemia among the population of a large region of Eastern Siberia and its association with sociodemographic and behavioral factors]. Pro lakticheskaya Meditsina [Preventive Medicine]. 2018;21(5):63 69.(In Russ.)]. DOI: 10.17116/profmed20182105163

  11. Комплексное наблюдение условий жизни населения проводится во исполнение постановления Правительства Российской Федерации от 27 ноября 2010 года No 946 «Об организации в Российской Федерации системы федеральных статистических наблюдений по социально-демографическим проблемам и мониторинга экономических потерь от смертности, заболеваемости и инвалидизации населения» [Kompleksnoe nablyudenie uslovij zhizni naseleniya provoditsya vo ispolnenie postanovleniya Pravitel’stva Rossijskoj Federacii ot 27 noyabrya 2010 goda No 946 «Ob organizacii v Rossijskoj Federacii sistemy federal’nyh statisticheskih nablyudenij po social’no-demogra cheskim problemam i monitoringa ekonomicheskih poter’ ot smertnosti, zabolevaemosti i invalidizacii naseleniya» [Comprehensive monitoring of the living conditions of the population is carried out pursuant to the Decree of the Government of the Russian Federation No 946 of November 27, 2010 «On the organization in the Russian Federation of a system of federal statistical observations on socio-demographic problems and monitoring of economic losses from mortality, morbidity and disability of the population»]. (In Russ.)]. (https://www.gks.ru/free_doc/new_site/KOUZ/ survey0/index.html)

  12. Cífková R, Skodová Z, Bruthans J, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis. 2010 Aug;211(2):676-81. DOI: 10.1016/j. atherosclerosis.2010.04.007

  13. Unal B, Sözmen K, Arık H, et al. Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008. BMC Public Health. 2013 Dec 5;13:1135. DOI: 10.1186/1471-2458-13-1135

  14. Kaleta D, Makowiec-Dąbrowska T, Dziankowska-Zaborszczyk E, Fronczak A. Prevalence and socio-demographic correlates of daily cigarette smoking in Poland: results from the Global Adult Tobacco Survey (2009-2010). Int J Occup Med Environ Health. 2012 Jun;25(2):126-36. DOI: 10.2478/S13382-012-0016-8

  15. Nagelhout GE, de Korte-de Boer D, Kunst AE, et al. Trends in socioeconomic inequalities in smoking prevalence, consumption, initiation, and cessation between 2001 and 2008 in the Netherlands. Findings from a national population survey. BMC Public Health. 2012 May 18;12:303. DOI: 10.1186/1471-2458-12-303

  16. Hallal PC, Andersen LB, Bull FC, et al. Lancet Physical Activity Series Working Group. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012 Jul 21;380(9838):247-57. DOI: 10.1016/ S0140-6736(12)60646-1

  17. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2224-60. DOI: 10.1016/S0140-6736(12)61766-8

  18. Prevalence of insu cient physical activity, age 15+, age-standardized: both sexes. Geneva: World Health Organization 2008. http://gamapserver.who. int/gho/ interactive_charts/ncd/risk_factors/physical_inactivity/ atlas.html

  19. World Health Organization. Global health observatory data repository, 2011. http://apps.who.int/ghodata/

  20. Gordon T, Kannel WB, Hjortland MC. Menopause and coronary heart disease: the Framingham study. Ann Intern Med 1978;89:157–61

  

UDC: 616-056.257-053.2-02-06:616.1

DOI: 10.20969/VSKM.2023.16(4).37-48

PDF download FEATURES OF RISK FACTORS FOR THE DEVELOPMENT OF CARDIOVASCULAR COMPLICATIONS IN CHILDREN WITH OBESITY

OLEYNIK OХANA A., ORCID ID: 0000-0002-2915-384X; C. Med. Sci., Associate Professor of the Department of Pediatrics with a course of Endocrinology, Associate Professor of the Department of Internal medicine with a course of Clinical Pharmacology, expert of the Center for Clinical Research of the Siberian State Medical University, Russia, 634050, Tomsk, Moskovsky Trakt str., 2; Chief freelance specialist of the Department healthcare of the Tomsk region for the organization of high-tech medical care in the pro le «Endocrinology», 634041, Tomsk, Kirov Ave., 41, e-mail: oleynikoa@mail.ru

SAMOYLOVA YULIA G., ORCID ID: 0000-0002-2667-4842; D. Med. Sci., Head of the Department of Pediatrics with a course of Endocrinology, Professor of the Department of Internal medicine with a course of Clinical Pharmacology, Head of the Center for Clinical Research of the Siberian State Medical University, Russia, 634050, Tomsk, Moskovsky Trakt str., 2; Chief freelance specialist of the Department of Health of the Tomsk Region for medical prevention, 634041, Tomsk, Kirov Ave., 41, e-mail: samoilova_y@inbox.ru

MATVEEVA MARIA V., ORCID ID: 0000-0001-9966-6686; D. Med. Sci., Professor of the Department of Pediatrics with the course of Endocrinology of the Siberian State Medical University, Russia, 634050, Tomsk, Moskovsky Trakt str., 2, e-mail: matveeva.mariia@yandex.ru

PODCHINENOVA DARYA V., ORCID ID: 0000-0001-6212-4568; C. Med.Sci., Associate Professor of the Department of Pediatrics with the course of Endocrinology of the Siberian State Medical University, Russia, 634050, Tomsk, Moskovsky Trakt str., 2, e-mail: darvas_42@mail.ru

VOROZHTSOVA IRINA N., ORCID 0000-0002-1610-0896, Professor of the Department of fInternal medicine with a course of Clinical Pharmacology, Siberian State Medical University, Doctor of Medical Sciences, е-mail: abv@mail. tomsknet.ru

KOVARENKO MARGARITA A., ORCID ID: 0000-0002-5012-0364; C. Med. Sci., assistant professor of Department of Pediatrics with the course of Endocrinology of the Siberian State Medical University, Russia, 634050, Tomsk, Moskovsky trakt str., 2, e-mail: grun-wald@yandex.ru

ZAKHARCHUK POLINA I., ORCID ID: 0000-0002-9809-4716; clerk of the Clinical Research Center, 6th year student of the Pediatric Faculty of the Siberian State Medical University, Russia, 634050, Tomsk, Moskovsky Trakt str., 2, e-mail: zaharchuk.polya@yandex.ru

SHULIKO LYUDMILA M., ORCID ID: 0000-0001-5299-2097; 5th year student of the Faculty of Medicine of the Siberian State Medical University, Russia, 634050, Tomsk, Moskovsky Trakt str., 2, e-mail: ludmila.shuliko.15@mail.com

FILIMONOV ALEXEY E., ORCID ID: 0000-0002-6360-1263; Acting Deputy Head of the Department - Chairman of the Youth Policy Committee of the Department for Youth Policy, Physical Culture and Sports of the Tomsk Region, 634050, Tomsk, Lenin Square, 8, e-mail: limonov.94.alex@mail.ru

Abstract. Introduction. The most common risk factors for the development of cardiovascular diseases are hypertension and obesity, which are formed in childhood, however, the most signi cant clinical and metabolic markers of cardiovascular risk have not yet been identi ed in pediatric practice. Aim. To study the characteristics and interrelations of cardiovascular risk factors in obese children and adolescents for planning correction at the stage of functional changes. Material and methods. The study included 141 obese children – 69 boys and 72 girls (in whom the degree of standard deviation of the body mass index was 2.88 [2.75; 3.41] and 2.93 [2.59; 4.05], respectively) and 78 healthy children (40 boys and 38 girls), comparable by sex and age. Results and discussion. In the examined children, there is an insu cient decrease in blood pressure at night from both systolic blood pressure and diastolic blood pressure, in the absence of clinically and statistically signi cant deviations in single measurements. The triglyceride-glucose index and the N-terminal inactive peptide of natriuretic hormone demonstrated high concentrations in normoglycemia and the absence of dyslipidemia. Against the background of obesity, trimethylaminoxide concentrations were lower than in healthy children. Conclusion. In order to timely correct blood pressure, it is necessary to use daily monitoring in obese children, even against the background of the absence of signs of arterial hypertension with single measurements. Even against the background of lean normoglycemia in obese children and adolescents, it is advisable to diagnose the formation of insulin resistance and hyperinsulinemia using indicators of insulin levels, calculation of the HOMA-IR index, triglyceride-glucose index. Correction of blood pressure variability is possible with changes in certain parameters of body composition (decrease in fat mass and increase in muscle mass) and hormonal and metabolic parameters (decrease in glycemia, very low-density lipoproteins, insulin and increase in high-density lipoproteins). The level of trimethylaminoxide showed lower rates of obesity in children compared to healthy peers, which di ers from the literature data on the adult population and limits its use as a biomarker for the development of cardiovascular complications in obesity in children.

Keywords: obesity, children, daily monitoring of blood pressure, trimethylaminoxide, N-terminal inactive peptide of natriuretic hormone.

For reference: Oleynik OA, Samoylova YuG, Matveeva MV, et al. Features of risk factors for the development of cardiovascular complications in children with obesity. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 37-48. DOI: 10.20969/VSKM.2023.16(4).37-48.

References

  1. World Health Organization, Regional O ce for Europe. The European Health Report 2021. Taking stock of the health-related Sustainable Development Goals in the COVID-19 era with a focus on leaving no one behind: License: CC BY-NC-SA 3.0 [serial online]. Copenhagen; 2022 [cited 2023 Feb 11]. Available from: URL: https:// apps.who.int/iris/handle/10665/352137. ISBN: 978-92-890-5754-7

  2. Jacobs DR, Woo JG, Sinaiko AR, et al. Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events. N Engl J Med. 2022; 386(20): 1877-1888. DOI:10.1056/NEJMoa2109191

  3. Drozdz D, Alvarez-Pitti J, Wójcik M, et al. Obesity and Cardiometabolic Risk Factors: From Childhood to Adulthood. Nutrients. 2021; 13(11): 4176. DOI: 10.3390/ nu13114176

  4. Barroso WK, Souza AL. Obesity, Overweight, Body Adiposity and Cardiovascular Risk in Children and Adolescents. Arq Bras Cardiol. 2020; 115(2): 172-173. DOI: 10.36660/abc.20200540

  5. Kim MS, Kim WJ, Khera AV, et al. Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies. Eur Heart J. 2021; 42 (34): 3388-3403. DOI: 10.1093/eurheartj/ehab454

  6. Маскова Г.С., Черная Н.Л., Шубина Е.В., Александрова С.В. Возрастные особенности первичного ожирения у детей // Практическая медицина. – 2014. – No 9. – С. 126–130. [Maskova GS, Tchernaya NL, Shubina EV, Aleksandrova SV. Vozrastnye osobennosti pervichnogo ozhireniya u detey [The age features of primary obesity in children]. Prakticheskaya meditsina [Practical medicine]. 2014; (9): 126-130. (In Russ.)].

  7. Чубаров Т.В., Петеркова В.А., Батищева Г.А. и др. Характеристика уровня артериального давления у детей с различной массой тела // Ожирение и метаболизм. – 2022. – Т. 19, No 1. – С. 27–34. [Chubarov TV, Peterkova VA, Batischeva GA, et al. Kharakteristika urovnya arterial’nogo davleniya u detey s razlichnoy massoy tela [Characteristics of blood pressure level in children with di erent body weight]. Ozhirenie i metabolizm [Obesity and metabolism]. 2022; 19(1): 27-34. (In Russ.)]. DOI: 10.14341/omet12721

  8. Кожевникова О.В., Намазова-Баранова Л.С., Маргиева Т.В. и др. Факторы риска и маркеры ночной гемодинамики для персонифицированной профилактики сердечно-сосудистых болезней у детей // Педиатрическая фармакология. – 2017. – Т. 14, No 3. – С. 156–164. [Kozhevnikova OV, Namazova-Baranova LS, Margieva TV, et al. Faktory riska i markery nochnoy gemodinamiki dlya personi tsirovannoy pro laktiki serdechno-sosudistykh bolezney u detey [Night hemodynamic disorder risk factors and markers for patient-speci c approach to cardiovascular disease prevention in children]. Pediatricheskaya farmakologiya [Pediatric pharmacology]. 2017; 14(3): 156-164. (In Russ.)]. DOI: 10.15690/pf.v14i3.1739

  9. Ding X, Wang X, Wu J, et al. Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies. Cardiovasc Diabetol. 2021; 20(1): 76. DOI: 10.1186/s12933-021-01268-9

  10. Xu L, Wu M, Chen S, et al. Triglyceride-glucose index associates with incident heart failure: A cohort study. Diabetes Metab. 2022; 48(6): 101365. DOI: 10.1016/j. diabet.2022.101365

  11. Самойлова Ю.Г., Ворожцова И.Н., Олейник О.А. и др. Cубклинические маркеры кардиометаболического риска у детей и подростков с ожирением // Сибирский журнал клинической и экспериментальной медицины. – 2020. – Т. 35, No 3. – С. 32–37. [Samoilova JG, Vorozhtsova IN, Oleynik OA, et al. Cubklinicheskie markery kardiometabolicheskogo riska u detey i podrostkov s ozhireniem [Subclinical markers of cardiometabolic risk in obese children and adolescents]. Sibirskiy zhurnal klinicheskoy i eksperimental’noy meditsiny [The Siberian Journal of Clinical and Experimental Medicine]. 2020; 35(3): 32-37. (In Russ.)]. DOI: 10.29001/2073-8552-2020-35-3-32-37

  12. Brito AD, Hermsdor HH, Filgueiras MS, et al. TAG-glucose (TyG) index in childhood: an estimate of cut-o points and the relation to cardiometabolic risk in 4- to 9-year-old children. Public Health Nutr. 2021; 24(9): 2603-2610. DOI: 10.1017/S1368980020000944

  13. Andraos S, Jones B, Lange K, et al. Trimethylamine N-oxide (TMAO) Is not Associated with Cardiometabolic Phenotypes and In ammatory Markers in Children and Adults. Curr Dev Nutr. 2021; 5(1): nzaa179. DOI: 10.1093/cdn/nzaa179

  14. Алиева А.М. Натрийуретические пептиды: использование в современной кардиологии // Атмосфера. Новости кардиологии. – 2017. – No 1. – С. 26–31. [Alieva AM. Natriyureticheskie peptidy: ispol’zovanie v sovremennoy kardiologii [Natriuretic Peptides: Role in Current Cardiology]. Atmosfera. Novosti kardiologii [Atmosfhere. Cardiology News]. 2017; (1): 26-31. (In Russ.)].

  15. Саперова Е., Вахлова И. Клиническое значение натрийуретических пептидов // Патология кровообращения и кардиохирургия. – 2017. – Т. 21, No 1. – С. 117–127. [Saperova EV, Vakhlova IV. Klinicheskoe znachenie natriyureticheskikh peptidov [A clinical importance of natriuretic peptides in pediatric practice]. Patologiya krovoobrashcheniya i kardiokhirurgiya [Cardiology and Cardiovascular Medicine]. 2017; 21(1): 117-127. (In Russ.)]. DOI: 10.21688/1681-3472-2017-1-117-127

 

UDC:[616.12-008.331.1:616.72-002]:616-08

DOI: 10.20969/VSKM.2023.16(4).49-57

PDF download THE HYPOTENSIVE THERAPY IMPACT ON HEMODYNAMIC PARAMETERS IN PATIENTS WITH HYPERTENSION COMBINED WITH RHEUMATOID ARTHRITIS

SAMORODSKAYA NATALYA A., ORCID ID: 0000-0002-9723-11; Candidate of Medical Sciences, Associate Professor of the Internal Medicine Department, Kuban State Medical University, Health Care Ministry of Russia, Russia, 350063, Krasnodar, Mitrofana Sedina str., 4, e-mail: samnatdoc@mail.ru

ELISEEVA LUDMILA N., ORCID ID: 0000-0002-5275-3261; Doctor of Medical Sciences, Professor of the Internal Medicine Department, Kuban State Medical University, Russia, 350063, Krasnodar, Mitrofana Sedina str., 4, e-mail: yeliseyeva@mail.ru

KHUAKO MARIET SH., ORCID ID: 0000-0003-2129-8806; Candidate of Medical Sciences, Associate Professor of the Radiation Diagnostics Department, Kuban State Medical University, Russia, 350063, Krasnodar, Mitrofana Sedina str., 4, e-mail: mariiet@yandeх.ru

Abstract. Introduction. The appointment of antihypertensive therapy in patients with comorbidity of primary hypertension and rheumatoid arthritis, considering the activity of rheumatoid arthritis is not always speci ed, and therefore is an urgent issue that may cause a discrepancy between the hemodynamic in uence of the prescribed therapy and the nature of existing hemodynamic shifts in this category of patients. Aim. Impact evaluation of the 6-month antihypertensive therapy with drugs of various classes on the hemodynamic parameters of the circulatory system in patients with hypertension stage II combined with rheumatoid arthritis, including its activity. Material and methods. Patients complying the inclusion criteria by age (58.6±6.4 years), hypertension duration (11.2±1.6 years), debut (aged 45-64 years) and rheumatoid arthritis experience (7.2±2.1 years) were formed into three groups: Group I included 277 patients with hypertension stage II (136 men, 141 women); Group II consists of 142 patients (28 men, 114 women) with hypertension stage II and rheumatoid arthritis (in the stage of clinical and laboratory remission); and in Group III there were 112 patients (20 men, 92 women) with hypertension stage II and rheumatoid arthritis (in the stage of clinical and laboratory exacerbation). Antihypertensive therapy was administered by polyclinic physicians. Lisinopril, nebivolol, losartan, amlodipine, indapamide and an un xed combination of lisinopril and indapamide were prescribed as monotherapy drugs. The follow up period has lasted for 6 months. Results and discussion. E ectiveness control of the prescribed therapy in 6 months was presented in patients in Groups I and II with positive dynamics of morphometric and velocity parameters, in patients in Group III, the indicators were less signi cant and more delayed. Conclusion.Rheumatoid arthritis presence adds additional changes in the dynamics of the hemodynamic in uence of the prescribed antihypertensive therapy, and is determined by the activity degree of the disease and the adequacy of basic antiin ammatory therapy.

Key words: antihypertensive therapy, arterial hypertension, rheumatoid arthritis.

For reference: Samorodskaya NA, Eliseeva LN, Huako MS. The hypotensive therapy impact on hemodynamic parameters in patients with hypertension combined with rheumatoid arthritis. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 49-57. DOI: 10.20969/VSKM.2023.16(4).49-57.

References

Литература

  1. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии // Системные гипертензии. – 2019. –No 16, вып.1. – С. 6–31. [Chazova IE, Zhernakova YuV. ot imeni ekspertov. Klinicheskie rekomendacii. Diagnostika i lechenie arterialnoj gipertonii. [Clinical guidelines. Diagnosis and treatment of arterial hypertension] Sistemnye gipertenzii [Systemic Hypertension]. 2019; 16(1): 6–31. (In Russ.)]. DOI: 10.26442/2075082X.2019.1.190179
  2. Фомичева О.А., Попкова Т.В., Круглый Л.Б. и др. Факторы прогрессирования и развития атеросклероза при ревматоидном артрите // Кардиология. – 2021. – No.61, вып.1. – С. 12-21. [Fomicheva OA, Popkova TV, Kruglyj LB i dr. Faktory progressirovaniya i razvitiya ateroskleroza pri revmatoidnom artrite [Factors of Progression and Occurrence of Atherosclerosis in Rheumatoid Arthritis]. Kardiologiya [Kardiologiia]. 2021; 61(1): 12-21. (In Russ.)] DOI:10.18087/ cardio.2021.1.n1331
  3. Wilson JC, Sarsour K, Gale S, et al. Incidence and risk of glucocorticoid-associated adverse e ects in patients with rheumatoid arthritis. Arthritis Care Res. 2019; 71(4): 498–511. DOI: 10.1002/acr.23611
  4. Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени // Научно-практическая ревматология. – 2017. – No.55, вып.4. – С. 409-419. [Nasonov EL Farmakoterapiya revmatoidnogo artrita: novaya strategiya, novye misheni [Pharmacotherapy for rheumatoid arthritis: new strategy, newtargets]. Nauchno-prakticheskaya revmatologiya [Rheumatology Science and Practice]. 2017; 55(4): 409-419. (In Russ.)]. DOI: 10.14412/1995-4484-2017-409-419
  5. Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата // Научно-практическая ревматология. – 2014. – No52. – С.8-26. [Nasonov EL, Karateev DE, Chichasova NV. Novye rekomendacii po lecheniyu revmatoidnogo artrita (EULAR, 2013): mesto metotreksata [New recommendations for the management of rheumatoid arthritis (EULAR, 2013): The role of methotrexate]. Nauchno-prakticheskaya revmatologiya [Rheumatology Science and Practice]. 2014; 52(1): 8-26. (In Russ.)]. DOI: 10.14412/1995-4484-2014-8-26
  6. Стрюк Р.И., Брыткова Я.В., Татаринова О.В. Моноили комбинированная антигипертензивная терапия у женщин с артериальной гипертонией и умеренным риском сердечно - сосудистых осложнений: что лучше? // Медицинский Совет. – 2017. – No20. – С.40-44. [Stryuk RI, Brytkova YV, Tatarinova OV. Mono- ili kombinirovannaya antigipertenzivnaya terapiya u zhenshin s arterialnoj gipertoniej i umerennym riskom serdechno - sosudistyh oslozhnenij: chto luchshe? [Mono- or combined antihypertensive therapy in women with arterial hypertension and moderate risk of cardiovascular diseases: what’s better?]. Medicinskij Sovet [Medical Council]. 2017; 20: 40-44. (In Russ.)]. DOI: 10.21518/2079-701X-2017-20-40-44
  7. Никитина, Н.М., Романова Т.А., Ребров А.П. Суточное мониторирование артериального давления как ме-тод ранней диагностики артериальной гипертензии у больных ревматоидным артритом // Российский кар-диологический журнал. – 2017 – No.4, вып.144. – С.29-36. [Nikitina NM, Romanova TA, Rebrov AP. Sutochnoe monitorirovanie arterialnogo davleniya kak metod rannej diagnostiki arterialnoj gipertenzii u bolnyh revmatoidnym artritom [Blood pressure ambulatory monitoring as a method for early hypertension diagnostics in rheumatoid arthritis patient]. Rossijskij kardiologicheskij zhurnal  [Russian Journal of Cardiology]. 2017; 4: 29-34. (In Russ.)]. DOI: 10.15829/1560-4071-2017-4-29-34
  8. Каратеев А.Е. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы // Современная ревматология. – 2018. – No.2, вып.12. – С. 64-72. [Karateev AE. Destabilizaciya arterialnoj gipertenzii kak oslozhnenie terapii nesteroidnymi protivovospalitelnymi preparatami: znachenie problemy [Destabilized hypertension as a complication of therapy with nonsteroidal anti- in ammatory drugs: the importance of the problem]. Sovremennaya revmatologiya [Modern Rheumatology Journal]. 2018;12(2): 64–72. (In Russ.)]. DOI:10/14412/1996-7012-2018-2-64-72
  9. Lovell AR, Ernst ME. Drug-Induced Hypertension: Focus on Mechanisms and Management. Curr Hypertens Rep. 2017; 19(5): 39-40. DOI: 10.1007/s11906-017-0736-z
  10. Горбунов В. М., Карпов Ю. А., Платонова Е.В., Кошеляевская Я.Н. Суточное мониторирование и клиническое измерение артериального давления в комплексной оценке эффективности 12-недельной терапии тройной фиксированной комбинацией амлодипин/ индапамид/периндоприл у пациентов с артериальной гипертензией в реальной клинической практике // Российский кардиологический журнал. – 2021. – No.26. вып.5. – С. 4498. [Gorbunov VM, Karpov YuA, Platonova EV, Koshelyaevskaya YaN. Sutochnoe monitorirovanie i klinicheskoe izmerenie arterialnogo davleniya v kompleksnoj ocenke e ektivnosti 12-nedelnoj terapii trojnoj ksirovannoj kombinaciej amlodipin/indapamid/ perindopril u pacientov s arterialnoj gipertenziej v realnoj klinicheskoj praktike [Twenty-four-hour and o ce blood pressure measurement in a comprehensive assessment of the e ectiveness of 12-week therapy with a triple xed-dose combination of amlodipine/indapamide/ perindopril in hypertensive patients in actual clinical practice]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2021; 26(5): 4498. (In Russ.)]. DOI: 10.15829/1560-4071-2021-4498
  11. Panoulas VF, Douglas KMJ, Milionis HJ, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology. 2007; 46: 77–82. DOI: 10.1093/rheumatology/kem169
  12. Остроумова О.Д., Кочетков А.И., Лопухина М.В., Павлеева Е.Е. Гиперсимпатикотония в развитии гипертрофии миокарда левого желудочка и возможности бета-блокаторов для регресса // Российский кардиологический журнал. – 2018. – No9. – С. 77-88. [Ostroumova OD, Kochetkov AI, Lopuhina MV, Pavleeva EE. Gipersimpatikotoniya v razvitii gipertro i miokarda levogo zheludochka i vozmozhnosti beta-blokatorov dlya regressa [High sympathetic tone in development of the left ventricle hypertrophy and beta-blockers for regression]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2018; 9: 77-88. (In Russ.)]. DOI: 10.15829/1560-4071-2018-9-77-88
  13. Оранский С.П., Елисеева Л.Н., Куринная В.П., Давыдова А.Ф. Поражение почек при ревматоидном артрите: связь с факторами сердечно - сосудистого риска // Санкт Петербург. Нефрология. – 2017. – No.21. вып.5. – С. 42-47. [Oranskij SP, Eliseeva LN, Kurinnaya VP, Davydova AF. Porazhenie pochek pri revmatoidnom artrite: svyaz s faktorami serdechno - sosudistogo riska [Kidney injury in rheumatoid arthritis: relationship with cardiovascular risk factors]. Sankt-Peterburg; Nefrologiya [Saint-Petersburg: Nephrology]. 2017; 21(5): 42-47. (In Russ.)]. DOI: 10.24884/1561-6274-2017-21-5-44-53
  14. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104. DOI: 1093/eurheartj/ehy339
  15. Boddi M. Renal Ultrasound (and Doppler Sonography) in hypertension: an update. Adv Exp Med Biol. 2017; 956: 191–208. DOI: 10.1007/5584_2016_170

 

UDC 616.981.42:616-084

DOI: 10.20969/VSKM.2023.16(4).58-62

PDF download EVALUATION OF THE INCIDENCE OF BRUCELLOSIS IN CHILDREN IN CONDITIONS OF INTENSIFICATION OF INDIVIDUAL LIVESTOCK BREEDING

TAGHI-ZADEH TARANA GADIR, ORCID ID: 0000-0001-8816-594X, Doctor of Philosophy in Medicine, Associate Professor, Department of Children’s Diseases II; Azerbaijan Medical University, Baku, Azerbaijan, AZ 1007, Gasimzade, 14; e-mail: mic_amu@mail.ru

Abstract. Introduction. Despite not huge e orts to combat brucellosis, in a number of countries, including Azerbaijan, decisive positive results have not yet been achieved. Many households began to keep livestock, which could lead to an increased risk of brucellosis in children. Aim. Assessment the in uence of individualization of livestock breeding on the incidence of brucellosis in children. Material and methods. The work was carried out in 14 settlements of the Baku urban agglomeration located on the Absheron Peninsula. An epidemiological survey was carried out on 486 individual farms, selected by a blind method, 331 of them kept livestock. Serological diagnosis was carried out using the Huddleson and Wright tests. A total of 1702 children were examined, of which 533 children lived in households that did not contain livestock, 796 children lived in farms that kept livestock, and 373 children lived in village 2-7-storey buildings. When statistically processing the results of the study, the de nition of Student’s t-criterion, χ2 and correlation coe cient was used. Results and discussion. Infection of children averaged 15.2±0.9%, as the age of children (≤3>15 years) increases, it increases from 6.0±1.8 to 21.1±2.8%. The infection rate of children living in households with livestock is higher than without them - 10.5±0.7 and 2.8±0.4%. As the number of livestock increases, the infection rate in children increases from 9.1±4.4 to 29.6±2.1%. The seropositivity of children living in individual households that do not keep livestock and in village 2-7-stage buildings is approximately the same and amounts to 2.8±0.4 and 1.9±0.3%, respectively (t= 1.80; P>0.05) and is much inferior to the seropositivity of children living in individual households with livestock: 10.5±0.7% (t=9.63; P<0.001). Conclusion. The epidemiological situation of brucellosis among children has deteriorated in recent years, which is associated with the individualization of livestock breeding. Therefore, the search for new approaches to the prevention of brucellosis in the population should be carried out taking into account these changes.

Key words: brucellosis, morbidity, children, individual animal husbandry, diagnostics.

For reference: Taghi-zadeh TG. Evaluation of the incidence of brucellosis in children in conditions of intensi cation of individual livestock breeding. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 58-62.
DOI: 10.20969/VSKM.2023.16(4).58-62.

References

  1. Онищенко Г.Г., Куличенко А.Н. Бруцеллез. Современное состояние проблемы // Ставрополь: ООО «Губерния». – 2019. – 336 с. [Onishhenko GG, Kulichenko AN. Brucellez. Sovremennoe sostojanie problemy [Brucellosis. The current state of the problem]. Stavropol’: ООО Guberniya [Stavropol: Gubernia LLC]. 2019; 336 р. (In Russ.)].

  2. Yang H, Zhang S, Wang T, et al. Epidemiological Characteristics and Spatiotemporal Trend Analysis of Human Brucellosis in China, 1950-2018. Int J Environ Res Public Health. 2020;17(7):2382. DOI: 10.3390/ ijerph17072382

  3. Guler S, Kokoglu OF, Ucmak H, et al. Human brucellosis in Turkey: di erent clinical presentations. J Infect Dev Ctries. 2014;8(5):581-8. DOI: 10.3855/jidc.3510

  4. García Casallas JC, Villalobos Monsalve W, Arias Villate SC, Fino Solano IM. Acute liver failure complication of brucellosis infection: a case report and review of the literature. J Med Case Rep. 2018;12(1):62. DOI: 10.1186/s13256-018-1576-4

  5. Djalalinia S, Arjmand R, Gholami M, et al. Frequency and Clinical Manifestations of Pediatric Brucellosis in Iran: A Systematic Review. International Journal of Pediatrics. 2019; 7(2), 9037-9047. DOI: 10.22038/ ijp.2018.33178.2927

  6. Голубева М.В, Ткачева Л.И., Боричева Л.Ю., Погорелова Л.В. Бруцеллез у детей и взрослых. Клинические рекомендации // Международная общественная организация «Евро-Азиатское общество по инфекционным болезням» (МОО «ЕАОИБ»), Межрегиональная общественная организация «Ассоциация врачей инфекционистов Санкт-Петербурга и Ленинградской области» (МОО «АВИСПО»). – С.Петербург, 2020. –63 с. [Golubeva MV, Tkacheva LI, Boricheva LYu, Pogorelova LV. Brucellez u detej i vzroslyh. Klinicheskie rekomendacii [Brucellosis in children and adults. Clinical recommendations]. Mezhdunarodnaya obshchestvennaya organizaciya «Evro-Aziatskoe obshchestvo po infekcionnym boleznyam» (MOO «EAOIB»), Mezhregional’naya obshchestvennaya organizaciya «Associaciya vrachej infekcionistov Sankt-Peterburga i Leningradskoj oblasti» (MOO «AVISPO») [International public organization «Euro-Asian Society for Infectious Diseases» (IPO «EAOIB»), Interregional public organization «Association of Doctors of Infectious Diseases of St. Petersburg and the Leningrad Region» (IPO «AVISPO»)]. S.Peterburg [St. Petersburg]. 2020; 63 p. (In Russ.)].

  7. Пономаренко Д.Г., Русанова Д.В., Бердникова Т.В. и др. Обзор эпизоотологической и эпидемиологической ситуации по бруцеллезу в Российской Федерации в 2017 г. и прогноз на 2018 г. // Проблемы особо опасных инфекций. – 2018. – No 2. – С.23–29. [Ponomarenko DG, Rusanova DV, Berdnikova TV, et al. Obzor jepizootologicheskoj i jepidemiologicheskoj situacii po brucellezu v Rossijskoj Federacii v 2017 g. i prognoz na 2018 g [Overview of the epizootological and epidemiological situation of brucellosis in the Russian Federation in 2017 and forecast for 2018]. Problemy osobo opasnyh infekcij [Problems of especially dangerous infections]. 2018; 2: 23–29. (In Russ.)]. DOI:10.21055/0370-1069-2018-2-23-29

  8. Serpa JA, Knights S, Farmakiotis D, Campbell J. Brucellosis in Adults and Children: A 10-Year Case Series at Two Large Academic Hospitals in Houston, Texas. South Med J. 2018;111(6):324-327. DOI: 10.14423/SMJ.0000000000000810

  9. Khazaei S, Shojaeian M, Zamani R, et al. Epidemiology and Risk Factors of Childhood Brucellosis in West of Iran. International Journal of Pediatrics, 2016; 4(7), 2099-2104. DOI: 10.22038/ijp.2016.6966

  10. Bukhari EE. Pediatric brucellosis. An update review for the new millennium. Saudi Med J. 2018;39(4):336-341. DOI: 10.15537/smj.2018.4.21896

  11. Ma L, Ma J, Chen X, Dong L. A 10-year retrospective comparative analysis of the clinical features of brucellosis in children and adults. J Infect Dev Ctries. 2021;15(8):1147-1154. DOI:10.3855/jidc.13962

  12. Parlak M, Akbayram S, Doğan M, et al. Clinical manifestations and laboratory ndings of 496 children with brucellosis in Van, Turkey. Pediatr Int. 2015 Aug; 57(4): 586-9. DOI: 10.1111/ped.12598

  13. Оракбай Л.Ж., Черепанова Л.Ю., Денисова Т.Г. Современные аспекты эпидемического процесса бруцеллеза // Современные проблемы науки и образования. – 2015. – No 6. [Orakbaj LZh, Cherepanova LJu, Denisova TG. Sovremennye aspekty jepidemicheskogo processa brucelleza [Modern aspects of the epidemic process of brucellosis]. Sovremennye problemy nauki i obrazovanija [Modern problems of science and education]. 2015; 6; (In Russ.)]. https://science-education.ru/ru/article/view?id=22737 (дата обращения: 12.11.2021)

  14. Шахмарданов М.З., Абусуева А.С., Никифоров В.В., и др. Заболеваемость бруцеллёзом в Республике Дагестан в 2019 г. // Эпидемиология и инфекционные болезни. – 2020. –T.25, No3. – C.112−116. [Shahmardanov MZ, Abusueva AS, NikiforovVV, et al. Zabolevaemost’ brucelljozom v Respublike Dagestan v 2019 g [The incidence of brucellosis in the Republic of Dagestan in 2019]. Epidemiologija i infekcionnye bolezni [Epidemiology and infectious diseases]. 2020;25(3):112−116. (In Russ.)]. DOI: 10.17816/ EID50362

 

UDC: 616-053.9

DOI: 10.20969/VSKM.2023.16(4).63-70

PDF download VITAMIN D IN VARIOUS AGE-RELATED PATHOLOGY IN CENTENARIANS AND VERY ELDERLY PATIENTS WITH CORONARY ARTERY DISEASE

TOPOLYANSKAYA SVETLANA V., ORCID ID: 0000-0002-4131-8432; C. Med. Sci., Associate professor, Department of Advanced Internal Medicine N2, First Moscow State Medical University, Russia, 119991, Moscow, Trubetskaya str., 8/2; internal medicine doctor of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: sshekshina@yandex.ru

MАMCHICH DARYA S., ORCID ID: 0000-0003-3331-4033; student, First Moscow State Medical University, Russia, 119991, Moscow, Trubetskaya str., 8/2; e-mail: dasha.mamchich@gmail.com

ELISEEVA TATYANA A., ORCID ID: 0000-0002-6921-0589; geriatrician of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: eliseet@yandex.ru

TURNA OLGA I., ORCID ID: 0000-0002-2933-7550; geriatrician of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: olga1414@mail.ru

ROMANOVA MARGARITA A., ORCID ID: 0000-0001-5351-1996; the head of 13 geriatric department of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: mur1-3@mail.ru

VAKULENKO OLGA N., ORCID ID: 0000-0002-4139-5075; the head of 6 geriatric department of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: onv.62@mail.ru

BUBMAN LEONID I., ORCID ID: 0000-0002-4195-3188; the head of 7 surgery department of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: bubmanleo@gmail.com

KOSHURNIKOV DMITRY S., ORCID ID: 0000-0002-7024-9560; the head of X-ray department of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: koshurdmitr@rambler.ru

LYTKINA KARINA A., ORCID ID: 0000-0001-9647-7492; C. Med. Sci., Deputy Chief Physician of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, tel.: +7 (495) 474-99-10, e-mail: lytkina.k@mail.ru

MELKONYAN GEORGYI G., ORCID ID: 0000-0002-4021-5044; D. Med. Sci., Chief Physician of War Veterans Hospital N3, Russia, 129336, Moscow, Startovaya str., 4, e-mail: gvv3@zdrav.mos.ru

VAKOLUK ROSA M., ORCID ID: 0000-0003-1160-0514; C. Med. Sci., Associate professor, Department of Advanced Internal Medicine N2, First Moscow State Medical University, Russia, 119991, Moscow, Trubetskaya str., 8/2, e-mail: roza2001@rambler.ru

RATCHINA SVETLANA A., ORCID ID: 0000-0002-3329-7846; D. Med. Sci., Professor, the head of Department of Advanced Internal Medicine N2, First Moscow State Medical University, Russia, 119991, Moscow, Trubetskaya str., 8/2; e-mail: svetlana.ratchina@antibiotic.ru

DVORETSKI LEONID I., ORCID ID: 0000-0003-3186-0102; D. Med. Sci., Professor, Department of Advanced Internal Medicine N2, First Moscow State Medical University, Russia, 119991, Moscow, Trubetskaya str., 8/2; e-mail: dvoretski@ mail.ru

Abstract. Introduction. Vitamin D de ciency is associated with many pathological conditions. The elderly is at high risk of vitamin D de ciency due to their reduced ability to produce vitamin D precursors in the skin. Aim. To analyze 25-Hydroxycalciferol relationships with various clinical and laboratory parameters in centenarians and very elderly patients with coronary artery disease. Material and methods. This work was cross-sectional study. The study included 230 patients aged 76 to 99 years, hospitalized with the diagnosis of coronary heart disease. The concentration of 25-hydroxycalciferol was determined by immunochemiluminescent analysis. A 25-hydroxycalciferol level <10 ng/mL was considered as severe vitamin D de ciency, 10-19 as de ciency, 20-29 as insu ciency, and ≥30 ng/mL as normal.Results and discussion. The mean 25-Hydroxycalciferol concentration was 14.9+10.2 ng/mL. Only 7.5% of patients had normal 25-Hydroxycalciferol level, 12.3% - insu ciency, 43.6% - de ciency, 36.6% - severe vitamin de ciency. In centenarians the mean concentration of vitamin D was 12.9+9.9 ng/ml, in patients <90 years – 16.4+10.2 ng/ml (p=0.01). Signi cant positive correlations were registered between vitamin D level and hand grip strength measured by dynamometry (r=0.2; p=0.008) and the instrumental activity scale (r=0.1; p=0.03). The mean level of vitamin D in the group of patients with high risk of cognitive impairment was 11.2+5.8 ng/ml, with low risk of cognitive impairment – 20.8+18.5 ng/ml (p<0.0001). Negative correlations were registered between 25-Hydroxycalciferol level and the Morse fall scale (r=-0.2, p=0.03). Signi cant direct correlation between serum uric acid and vitamin D was registered (r=0.3; p=0.001). No signi cant relationships were found between vitamin D levels and bone mineral density in various parts of the skeleton, with the exception of the T-score in the lumbar spine in centenarians (р=0.004). Conclusion. The study results indicate presence of various relationships between 25-Hydroxycalciferol blood concentration and various clinical and laboratory parameters in centenarians and very elderly patients with coronary artery disease and, above all, with functional insu ciency, cognitive impairment and hyperuricemia.

Key words: vitamin D, centenarians, old age, coronary artery disease.

For reference: Topolyanskaya SV, Mamchich DS, Eliseeva TA, et al. Vitamin D in various age-related pathology in centenarians and very elderly patients with coronary artery disease. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 63-70. DOI: 10.20969/VSKM.2023.16(4).63-70.

References

Литература

  1. Kupisz Urbańska M, Broczek K, Galus K, et al. Age related di erences in vitamin D status in Polish centenarians compared with 65 year olds. Polish archives of internal medicine. 2020; 130 (10): 853-859. DOI: 10.20452/pamw.15460

  2. Tsiaras WG, Weinstock MA. Factors In uencing Vitamin D Status. Acta Derm Venereol. 2011; 91: 115–124. DOI: 10.2340/00015555-0980

  3. Yao Y, Fu S, Shi Q, et al. Prevalence of functional dependence in Chinese centenarians and its relationship with serum vitamin D status. Clinical Interventions in Aging. 2018; 13: 2045–2053. DOI: DOI: 10.2147/CIA

  4. Passeri J, Pini G, Troiano L, et al. Low Vitamin D Status, High Bone Turnover, and Bone Fractures in Centenarians. J Clin Endocrinol Metab. 2003; 88(11): 5109–5115. DOI: 10.1210/jc.2003-030515

  5. Hill TR, Aspray TJ, Francis RM. Vitamin D and bone health outcomes in older age. Proceedings of the Nutrition Society. 2013; 72: 372–380. DOI: 10.1017/ S0029665113002036

  6. Matheї C, Van Pottelbergh G, Vaes B, et al. No relation between vitamin D status and physical performance in the oldest old: results from the Belfrail study. Age and Ageing. 2013; 42: 186–190. DOI: 10.1093/ageing/afs186

  7. Annweiler C, Montero-Odasso M, Schott AM, et al. Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone e ects. J Neuro Engineering and Rehabilitation.2010; 7:5. DOI: 10.1186/1743-0003-7-50

  8. Gussago C, Arosio B, Guerini FR, et al. Impact of vitamin D receptor polymorphisms in centenarians. Endocrine. 2016; 53(2): 558-564. DOI: 10.1007/s12020-016-0908-7

  9. Savicheva A, Eruslanova K, Dudinskaya E, Matchekhina L. Vitamin D and geriatric syndromes in centenarians. Endocrine Abstracts. 2021; 75: M09. DOI:10.1530/ endoabs.75.M09

  10. Yao Y, Fu S, Li N, et al. Sex, Residence and Fish Intake Predict Vitamin D Status in Chinese Centenarians. J Nutr Health Aging. 2019; 23(2): 165-171. DOI:10.1007/ s12603-018-1126-1

  11. Haslam A, Johnson MA, Hausman DB, et al. Vitamin D status is associated with grip strength in centenarians. J Nutr Gerontol Geriatr. 2014; 33(1): 35-46. DOI: 10.1080/21551197.2013.867825

  12. Ferri E, Casati M, Cesari M, et al. Vitamin D in physiological and pathological aging: Lesson from centenarians. Rev Endocr Metab Disord. 2019; 20(3): 273-282. DOI: 10.1007/s11154-019-09522-y

13. Ling Y, Xu F, Xia X, et al. Vitamin D supplementation reduces the risk of fall in the vitamin D de cient elderly: An updated meta-analysis. Clin Nutr. 2021; 40(11): 5531-5537. DOI: 10.1016/j.clnu.2021.09.031

14. Kalyani RR, Stein B, Valiyil R, et al. Vitamin D treatment for the prevention of falls in older adults: systematic review and meta-analysis. J Am Geriatr Soc. 2010; 58(7): 1299-310. DOI: 10.1111/j.1532-5415.2010.02949.x

15. Łukaszyk E, Bień-Barkowska K, Bień B. Cognitive Functioning of Geriatric Patients: Is Hypovitaminosis D the Next Marker of Cognitive Dysfunction and Dementia? Nutrients. 2018; 10(8): 1104. DOI: 10.3390/nu10081104

16. Grimm MOW, Thiel A, Lauer AA, et al. Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation. Int J Mol Sci. 2017; 18(12): 2764. DOI: 10.3390/ijms18122764

17. Sultan S, Taimuri U, Basnan SA, et al. Low Vitamin D and Its Association with Cognitive Impairment and Dementia. J Aging Res. 2020; 2020: 6097820. DOI: 10.1155/2020/6097820

18. Sommer I, Griebler U, Kien C, et al. Vitamin D de ciency as a risk factor for dementia: a systematic review and meta-analysis. BMC Geriatr. 2017; 17(1): 16. DOI: 10.1186/s12877-016-0405-0

19. Isnuwardana R, Bijukchhe S, Thadanipon K. et al. Association Between Vitamin D and Uric Acid in Adults: A Systematic Review and Meta-Analysis. Horm Metab Res. 2020; 52(10): 732–741. DOI: 10.1055/a-1240-5850 

20. Peng H, Li H, Li C, et al. Association between vitamin D insu ciency and elevated serum uric acid among middle-aged and elderly Chinese Han women. PLoS One. 2013; 8(4): e61159. DOI: 10.1371/journal.pone.0061159

21. Sipahi S, Acikgoz SB, Genc AB, et al. The Association of Vitamin D Status and Vitamin D Replacement Therapy with Glycemic Control, Serum Uric Acid Levels, and Microalbuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease. Med Princ Pract. 2017; 26(2): 146-151. DOI: 10.1159/000454952

22. Chen W, Roncal-Jimenez C, Lanaspa M, et al. Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. Metabolism. 2014; 63(1):150-160. DOI: 10.1016/j. metabol.2013.09.018

23. Thakkinstian A, Anothaisintawee T, Chailurkit L, et al. Potential causal associations between vitamin D and uric acid: Bidirectional mediation analysis. Sci Rep. 2015; 5: 14528. DOI: 10.1038/srep14528

 

UDC: 618.3: 615.838

DOI: 10.20969/VSKM.2023.16(4).71-77

PDF download SPA AND RESORT POSSIBILITIES IN REPRODUCTIVE HEALTH RECOVERY IN PATIENTS WITH EARLY GESTATIONAL LOSSES

YAVORSKAYA SVETLANA D., ORCID ID: 0000-0001-6362-5700; D. Med. Sci, professor of the Department of Obstetrics and Gynecology of Altai State Medical University, 656038, The Russian Federation, Altai Region, Barnaul, 9 Molodezhnaya str., tel.: +7 (962) 792-79-42, e-mail: L2001@bk.ru

REMNEVA OLGA V., ORCID ID: 0000-0002-5984-1109; D. Med. Sci., professor, head of the Department of Obstetrics and Gynecology of Altai State Medical University, 656038, The Russian Federation, Altai Region, Barnaul,154 Fomina str., tel.: +7 (913) 250-02-80, e-mail: rolmed@yandex.ru

CHERNOVA ANASTASIYA E., ORCID ID: 0000-0002-0598-6396; postgraduate student of the Department of Obstetrics and Gynecology of Altai State Medical University, 656038, The Russian Federation, Altai Region, Barnaul, 9 Molodezhnaya, 9, tel.: + 7 (905) 080-78-07, е-mail: anastasiya.chernova.1993@mail.ru

DMITRIENKO KSENIYA V., ORCID ID: 0000-0003-0886-4471; C. Med. Sci., associate professor of the Department of Obstetrics and Gynecology of Altai State Medical University, 656038, The Russian Federation, Altai Region, Barnaul, 9 Molodezhnaya str., tel.: +7 (962) 810-17-52, e-mail: tishovakseni@mail.ru

PETROV ANDREY V., ORCID ID: 0000-0002-8732-5291; obstetrician-gynecologist of the highest quali cation category of Spa and Resort «Altai Castle», 659900, The Russian Federation, Altai Region, Belokurikha, 29 Slavskogo str., tel.: +7(903) 911-98-12, e-mail: pav030661@yandex.ru

GREBTSOV IVAN V., ORCID ID: 0000-0001-7658-9243; pathologist of Altai Regional Oncological Hospital, 656045, The Russian Federation, Altai Region, 110 Zmeinogorsky tract, tel.: + 7 (923) 644-34-77, e-mail: grebtsov.ivan@gmail.com

Abstract. Introduction. Early pregnancy loss is still an unresolved problem in obstetric and gynecology. The pathogenesis is based on the comorbidity of pathological factors such as subclinical hormonal, immune, psychoneurotic disorders and endometrial pathology. It requires complex rehabilitation pregnancy planning programs for such patients. Aim. Aim of research is to optimize treatment and rehabilitation measures in patients with the history of early pregnancy lost using the Belokurikha’s spa and resort clusters. Material and methods. 79 patients with early reproductive lost history underwent a course of medical and rehabilitation treatment in the «Altai Castle» spa and resort (Belokurikha, Altai Region). Complex spa treatment included climatotherapy and combination of various methods: balneo-, peloid-, physiotherapy and a prolonged course of herbal medicine. Results and discussion. Women with a history of early pregnancy loss had signi cant improvement in physical and mental health, ultrasound chronic endometritis markers were decreased. The rst year onset pregnancy occurred in 70.9% after rehabilitation and most of them (92.8%) delivered at term. Proposed rehabilitation program is highly e cient due to the multidirectional potentiating action of natural factors that have powerful immunomodulatory, anti-in ammatory and regenerating e ects. Conclusion. A complex rehabilitation program for patients with a history of early pregnancy lost in Belokurikha’s spa and resort with a prolonged course of herbal medicine helps to make rapid psychosomatic and reproductive health recovery.

Key words: early pregnancy loss, health resort, herbal medicine.

For reference: Yаvorskaya SD, Remneva OV, Cрernova AE, et al, Spa and resort possibilities in reproductive health recovery in patients with early gestational losses. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 71-77.DOI: 10.20969/VSKM.2023.16(4).71-77.

References

Литература

  1. Концепция демографической политики РФ на период до 2025 г. (утв.Указом Президента РФ от 9 октября 2007 г. No 1351) (дата обращения: 05.11.2022) [Koncepciya demogra cheskoj politiki RF na period do 2025 g. (utv. Ukazom Prezidenta RF ot 9 oktyabrya 2007 g. No 1351) [The concept of the Russian Federation demographic policy for the period up to 2025 year (approved Decree of the President of the Russian Federation of 9 October, 2007, No 1351)] https://base. garant.ru/191961/53f89421bbdaf741eb2d1ecc4ddb 4c33/#friends/ data obrashcheniya [date of request]: 05.11.2022 (In Russ.)].
  2. Fossé NA, Hoorn MP, Lith JM, et al. Advance paternal age is associated with an increased risk of spontaneous miscarriage: a systematic review and meta-analysis. Hum Reprod Update. 2020; 26(5):650-669. DOI: 10.1093/humupd/dmaa010
  3. Ravel J, Moreno I, Simo C. Bacterial vaginosis and its association with infertility, endometritis, and pelvic in ammatory disease. Am J Obstet Gynecol. 2021; 224(3): 251-257. DOI: 10.1016/j.ajog.2020.10.019
  4. Vitagliano A, Noventa M, Gizzo S. Autoimmunity, systemic in ammation, and their correlation with repeated implantation failure and recurrent miscarriage: Is chronic endometritis the missing piece of the jigsaw? Am J Reprod Immunol. 2017; 77(1): 116-121. DOI: 10.1111/aji.12597
  5. Vitagliano A, Saccardi C, Litta PS, et al. Chronic endometritis: Really so relevant in repeated IVF failure? Am J Reprod Immunol. 2017; 78(6). DOI: 10.1111/ aji.12758
  6. Bruce K, Young BK. A multidisciplinary approach to pregnancy loss: the pregnancy loss prevention center. J Perinat Med. 2018; 47(1): 41-44. DOI: 10.1515/jpm-2018-0135
  7. Радзинский В.Е., Оразмурадов А.А. Беременность ранних сроков. От прегравидарной подготовки к здоровой гестации. Изд. 3-е, перераб. и доп. М.: StatusPraesens, 2020; 800. [Radzinskiy VE, Orazumuradov AA, Abramov AU. Early gestational ages pregnancy. From pregnancy planning to health gestation. 3-rd ed. [Beremennost’ rannih srokov. Ot pregravidarnoj podgotovki k zdorovoj gestacii]. M.: StatusPraesens. 2020; 800. (In Russ.)]. https://kingmed. info/media/book/5/4690.pdf
  8. Alonso L, Carungo J. Chronic Endometritis: Three-dimensional ultrasound and hysteroscopy correlation. Journal of minimally invasive gynecology. 2020; 27(5): 993-994. DOI: 10.1016/j.jmig.2019.08.028
  9. Murdock TA, Veras EFT, Kurman RJ, Mazur MT. Diagnosis of endometrial biopsies and curretings. Springer. 2019; 3: 199. DOI: 10.1007/978-3-319-98608-1
  10. W. Glenn McCluggage. Benign Diseases of the Endometrium. Blaustein’s Pathology of the Female Genital Tract. 2011; 305–358 DOI:10.1007/978-1-4419-0489-8_7
  11. Джабарова Н.К., Яковенко Э.С., Сидорина Н.Г. и др. Перспективы развития Белокурихинской курортной зоны Алтайского края // Вопросы курортологии, физиотерапии и лечебной физической культуры. – 2016. – Т.93, вып.2. – С.43-47. [Dzhabarova NK, Iakovenko S, Sidorina NG, et al. Perspektivy razvitiya Belokurikhinskoy kurortnoy zony Altayskogo kraya [The prospects for the further development of the Belokurikha spa and health resort territory in the Altai region]. Voprosy kurortologii, zioterapii, i lechebnoi zicheskoi kultury [Questions of balneology, physiotherapy and therapeutic physical culture]. 2016; 93(2): 43-47. (In Russ.)]. DOI: 10.17116/ kurort2016243-47
  12. Патент No2408397 Российская Федерация, МПК A61M 21/00(2006.01). Способ формирования аудиорядов музыки для музыкотерапии: 2009136016/14: заявл. 29.09.2009: опубл. 10.11.2011 / Анисимов Б.Н. – 5 c.: ил.- Текст: непосредственный [Patent No2408397 Rossiyskaya Federatsiya, MPK A61M 21/00(2006.01). Sposob formirovaniya audioryadov muzyki dlya muzykoterapii [A method of forming audio sequences of music for music therapy]: 2009136016/14:13.zayavl. 29.09.2009: opubl. 10.11.2011 / Anisimov BN. – 5 c.: ill. - Tekst: neposredstvennyy. (In Russ.)].
  13. Патент No25500930 Российская Федерация, МПК A61H 9/00(2006.01). Устройство для проведения гидродинамического массажа и способ его использования: 2014106766/14: заявл. 24.02.2014: опубл. 20.05.2015 / Анисимов Б.Н., Курочка С.П., Карбышева Н.В. и др. – 7 с.: ил.Текст: непосредственный [Patent No25500930 Rossiyskaya Federatsiya, MPK A61H 9/00(2006.01). Ustroystvo dlya provedeniya gidrodinamicheskogo massazha i sposob ego ispol’zovaniya [A device for hydrodynamic massage and the method of its use]: 2014106766/14: zayavl. 24.02.2014: opubl. 20.05.2015 / Anisimov BN, Kurochka SP, Karbysheva NV i dr. – 7 s.: ill. - Tekst: neposredstvennyy. (In Russ.)].
  14. Разумов А.Н., Пурига А.О., Юрова О.В. Современные возможности радонотерапии в медицинской реабилитации пациентов // Вопросы курортологии, физиотерапии и лечебной физической культуры. – 2015. – Т.92, вып.4. – С. 54-60. [Razumov AN, Puriga AO, Yurova OV. Sovremennye vozmozhnosti radonoterapii v meditsinskoy reabilitatsii patsientov [The modern applications of radon therapy for the medical rehabilitation of the patients]. Voprosy kurortologii, zioterapii i lechebnoj zicheskoj kul’tury [Questions of balneology, physiotherapy and therapeutic physical culture]. 2015; 92 (4): 54-60. (In Russ.)]. DOI: 10.17116/ kurort2015454-60
  15. Пономаренко Г.Н. Физическая и реабилитационная терапия // Национальное руководство. Геотар-Медиа. – 2016. – C.164-172. [Ponomarenko GN. Fizicheskaya i reabilitatsionnaya terapiya [Physical and Rehabilitation Therapy]. Natsional’noe rukovodstvo [National guide]. Geotar-Media. 2016; 164-172. (In Russ.)].
  16. Açma A., Carrat F., Hejblum G. Comparing SF-36 Scores collected through Web-Based Questionnaire Self-completions and Telephone Interview: An Ancillary study of SENTIPAT Multicenter Randomized Controlled Trial. J Med Internet Res. 2022. 24(3): e29009. DOI: 10.2196/29009
  17. Румянцев П.О., Саенко У.В., Румянцева У.В. Статистические методы анализа в клинической практике. Часть I. Одномерный статистический анализ. Проблемы Эндокринологии. – 2009. – Т. 55, вып.5 – С. 48-55. [Rumanzev PO, Saenko UV, Rumanzeva UV. Statisticheskie metody analiza v klinicheskoj praktike. CHast’ I. Odnomernyj statisticheskij analiz [Analysis statistical methods in clinical practice. Part I. Univariate statistical analysis]. Problemy Endokrinologii [Problems of Endocrinology]. 2009; 55(5): 48-55 (In Russ.)]. DOI: 10.14341/probl200955548-55
  18. Reshetnikov E.A., Ponomarenko I.V., Chursov M.I. Menarche age in Russian women is associated with the ESR2 candidate gene. Gene. 2019;20 (686):228-236 doi: 10.1016/j.gene.2018.11.042.

  19. Амирджанова В.Н. Популяционные показатели качества жизни по опроснику SF-36 (результаты многоцентрового исследования качества жизни «Мираж»). Научно-практическая ревматология. – 2008 – Т. 46, вып.1. – С. 36-48. [Amirjdanovа VN. Population indicators of quality of life according to the SF-36 questionnaire (results of the Mirage multicenter study of quality of life) [Populyacionnye pokazateli kachestva zhizni po oprosniku SF-36 (rezul’taty mnogocentrovogo issledovaniya kachestva zhizni «Mirazh»)]. Scienti cand practical rheumatology [Nauchno-prakticheskaya
    revmatologiya.]. 2008; 46 (1): 36-48 (In Russ.)].

  20. Макарова О.Г., Мазко О.Н., Голубенко Ю.В. Лечебные грязи как биоресурсы Алтайского края. Бюллетень медицинской науки. – 2018 – Т. 2, вып.10. – С. 16-19. [Makarova OG, Mazko ON, Golubenko UV. Lechebnye gryazi kak bioresursy Altayskogo kraya [Therapetic mugs as bioresourses of Altay region]. Byulleten’ meditsinskoy nauki [Bulletin of Medical Science]. 2018; 2 (10): 16-19 (In Russ.)].

  21. Hofmann W, Lettner H, Hubmer A. Dosimetric Comparison of Exposure Pathways to Human Organs and Tissues in Radon Therapy. Int J Environ Res Public Health. 2021; 18(20): 10870. DOI: 10.3390/ ijerph182010870

  22. Кречетова Л.В., Тетруашвили Н.К., Вторушина В.В., и др. Динамика субпопуляционного состава лимфоцитов периферической крови в первом триместре беременности у женщин с привычным выкидышем на фоне проведения иммуноцитотерапии. Акушерство и гинекология. – 2015 – Т. 6. – С. 59-66. [Krechetova LV, Tetruashvili NK, Vtorushina VV et al. Dinamika subpopulyacionnogo sostava limfocitov perifericheskoj krovi v pervom trimestre beremennosti u zhenshchin s privychnym vykidyshem na fone provedeniya immunocitoterapii [Dynamics of the subpopulation composition of peripheral blood lymphocytes in the rst trimester of pregnancy in women with recurrent miscarriage during immunocytotherapy]. [Akusherstvo i ginekologiya Obstetrics and gynecology]. 2015; 6: 59-66 (In Russ.)]. DOI: 10.1134/S0006297920050077

  23. Ткаченко Л.В., Линченко Н.А., АндрееваМ.В., Шевцова Е.П. Особенности комплексной прегравидарной подготовки женщин с привычным невынашиванием беременности инфекционного генеза. Вестник ВолГМУ. – 2022 – Т. 1. [Tkachenko LV, Linchenko NA, Andreeva MV, Shevzova EP. Osobennosti kompleksnoj pregravidarnoj podgotovki zhenshchin s privychnym nevynashivaniem beremennosti infekcionnogo geneza [Complex planing pregnancy preparation in woman with recurrent pregnancy lost with infectious etiology]. Vestnik VolGMU. 2022; 1. (In Russ.)]. URL: https://cyberleninka. ru/article/n/osobennosti-kompleksnoy-pregravidarnoy-podgotovki-zhenschin-s-privychnym-nevynashivaniem-beremennosti-infektsionnogo-geneza

 

REVIEWS

UDC 618.11-006.55

DOI: 10.20969/VSKM.2023.16(4).78-82

PDF download ON THE RISKS OF MALIGNISATION OF OVARIAN ENDOMETRIOMAS

GABIDULLINA RUSHANIA I., ORCID ID: 0000-0002-7567-6043; Scopus AU-ID 57215670415, D. Sci (Med.), D. Med. Sci, Professor of the Department of Obstetrics and Gynecology named after prof. V.S. Gruzdev, Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. +7-917-28-99-310, e-mail: ru.gabidullina@yandex.ru

MINNULLINA FARIDA F., , ODCID ID: 0000-0001-8270-085x, C. Med. Sci, associate professor of the department of obstetrics and gynecology of Institute of Biology and Fundamental Medicine of Kazan Federal University, Russia, 420012, Kazan, Karl Marx Str., 74, head of the gynecological department of the State Clinical Hospital No. 7, Russia, 420103, Kazan, Marshal Chuikov street, 54, tel.: +7(987)233-04-78, e-mail: minnullina_f@mail.ru

AKHMETOVA DINARA I., ORCID ID: 0009-0000-9612-454X, assistant professor of the Department of Obstetrics and gynecology named after prof. V.S. Gruzdev, Kazan State Medical University, 420012 Russia, Kazan, Butlerova Str., 49, obstetrician-gynecologist of the State Clinical Hospital No. 7, Russia, 420103, Kazan, Marshal Chuikov street, 54tel. +79172531578, e-mail: dinara.akhmetova.2496@mail.ru

ZARIPOVA ALIYA SH., ORCID ID 0000-0002-2701-319X, postgraduate student of the Department of Obstetrics and Gynecology named after V.S. Gruzdev, Kazan State Medical University, 420012 Russia, Kazan, Butlerova Str., 49, tel. +7-917-25-05-070, e-mail: zaripovaash@yandex.ru

ZIDIHANOVA KAMILYA I. ORCID ID 0009-0006-3349-1573 resident of the Department of Obstetrics and gynecology named after prof.V.S. Gruzdev, Kazan State Medical University, 420012 Russia, Kazan, Butlerova Str., 49, e-mail: kamilya.zidihanova@yandex.ru

ROOT DARYA A., ORCID ID 0009-0001-2214-536 student of the faculty of Medicine and Biology, Kazan State Medical University, 420012 Russia, Kazan, Butlerova Str., 49, e-mail: dariayaalexandrovna@mail.ru

Abstract. Introduction. Endometriosis is a widespread gynecological disease. In the last few years, new data have been accumulating con rming that endometriosis leads to an increased risk of malignant neoplasms of the ovaries, endometrium, breast and thyroid gland. The most commonly found form of endometriosis is endometrioma. Objective:to analyze epidemiological and genetic studies of the risks of neoplastic transformation of ovarian endometriomas based on search results in electronic resources MEDLINE, EMBASE, Elibrary from 2012 to 2023. Results. Epidemiological and genetic studies have proven the risk of malignancy of endometriosis with the development of ovarian cancer related to endometriosis. Studies con rmed, that two histotypes of epithelial ovarian cancer, such as clear-cell and endometrioid cancer, most closely related to endometriosis. Genome-wide association studies (GWAS) have con rmed the risk of endometrial cancer in women with endometriosis, which was shown earlier than epidemiological studies. Finding the genes and pathways underlying these complex diseases is an essential step toward developing better diagnostic and therapeutic tools. Conclusion. The review presents epidemiological and genetic evidence of the risks of ovarian cancer and endometrial cancer in women with endometriosis.

Keywords: endometriosis, endometrioma, ovarian cancer, endometrial cancer, genetic association.

For reference: Gabidullina RI, Minnullina FF, Akhmetova DI, et al. On the risks of malignisation of ovarian endometriomas. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 78-82. DOI: 10.20969/VSKM.2023.16(4).78-82.

References

  1. Younis JS. Endometriosis-Associated Ovarian Cancer: What Are the Implications for Women with Intact Endometrioma Planning for a Future Pregnancy? A Reproductive Clinical Outlook. Biomolecules. 2022;12(11):1721. DOI: 10.3390/biom12111721

  2. Samartzis EP, Labidi-Galy SI, Moschetta M, et al. Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review. Ann Transl Med. 2020;8(24):1712. DOI: 10.21037/atm-20-3022a

  3. Гаспарян С.А., Василенко И.А., Попова О.С., Лифенко Р.А. Эндометриома: новая парадигма диагностики и лечебной тактики // Проблемы репродукции. - 2019. - No25(6). -С.78-85. [Gasparyan SA, Vasilenko IA, Popova OS, Lifenko RA. Endometrioma: novaya paradigma diagnostiki i lechebnoj taktiki [Endometrioma: a new paradigm of diagnostics and therapeutic tactics]. Problemy Reproduktsii [Russian Journal of Human Reproduction]. 2019;25(6):78-85. (In Russian)]. DOI: 10.17116/repro20192506178

  4. Давыдов А.И., Михалёва Л.М., Хабарова М.Б., и др. Эндометриоидная цистаденома – глубокий яичниковый эндометриоз // Вопросы гинекологии, акушерства и перинатологии. - 2022. - No21(3). - С.130–137. [Davydov AI, Mikhaleva LM, Khabarova MB, et al. Endometrioidnaya cistadenoma – glubokij yaichnikovyj endometrioz [Endometrioid cystadenoma – deep ovarian endometriosis]. Voprosy ginekologii, akusherstva i perinatologii [Gynecology, Obstetrics and Perinatology]. 2022; 21(3): 130–137. (In Russian)]. DOI: 10.20953/1726-1678-2022-3-130-137

  5. Ярмолинская М.И., Ревенко А.С., Денисова А.С. Наружный генитальный эндометриоз и риски малигнизации // Эффективная фармакотерапия. - 2022. - No18(24).-С.30–37. [Yarmolinskaya MI, Revenko AS, Denisova AS. Naruzhnyj genital’nyj endometrioz i riski malignizacii [Malignancy Risk Associated with Genital Endometriosis]. Эффективная фармакотерапия [E ektivnaya farmakoterapiya]. 2022; 18 (24): 30–37. (In Russian)]. DOI: 10.33978/2307-3586-2022-18-24-30-37

  6. Chen LH, Lo W, Huang HY, Wu HM. A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment. Int J Mol Sci. 2023; 24(8): 7503. DOI: 10.3390/ijms24087503

  7. Адамян Л.В., Мартиросян Я.О., Асатурова А.В. Эндометриоз и канцерогенез яичников (обзор литературы) // Проблемы репродукции. - 2018. – No24(4). - С.7-12. [Adamyan LV, Martirosyan YO, Asaturova AV. Endometrioz i kancerogenez yaichnikov (obzor literatury) [Endometriosis and cancerogenesis of the ovaries (a review)]. Problemy reprodukcii [Russian Journal of Human Reproduction]. 2018;24(4):7-12. (In Russian)]. DOI: 10.17116/repro2018240417

  8. Kvasko M., Mahamat-Saleh Y., Farland L.V. et al. Endometriosis and cancer: A systematic review and meta-analysis. Hum Reprod Update. 2021;27(2):393-420. DOI: 10.1093/humupd/dmaa045.

  9. Sampson JA. Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch Surg 1925;10:1-72. DOI: 10.1001/archsurg.1925.01120100007001

  10. Vercellini P, Vigano P, Buggio L, et al. Perimenopausal management of ovarian endometriosis and associated cancer risk: When is medical or surgical treatment indicated? Best Pract Res Clin Obstet Gynaecol 2018;51:151-68. DOI: 10.1016/j.bpobgyn.2018.01.017

  11. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012;13:385-94. DOI: 10.1016/ S1470-2045(11)70404-1.

  12. Hermens M, van Altena AM, Nieboer TE et al. Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis. The ENOCA population-based cohort study. Am J Obstet Gynecol 2020;223:107.e1-107.e11. DOI: 10.1016/j.ajog.2020.01.041

  13. Park HK, Ruterbusch JJ, Cote ML. Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes. Cancer Epidemiol Biomarkers Prev 2017;26:1511-8. DOI: 10.1158/1055-9965.EPI-17-0290

  14. Thomsen LH, Schnack TH, Buchardi K. et al. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. Acta Obstet Gynecol Scand 2017;96:761-78. DOI:10.1111/aogs.13010

  15. Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet 2019;393:1240-53. DOI:10.1016/S0140-6736(18)32552-2

  16. Shinmura H., Yoneyama K., Harigane E. et al. Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma. Int. J. Gynecol Cancer 2020;30(6):831-836. DOI: 10.1136/ijgc-2020-001210.

  17. Lu Y, Cuellar-Partida G, Painter JN, Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Hum Mol Genet. 2015 Oct 15;24(20):5955-64. DOI: 10.1093/hmg/ddv306.

  18. Mortlock S, Corona RI, Kho PF et al. A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes. Cell Rep Med. 2022;3(3):100542. DOI: 10.1016/j. xcrm.2022.100542.

  19. Zondervan KT, Becker CM, Koga K, et al. Endometriosis. Nat. Rev. Dis. Primers. 2018;4:9. DOI: 10.1038/s41572-018-0008-5

  20. Sun Y, Liu G. Endometriosis-associated Ovarian Clear Cell Carcinoma: A Special Entity? J Cancer. 2021; 12(22): 6773–6786. DOI: 10.7150/jca.61107

  21. Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: Clinical challenges and novel innovations. Lancet. 2021;397:839–852. DOI: 10.1016/ S0140-6736(21)00389-5.

  22. Berns K, Caumanns JJ, Hijmans EM, et al. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene 2018;37:4611-25. DOI:10.1038/s41388-018-0300-6

  23. Khalique S, Lord CJ, Banerjee S, et al. Translational genomics of ovarian clear cell carcinoma. Semin Cancer Biol 2020;61:121-31. DOI:10.1016/j. semcancer.2019.10.025

  24. Taylor SE, Chu T, Elvin JA, et al. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol 2020;156:32-7. DOI:10.1016/j.ygyno.2019.10.029

  25. Mogensen JB, Kjaer SK, Mellemkjaer L, and Jensen A. Endometriosis and risks for ovarian, endometrial and breast cancers: a nationwide cohort study. Gynecol. Oncol. 2016; 143:87–92. DOI: 10.1016/j. ygyno.2016.07.095

  26. Yu HC, Lin CY, Chang WC, et al. Increased association between endometriosis and endometrial cancer: a nationwide population based retrospective cohort study. Int. J. Gynecol. Cancer 2015;25:447–452. DOI: 10.1097/ IGC.00000000000000384

  27. Painter JN, O’Mara TA, Morris AP, et al. Genetic overlap between endometriosis and endometrial cancer: Evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med. 2018;7:1978–1987. DOI: 10.1002/cam4.1445.

  28. McKinnon BD, Kocbek V, Nirgianakis K, et al. Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics. Hum. Reprod Update 2016;22(3):382-403. DOI: 10.1093/humupd/dmv060.

  29. Prather GR, MacLean JA. 2nd, Shi M., Boadu D. K., et al. Niclosamide as a potential nonsteroidal therapy for endometriosis that preserves reproductive function in an experimental mouse model. Biol. Reprod. 2016;95(4):76. DOI: 10.1095/biolreprod.116.140236.

  30. Huang KJ, Li YX, Wu CJ, et al. Sonographic features di erentiating early-stage ovarian clear cell carcinoma from endometrioma with atypical features. J. Ovarian Res. 2022;15:84. DOI: 10.1186/s13048-022-01019-8

 

UDC: 616.1

DOI: 10.20969/VSKM.2023.16(4).83-89

PDF download PREDICTORS OF CORONARY IN-STENT RESTENOSIS

ENIKEEVA ALINA M., ORCID ID: 0000-0002-5588-0928, postgraduate student of the Department of Internal Medicine of the Bashkir State Medical University, Russia, 143350, Ufa, Lenina str., 3, e-mail: a.zalaldinovamd@yandex.ru

GAZIZOVA LYUTSIYA YU., ORCID ID: 0000-0002-5005-7190, doctor of the Department of Cardiology of Republic Cardiological Centre, Russia, 450106, Ufa, Kuvykina str., 96, e-mail: gazizoval89@mail.ru

GAREEVA DIANA F., ORCID ID: 0000-0002-1874-8661, C. Med. Sci, associate professor of the Department of Department of Internal Medicine of the Bashkir State Medical University, Russia, 143350, Ufa, Lenina str., 3, e-mail: d.f.gareeva@mail.ru

RAKHIMOVA ROZANA F., ORCID ID: 0000-0002-2958-616X, postgraduate student of the Department of Internal Medicine of the Bashkir State Medical University, Russia, 143350, Ufa, Lenina str., 3, tel. – 8-987-054-39-04, e-mail: R.r-7@mail.ru

AMINEVA ALLA M., ORCID ID: 0000-0002-1180-1335, postgraduate student of the Department of Internal Medicine of the Bashkir State Medical University, Russia, 143350, Ufa, Lenina str., 3, e-mail amineva03@yandex.ru

BUZAEV IGOR V., ORCID ID: 0000-0002-6716-4048, D. Med. Sci, professor of the Department of surgical disciplines of the Bashkir State Medical University, Russia, 143350, Ufa, Lenina str., 3, e-mail: igor@buzaev.com

ZAGIDULLIN NAUFAL SH., ORCID ID: 0000-0003-2386-6707, D. Med. Sci, professor, the Head of the Department of Internal Medicine of the Bashkir State Medical University, Russia, 143350, Ufa, Lenina str., 3, e-mail: znaufal@mail.ru

Abstract. Introduction. Cardiovascular disease has been the leading cause of death and disability worldwide for many years. The widespread use of percutaneous coronary intervention has signi cantly improved clinical outcomes in patients with cardiovascular diseases. However, in ammatory reactions that occur in response to mechanical stretch, endothelial exposure and subintimal hemorrhage play a key role, triggering a cascade of proliferative processes leading to neointimal hyperplasia and restenosis. Aim. Aim of this review was to study the known mechanisms of coronary restenosis and to search possible new risk factors for in-stent restenosis. Material and methods. A review of current medical publications in PubMed, MedLine, Google Scholar, ScienceDirect was carried out. Search coverage included articles published from 1993 to 2021. Results and discussion. Risk factors for restenosis have been shown, such as genetic, mechanical (under exploitation, fracture, excessive dilatation, polymer damage), high level of systemic in ammation. In addition, it has been shown that vitamin D de ciency can also be a risk factor for atherosclerosis and immune in ammation. Conclusion. The in-stent restenosis is an actual problem. Incidence of in-stent restenosis has been reported in up to 10% after percutaneous coronary intervention. Multiple mechanical, genetic and in ammatory factors might contribute to in-stent restenosis. In recent years, serum levels of NT-proBNP, pentraxin-3, vitamin D have been studied as restenosis risk factors. Further research of this subject may allowed to develop methods for preventing this complication.

Keywords: neoatherosclerosis, neointimal hyperplasia, restenosis, vitamin D, vitamin D receptor.

For reference: Enikeeva AM, Gazizova LYu, Gareeva DF, at all. Predictors of coronary in-stent restenosis. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 83-89. DOI: 10.20969/VSKM.2023.16(4).83-89.

References

1. Карпов Ю. А., Сорокин Е. В. Стабильная ишемическая болезнь сердца: стратегия и тактика лечения. 2-е изд., перераб. и доп.// Москва: Медицинское информационное агентство, 2012. - 271 с. [Karpov YuA, Sorokin EV. Stabil’naya ishemicheskaya bolezn’ serdtsa: strategiya i taktika lecheniya. 2-ye izd. pererab. i dop. [Stable ischemic heart disease: strategy and tactics of treatment. 2nd ed., Revised and enlarged]. Moskva: Meditsinskoye informatsionnoye agentstvo [Moscow: Medical Information Agency]. 2012. – 271 p. (In Russ.)].

2. Карпов Ю. А., Кухарчук В. В., Лякишев А. и др. Диагностика и лечение хронической ишемической болезни сердца. Практические рекомендации // Кардиологический вестник. – 2015. – Т.13. вып.3. – С. 3-33. [Karpov YuA, Kukharchuk VV, Lyakishev A, et al. Diagnostika i lecheniye khronicheskoj ishemicheskoj bolezni serdtsa. Prakticheskiye rekomendatsii [Diagnosis and treatment of chronic ischemic heart disease. Practical advice]. Kardiologicheskij vestnik [Cardiological Bulletin]. 2015; 13(3):3-33. (In Russ.)]. DOI: 10.15829/29/1560-4071-2020-4076

  1. Stone G, Maehara A, Lansky A et al. A prospective natural - history study of coronary atherosclerosis. N.Engl.J.Med. 2011. 364 (3): 226-235. DOI: 10.1056/ NEJMoa1002358

  2. Ullrich H, Olschewski M, Münzel T, Gori T. Coronary In-Stent Restenosis: Predictors and Treatment. Dtsch Arztebl Int. 2021. 118(38): 637-644. DOI: 10.3238/ arztebl.m2021.0254

  3. Nakazawa G, Otsuka F, Nakano M et al. The pathology of neoatherosclerosis in human coronary implants bare- metal and drug-eluting stents. J. Am. Coll. Cardiol. 2011. 57:1314–1322. DOI: 10.1016/j.jacc.2011.01.011

  4. Shlofmitz E, Case BC, Chen Y et al. In-Stent Restenosis Classi cation: A Mechanism-Based Approach to the Treatment of Restenosis. Cardiovasc Revasc Med. 2021. Dec;33: 62-67. DOI: 10.1016/j.carrev.2021.06.004

  5. Kuntz R, Baim D. De ning coronary restenosis. Newer clinical and angiographic paradigms. Circulation. 1993. 88 (3): 1310–1323 DOI:/10.1161/01.CIR.88.3.1310

  6. Mehran R, Dangas G, Abizaid A et al. Angiographic patterns of in-stent restenosis: classi cation and implications for long-term outcome. Circulation, 1999. 100(18):1872–1884. DOI: 10.1161/01.cir.100.18.1872

  7. Alfonso F, Byrne R, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am. Coll. Cardiol. 2014. 63(24): 2659–2673. DOI:10.1016/j.jacc.2014.02.545

  8. Nakamura N, Torii S, Tsuchiya H et al. Formation of calci ed nodule as a cause of early in-stent restenosis in patients undergoing dialysis. J Am Heart Assoc. 2020. 9:e016595. DOI: /10.1161/JAHA.120.016595

  9. Егшатян Л.В., Мокрышева Н.Г. Эктопическая кальцификация при хронической болезни почек. Часть 1. Классификация и патогенез // Нефрология. – 2017. – Т. 21. вып. 4. – C. 30-39. [Egshatyan LV, Mokrysheva NG. Ektopicheskaya kal’tsi katsiya pri khronicheskoj bolezni pochek. Chast’ 1. Klassi catsiya i patogenez. [Ectopic calci cation in chronic kidney disease. Part 1. Classi cation and pathogenesis]. Nephrologiya [Nephrology]. 2017; 21(4): 30-39. (In Russ.)]. DOI:10.24884/1561-6274-2017-21-4-30-39

  10. Gоrriz J, Molina P, Cerverоn M et al. Vascular calci cation in patients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol. 2015. 10:654-666. DOI: 10.2215/ CJN.07450714

  11. Nasrallah M, El-Shehaby A, Salem M et al. Fibroblast growth factor-23 is independently correlated to aortic calci cation in haemodialysis patients. Nephrol Dial Transplant. 2010. 25: 2679-2685. DOI: 10.1093/ndt/ gfq089

  12. Monraats P, Pires N, Agema W et al. Genetic infammatory factors predict restenosis after percutaneous coronary interventions. Circulation. 2005. 112:2417–2425. DOI:10.1096/fj.05-4634com

  13. Dangas G, Claessen B, Caixeta A et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010. 56:1897–1907. DOI:10.1016/j.jacc.2010.07.028

  14. Aoki J, Nakazawa G, Tanabe K et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv. 2007. 69:380–386. DOI: 10.1002/ccd.20950

  15. Aoki J, Tanabe K, Hoye A et al. Mechanisms of drug-eluting stent restenosis. Cardiovasc Intervention and Therapeutics. 2021. 36: 23-29. DOI:10.1007/s12928-020-00734-7

18. Wiemer M, Butz T, Schmidt W et al. Scanning electron microscopic analysis of di erent drug-eluting stents after failed implantation: from nearly undamaged to major damaged polymers. Catheter Cardiovasc Interv. 2010. 75:905–11. DOI: 10.1002/ccd.22347

19. Hamon M, Bauters C, McFadden E et al. Restenosis after coronary angioplasty. Eur Heart J., 1995. 16(Suppl I):33–48. DOI: 10.1007/s11936-001-0066-x

20. Jukema J, Verschuren J, Ahmed T, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol. 2011. 9:53–62. DOI: 10.1038/ nrcardio.2011.132

21. Huang S, Houghton P. Mechanisms of resistance to rapamycins. Drug Resist Updat. 2001. 4:378–91. DOI: 10.1054/drup.2002.0227

22. Costa M, Simon D. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005. 111:2257–73. DOI: 10.1161/01.CIR.0000163587.36485.A7

23. Orr G, Verdier-Pinard P, McDaid H, Horwitz S. Mechanisms of taxol resistance related to microtubules. Oncogene. 2003. 22:7280–7295. DOI: 10.1038/ sj.onc.1206934

24. Yusuf R, Duan Z, Lamendola D et al. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003. 3:1–19. DOI: 10.2174/1568009033333754

25. Niccoli G, Montone RA, Ferrante G, Crea F. The evolving role of infammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol. 2010. 56:1783– 1793. DOI: 10.1016/j.jacc.2010.06.045

26. Park D, Lee C, Yun S et al. Prognostic impact of preprocedural C-reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drugeluting stent implantation. Heart. 2007. 93:1087– 1092. DOI: 10.1136/hrt.2006.099762

27. Aoki J, Nakazawa G, Tanabe K et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv. 2007. 69:380–6. DOI: 10.1002/ccd.20950

28. Aoki J, Tanabe K, Hoye A, et al. Mechanisms of drug-eluting stent restenosis. Cardiovasc Intervention and Therapeutics. 2020. 36(1):23-29. DOI: 10.1007/s12928-020-00734-7

29. Yahagi K, Otsuka F, Virmani R et al. Neoatherosclerosis: mirage of an ancient illness or genuine disease condition? Eur Heart J. 2015. 36: 2136-8. DOI:10.1093/ eurheartj/ehv223

30. Мазаев В.П., Комков А.А., Рязанова С.В. Клиническое состояние и факторы сердечно-сосудистого риска как отражение неоатеросклероза в стентированных коронарных артериях при позднем развитии рестенозов // Кардиоваскулярная терапия и профилактика. – 2016. – 15(5). – C. 64-69. [Mazaev VP, Komkov AA, Ryazanova SV. Klinicheskoye sostoyaniye i faktory serdechno-sosudistogo riska kak otrazheniye neoateroskleroza v stentirovannyh koronarnyh arteriyah pri pozdnem razvitii restenozov [Clinical condition and cardiovascular risk factors displaying neoatherosclerosis in stented coronary arteries with developing restenosis]. Kardiovaskul’arnaya terapiya i pro laktika [Cardiovascular Therapy and Prevention]. 2016; 15(5): 64-69. (In Russ.)]. DOI: 10.15829/1728-8800-2016-5-64-69

31. Ионова Ж.И., Сергеева Е.Г., Беркович О.А. Генетические и эпигенетические факторы, регулирующие экспрессию и функционирование рецептора витамина D у больных ишемической болезнью сердца // Российский кардиологический журнал. – 2021. – Т. 26. вып. 1S. –С. 4251. [Ionova ZI, Sergeeva EG, Berkovich OA. Geneticheskiye i epigeneticheskiye factory, reguliruyushchiye ekspressiyu i funktsionirovaniye retseptora vitamina D u bol’nyh ishemicheskoj bolezn’yu serdtsa [Genetic and epigenetic factors regulating the expression and function of the vitamin D receptor in patients with coronary artery disease]. Rossiyskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2021; 26(1S): 4251. (In Russ.)]. DOI: 10.15829/1560-4071-2021-4251

32. Martinez-Moreno J, Herencia C, Montes de Oca A et al. Cardiomyocyte-Speci c Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells. FASEB J., 2016. 30(3):1367-76. DOI: 10.1096/fj.15-272872

33. Valcheva P, Cardus A, Panizo S. Lack of vitamin D receptor causes stress-induced premature senescence in vascular smooth muscle cells through enhanced local angiotensin-II signals. Atherosclerosis, 2014; 235(2): 247-55. DOI: 10.1016/j.atherosclerosis.2014.05.911

34. Yao T, Ying X, Zhao Y et al. Vitamin D receptor activation protects against myocardial reperfusion injury through inhibition of apoptosis and modulation of autophagy. Antioxid Redox Signal, 2015; 22; 8:633-50. DOI: 10.1089/ars.2014.5887

35. Tay H, Yeap W, Dalan R et al. Increased monocyte-platelet aggregates and monocyte-endothelial adhesion in healthy individuals with vitamin D de ciency. Faser J., 2020; 34(8):11133-42. DOI: 10.1096/fj.202000822R

 

UDC: 616.151.5:616.5-002.525.2

DOI: 10.20969/VSKM.2023.16(4).90-96

PDF download MECHANISMS OF THROMBO-INFLAMMATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

ISMAGILOVA REZIDA R., ORCID ID: 0000-0002-4653-7247, Scopus Author ID: 57216770383; Assistant Professor of the General Hygiene department, Kazan State Medical University, Russia, 420012, Republic of Tatarstan, Kazan, Butlerova str. 49, phone: 8-917-884-80-68, e-mail: rezida.ismagilova@kazangmu.ru

MAKSUDOVA ADELYA N., ORCID ID: 0000-0003-4237-4695, Scopus Author ID: 56480616300; D. Med. Sci, Professor of the Department of Advanced Internal Medicine, Kazan State Medical University, Russia, 420012, Republic of Tatarstan, Kazan, Butlerova str. 49, phone: 8-917-245-14-51, e-mail: adelyamaksudova@gmail.com

ZUBAIROVA LYAYLI D., ORCID ID: 0000-0003-4614-4045, Scopus Author ID: 6507234642; D. Med. Sci, Professor of the General Pathology Department, Kazan State Medical University, Russia, 420012, Republic of Tatarstan, Kazan, Butlerova str. 49, phone: 8-905-317-69-86, e-mail: zubairovalaily@gmail.com

NABIULLINA ROZA M., ORCID ID: 0000-0001-5942-5335, Scopus Author ID: 56728544700; C. Med. Sci, Associate Professor of Biochemistry and Clinical Laboratory Diagnostics Department, Kazan State Medical University, Russia, 420012, Republic of Tatarstan, Kazan, Butlerova str. 49, phone: 8-917-898-72-50, e-mail: nabiullina.rosa@yandex.ru

Abstract. Introduction. Systemic lupus erythematosus (SLE) is a systemic autoimmune in ammatory disease. According to di erent authors, the incidence of thrombotic complications in this disease is higher than the average in the population and can be up to 40%. Aim. The aim of the present review is to provide an overview of mechanisms of thrombosis in patients with systemic lupus erythematosus. Material and methods. Analytical review of foreign and native publications in PubMed and eLibrary.ru between 1985-2020. Results and discussion. SLE represents a model of in ammation-induced thrombosis. The hypercoagulability state which characterizes SLE seems to be associated with in ammation-driven alterations of the thrombotic balance. Tissue-nonspeci c autoantibodies, as well as cytokines and acute phase proteins induce a proin ammatory endothelial cell phenotype. Platelets are activated following endothelial dysfunction; they participate in in ammatory and thrombotic events occurring in an injured area. One of the possible initiators of the thrombosis process is considered to be an interaction of antiphospholipid antibodies with phospholipids of platelet membranes, endothelium and phospholipid-linked plasma proteins. Local unbalanced thrombin generation leading to hypercoagulability is another source central for thrombosis. Patients with systemic lupus erythematosus show multidirectional disorders of the coagulation system, with predominance of hypercoagulation especially in patients with II-III degree of disease activity. Conclusion. The mechanism of thrombo-in ammation in systemic lupus erythematosus is multifactorial, involving all components of the hemostatic system. Chronic endothelial dysfunction, platelet activation, hypercoagulation, suppression of brinolysis re ects an interplay between thrombosis and in ammation. Persisting autoimmune in ammation plays a key role in these abnormalities.

Key words: systemic lupus erythematosus, thrombo-in ammation, system of hemostasis.

For reference: Ismagilova RR, Maksudova AN, Zubairova LD, Nabiullina LD. Mechanisms of thrombo-in ammation in patients with systemic lupus erythematosus. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 90-96.DOI: 10.20969/VSKM.2023.16(4).90-96.

References

  1. Насонов Е.Л. Российские клинические рекомендации. Ревматология. - Москва: ГЭОТАР-Медиа, 2017. – 464с. [Nasonov EL. Rossijskie klinicheskie rekomendacii. Revmatologija [Russian clinical guidelines. Rheumatology]. Moskva: GJeOTAR-Media [GEOTAR-Media]. 2017; 464 p. (In Russ.)].

  2. Hinojosa-Azaola A, Romero-Diaz J, Vargas-Ruiz AG, et.al. Venous and Arterial Thrombotic Events in Systemic Lupus Erythematosus. J Rheumatol. 2016; 43(3): 576-86. DOI: 10.3899/jrheum.150506

  3. Емануйлов В.И., Аршинов А.В., Масина И.В., Дешеулин А.С. Показатели иммунного воспаления и нарушения процессов гемостаза у больных системной красной волчанкой в зависимости от наличия у них антифосфолипидного синдрома // Казанский медицинский журнал. – 2007. – Т. 88, No6. – С. 566-569. [Emanujlov VI, Arshinov AV, Masina IV, Desheulin AS. Pokazateli immunnogo vospalenija i narushenija processov gemostaza u bol’nyh sistemnoj krasnoj volchankoj v zavisimosti ot nalichija u nih antifosfolipidnogo sindroma [Indices of immune in ammation and hemostasis disorders in patients with systemic lupus erythematosus depending on the presence of antiphospholipid syndrome]. Kazanskij medicinskij zhurnal [Kazan Medical Journal]. 2007; 88(6): 566-569. (In Russ.)]. https://www.elibrary.ru/item. asp?id=12866134

  4. Исмагилова Р.Р., Заманова Э.С., Максудова А.Н. Выживаемость пациентов с системной красной волчанкой: данные регионального регистра // Научно-практическая ревматология. – 2020. Т. 58. – С. 154-159. [Ismagilova RR, Zamanova JeS, Maksudova AN. Vyzhivaemost’ pacientov s sistemnoj krasnoj volchankoj: dannye regional’nogo registra [Survival rate of patients with systemic lupus erythematosus: data from a regional registry]. Nauchno-prakticheskaja revmatologija [Scienti c and Practical Rheumatology]. 2020; 58: 154-159. (In Russ.)]. DOI: 10.14412/1995-4484-2020-154-159

  5. Luo S, Hu D, Wang M, Zipfel PF, Hu Y. Complement in Hemolysis- and Thrombosis- Related Diseases. Front Immunol. 2020; 10: 1211-1212. DOI:10.3389/ mmu.2020.01212

  6. Taraborelli M, Lazzaroni MG, Martinazzi N, Fredi M, Cavazzana I, Franceschini F, Tincani A. The role of clinically signi cant antiphospholipid antibodies in systemic lupus erythematosus. Reumatismo. 2016; 68(3): 137-143. DOI: 10.4081/reumatismo.2016.891

  7. Scherlinger M, Sisirak V, Richez C, Lazaro E, Du au P, Blanco P. New insights on platelets and platelet-derived microparticles in systemic lupus erythematosus. Curr Rheumatol Rep. 2017; 19(8): 48. DOI: 10.1007/s11926-017-0678-0

  8. Latger-Cannard V, Fenneteau O, Salignac S, Lecompte TP, Schlegel N. Platelet morphology analysis. Methods Mol Biol. 2013; 992: 207–225. DOI: 10.1007/978-1-62703-339-8_16

9. Holinstat M. Normal platelet function. Cancer Metastasis Rev. 2017; 36(2): 195-198. DOI:10.1007/s10555-017-9677-x

10. Doria A, Ghirardello A, Boscaro M, et al. Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud’s phenomenon, disease activity, in ammatory indices, anticardiolipin antibodies and corticosteroid therapy. Rheumatol Int. 1995; 14: 207–11. DOI: 10.1007/ BF00262299

11. Derksen R. Systemic Lupus Erythematosus and the Antiphospholipid Syndrome. Ann Rheumat Dis Supl. 2. 2017; 73: SP0087.

12. Бицадзе В. О., Хизроева Д. Х., Макацария Н. А., и др. Антифосфолипидные антитела, их патогенетическое и диагностическое значение при акушерской патологии // Акушерство, гинекология и репродукция. – 2014. – Т. 8(2). – С. 39-60. [Bicadze VO, Hizroeva DH, Makacarija NA, at all. Antifosfolipidnye antitela, ih patogeneticheskoe i diagnosticheskoe znachenie pri akusherskoj patologii [Antiphospholipid antibodies, their pathogenetic and diagnostic signi cance in obstetric pathology]. Akusherstvo, ginekologija i reprodukcija [Obstetrics, Gynecology and Reproduction]. 2014; 8(2): 39-60. (In Russ.)]. https://www.elibrary.ru/item. asp?id=21812805

13. Yu F, Tan Y, Zhao M. Lupus nephritis combined with renal injury due to thrombotic thrombocytopenic purpura – haemolytic uraemic syndrome. Nephrol Dial Transplant. 2010; 25(1): 145–152. DOI: 10.1093/ndt/gfp421

14. Bernardo A, Ball C, Nolasco L., et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leucocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005; 3(3): 562–570. DOI: 10.1111/j.1538-7836.2005.01122.x

15. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010; 107(36): 15880-15885. DOI:10.1073/ pnas.1005743107

16. Le er J, Gullstrand B, Jönsen A, et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2013; 15(4): R84. DOI: 10.1186/ ar4264

  1. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011;7(12): 691-699. DOI: 10.1038/nrrheum.2011.132

  2. L van den Hoogen L, Fritsch-Stork RD, G van Roon JA, Radstake TR. Low-density granulocytes are increased in antiphospholipid syndrome and are associated with anti-β2 -glycoprotein I antibodies: comment on the article by Yalavarthi et al. Arthritis Rheumatol. 2016; 68(5): 1320-1321. DOI: 10.1002/art.39576

  3. M de Bont C, Boelens WC, Pruijn GJM. NETosis, complement, and coagulation: a triangular relationship. Cell Mol Immunol. 2019; 16(1): 19-27. DOI: 10.1038/ s41423-018-0024-0. Epub 2018 Mar 23

  4. Lood C, Eriksson S, Gullstrand B, Jönsen A, Sturfelt G, Truedsson L, Bengtsson AA. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis? Lupus. 2012; 21(13): 1423-1432. DOI: 10.1177/0961203312457210

  5. Peerschke E, Yin W, Alpert D, Roubey R, et al. Serum complement activation on heterologous platelets associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus. 2009; 18(6): 530–538. DOI: 10.1177/0961203308099974

  6. Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood. 1986; 68(4): 875–880. https:// pubmed.ncbi.nlm.nih.gov/3092889/

  7. Heemskerk J, Bevers E, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost. 2002; 88(2): 186–193. DOI: 10.1055/s-0037-1613209

  8. Литвинов Р.И. Молекулярные механизмы и клиническое значение фибринолиза // Казанский медицинский журнал. – 2013. – Т. 94, вып. 5. – С. 711-718. [Litvinov RI. Molekuljarnye mehanizmy i klinicheskoe znachenie brinoliza [Molecular mechanisms and clinical signi cance of brinolysis]. Kazanskij medicinskij zhurnal [Kazan Medical Journal]. 2013; 94(5): 711-718. (In Russ.)]. https://www.elibrary.ru/item.asp?id=21033754

  9. Жалялов А.С., Баландина А.Н., Купраш А.Д., и др. Современные представления о системе фибринолиза и методах диагностики ее нарушений // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. – 2017. – Т. 16(1). – С. 69-82. [Zhaljalov AS, Balandina AN, Kuprash AD, at all. Sovremennye predstavlenija o sisteme brinoliza i metodah diagnostiki ee narushenij [Modern concepts of the system of brinolysis and methods of diagnosis of its disorders]. Voprosy gematologii/onkologii i immunopatologii v pediatrii [Problems of hematology/oncology and immunopathology in pediatrics]. 2017; 16(1): 69-82. (In Russ.)]. DOI: 10.24287/1726-1708-2017-16-1-69-82

  10. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006; 177(7): 4794–4802. DOI:10.4049/jimmunol.177.7.4794

  11. Flaumenhaft R, Dilks JR, Richardson J, et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood. 2009; 113(5): 1112–1121. DOI: 10.1182/blood-2008-06-163832

  12. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost. 2003; 1(7): 1655– 16 62. DOI: 10.1046/j.1538-7836.2003.00309.x

29. 29. Vallar L, Regnault V, Latger-Cannard V, Lecompte T. Beta 2-glycoprotein I binding to platelet microparticle membrane speci cally reduces immunoreactivity of glycoproteins IIb/IIIa. Thromb Haemost. 2001; 85(2): 314–319. https://pubmed.ncbi.nlm.nih.gov/11246554/

30. Jy W, Jimenez JJ, Mauro M, et al. Endothelial microparticles induce formation of aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to disassociation. J Thromb Haemost. 2005; 3(6): 1301–1308. DOI: 10.1111/j.1538-7836.2005.01384.x

31. Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in in ammation and thrombosis. Scand J Immunol. 2007; 66(2-3): 159-165. DOI: 10.1111/j.1365-3083.2007.01984.x

32. Nielsen CT, Østergaard O, Stener L, et al. Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum. 2012; 64(4): 1227–1236. DOI: 10.1002/art.34381

33. Скударнов Е.В., Выходцева Г.И., Шкурина Е.Ю. Нарушения конечного этапа свертывания крови у детей с системной красной волчанкой // Мать и Дитя в Кузбассе. – 2003. – No 2(13). – С. 19-21. [Skudarnov EV, Vyhodceva GI, Shkurina EJu. Narushenija konechnogo jetapa svertyvanija krovi u detej s sistemnoj krasnoj volchankoj [Disorders of the end stage of blood clotting in children with systemic lupus erythematosus]. Mat’ i Ditja v Kuzbasse [Mother and Child in Kuzbass]. 2003; 2(13): 19-21. (In Russ.)]. https://www.elibrary.ru/item. asp?id=24924962

34. Qushmaq K, Esdaile J, Devine D. Thrombosis in systemic lupus erythematosus: the role of antiphospholipid antibody. Arthritis Care Res. 1999; 12(3): 212–219. DOI: 10.1002/1529-0131(199906)12:3<212::aid-art9>3.0.co;2-m

35. Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 1993; 81(10): 2618–2625. https:// pubmed.ncbi.nlm.nih.gov/8166780/

36. Barranco-Medina S, Pozzi N, Vogt AD, et al. Histone H4 promotes prothrombin autoactivation. J Biol Chem. 2013; 288(50): 35749-35757. DOI: 10.1074/jbc.M113. 509786. Epub 2013 Oct 30

37. Varju I, Longsta C, Szabo L, et al. DNA, histones and neutrophil extracellular traps exert antibrinolytic e ects in a plasma environment. Thromb Haemost. 2015; 113(6): 1289-1298. DOI: 10.1160/TH14-08-0669

38. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010;16(8): 887-896. DOI: 10.1038/nm.2184

39. Michelson AD, Rajasekhar D, Bednarek FJ, Barnard MR. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: di erences between neonates and adults. Thromb Haemost. 2000; 84(4): 689–694. https://pubmed.ncbi.nlm.nih.gov/11057871/

40. Pereira J, Alfaro G, Goycoolea M, et al. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost. 2006; 95(1): 94–99. https://pubmed.ncbi.nlm.nih. gov/16543967/

41. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem. 1988; 263(34): 18205–18212. https://pubmed.ncbi.nlm.nih. gov/2848029/

  1. Kozarcanin H, Lood C, Munthe-Fog L, Sandholm K, Hamad OA, Bengtsson AA, et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboin ammation. J Thromb Haemost. 2016; 14(3): 531–545. DOI: 10.1111/jth.13208

  2. Gulla K, Gupta K, Krarup A, Gal P, Schwaeble W, Sim R, et al. . Activation of mannan-binding lectin-associated serine proteases leads to generation of a brin clot. Immunology. 2010; 129(4): 482–495. DOI: 10.1111/j.1365-2567.2009.03200.x

  3. Wojta J, Huber K, Valent P. New aspects in thrombotic research: complement induced switch in mast cells from a pro brinolytic to a prothrombotic phenotype. Pathophysiol Haemost Thromb. 2003; 33(5-6): 438–441. DOI: 10.1159/000083842

  4. Lupu F, Keshari R, Lambris J, Coggeshall K. Crosstalk between the coagulation and complement systems in sepsis. Thromb Res. 2014; 133 Suppl 1(0 1): 28–31. DOI: 10.1016/j.thromres.2014.03.014

  5. Le Minh G, Peshkova A, Andrianova I, Sibgatullin T, Maksudova A, Weisel J, Litvinov R. Impaired contraction of blood clots as a novel prothrombotic mechanism in systemic lupus erythematosus. Clin Sci (Lond). 2018; 132(2): 243-254. DOI: 10.1042/CS20171510

  6. Литвинов Р.И., Пешкова АД. Контракция (ретракция) сгустков крови и тромбов: патогенетическое и клиническое значение // Альманах клинической медицины. – 2018. – Т. 46, вып. 7. – С. 662–671. [Litvinov RI, Peshkova AD. Kontrakcija (retrakcija) sgustkov krovi i trombov: patogeneticheskoe i klinicheskoe znachenie [Contraction (retraction) of blood clots and thrombi: pathogenetic and clinical signi cance]. Al’manah klinicheskoj mediciny [Almanac of Clinical Medicine]. 2018; 46 (7): 662-671. (In Russ.)]. DOI: DOI: 10.18786/2072-0505-2018-46-7-662-671

  7. Dhillon P, Adams M. Thrombosis in systemic lupus erythematosus: role of impaired brinolysis. Semin Thromb Hemost. 2013; 39(4): 434-440. DOI: 10.1055/s-0033-1334484

  8. M Von Depka, Nowak-Göttl U, Eisert R, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood. 2000; 96(10): 3364– 3368. https://pubmed.ncbi.nlm.nih.gov/11071628/

50. Ao W, Zheng H, Chen X-W, et al. Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. Rheumatol Int. 2010; 31(7): 27–29. DOI: 10.1007/s00296-010-1379-4

51. Алекберова З. С., Герасимова Е. В., Голоева Р. Г., Насонов Е. Л. Тромбозы и ревматические заболевания: частота встречаемости и механизмы развития (обзор и собственные данные) // Научно-практическая ревматология. – 2012. – No 50(1). – С. 65-71. [Alekberova ZS, Gerasimova EV, Goloeva RG, Nasonov EL. Trombozy i revmaticheskie zabolevanija: chastota vstrechaemosti i mehanizmy razvitija (obzor i sobstvennye dannye) [Thrombosis and rheumatic diseases: incidence and mechanisms of development (review and own data)]. Nauchno-prakticheskaja revmatologija [Scienti c and Practical Rheumatology]. 2012; 50(1): 65-71. (in Russ.)]. https://www.elibrary.ru/ item.asp?id=17768014

52. Ohkura N, Hagihara Y, Yoshimura T, et al. Plasmin can reduce the function of human β2 glycoprotein I by cleaving domain V into a nicked form. Blood. 1998; 91(11): 4173–4179. https://pubmed.ncbi.nlm.nih. gov/9596664/

53. Yasuda S, Atsumi T, Ieko M, Koike T. β2-glycoprotein I, anti-β2-glycoprotein I, and brinolysis. Thromb Res. 2004; 114(5-6): 461–465. DOI: 10.1016/j. thromres.2004.07.013

54. Acquasaliente L, Peterle D, Pontarollo G, et al. β2GpI binds to brinogen and alters brin generation and degradation. Res Pract Thromb Haemost. 2017;1(Suppl 1): 1097. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC6058402/

55. Undas A, Ariëns R. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011; 31(12): e88-99. DOI: 10.1161/ ATVBAHA.111.230631

56. Harsfalvi J, Feller T, Domjan G, et al. Biophysical characterization of clot retraction in platelet rich plasma of patients with primary anti-phospholipid syndrome. Res Pract Thromb Haemost. 2017; 1(Suppl 1): 1091– 1092. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC6058402/

57. Collet J, Montalescot G, Lesty C, Weisel J. A structural and dynamic investigation of the facilitating e ect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res. 2002; 90(4): 428–434. DOI: 10.1161/ hh0402.105095

 

UDC 615.322:615.37:616-003.96

DOI: 10.20969/VSKM.2023.16(4).97-103

PDF download PROSPECTS FOR THE SEARCH AND DEVELOPMENT OF NEW ORIGINAL PHARMACEUTICAL SUBSTANCES - DERIVATIVES OF USNINIC ACID EXTRACTED FROM LICHENS (REVIEW)

KRYLOV ILYA AL., ORCID ID: 0000-0003-3042-4229; D. Med. Sci., Director of the Institute of Pharmacology and Pharmacy Northern State Medical University, 163000, Russia, Arkhangelsk, Troitskiy Ave., 51, 51; e-mail: krylov. ilya@mail.ru

SHERSTENNIKOV NIKOLAY V., ORCID ID: 0009-0004-1606-3775; postgraduate student of the Department of Pharmacology and Pharmacy Northern State Medical University, 163000, Russia, Arkhangelsk, Troitskiy Ave., 51; e-mail: shersten96@gmail.com

KUBASOVA ELENA D., ORCID ID: 0000-0001-9683-7814; C. Biol. Sci., Dean of the Faculty of Pharmacy, Associate Professor of the Department of Pharmacology and Pharmacy, Northern State Medical University, 163000, Russia, Arkhangelsk, Troitskiy Ave., 51; e-mail: lapkino@mail.ru

KORELSKAYA GALINA V., ORCID ID: 0000-0003-4236-1966; senior lecturer Departments of Pharmacology and Pharmacy Northern State Medical University, 163000, Russia, Arkhangelsk, Troitskiy Ave., 51; e-mail: galyusha12@ yandex.ru

KUBASOV ROMAN V., ORCID ID: 0000-0003-1698-6479; C. Biol. Sci., Associate Professor of the Department of Mobilization Training of Healthcare and Disaster Medicine, Northern State Medical University, 163000, Russia, Arkhangelsk, Troitskiy Ave., 51; e-mail: romanas2001@gmail.com

GRZYBOWSKI ANDREY M., ORCID ID: 0000-0002-5464-0498; PhD, Head of the Department of Scientific and Innovative Work Northern State Medical University, 163000, Russia, Arkhangelsk, Troitskiy Ave., 51; Professor of the Department of общественного здоровья, здравоохранения, общей гигиены и биоэтики, M.K. Ammosov North-Eastern Federal University, 58 Belinski St, Yakutsk, Sakha (Yakutia) Republic, 677000, Russian Federation; e-mail: andrej.grjibovski@gmail.com

LENINA JULIANA AL., ORCID ID: 0000-0001-6960-6631; student Northern State Medical University, 163000, Russia, Arkhangelsk, Troitskiy Ave., 51; e-mail: karaman2015@list.ru

KARAMAN SERGEY AL., ORCID ID: ID 0000-0003-3333-2653; student Northern State Medical University, 163000, Russia, Arkhangelsk, Troitskiy Ave., 51; e-mail: karaman2015@list.ru

Abstract. Relevance: scienti c and practical interest in usninic acid and its derivatives is increasing every year. This is due to their rather high biological activity, e ectiveness in the treatment of many pathological conditions. In addition, usninic acid is contained in signi cant volumes in plant raw materials, primarily in ubiquitous lichens. The process of its extraction from plants is relatively simple and economically favorable. The purpose of the work was to conduct a narrative review of the prospects for the practical (pharmaceutical) use of usninic acid. Materials for research. For literature analysis, we performed search from the international databases Web of Science, Scopus, PubMed, as well as the domestic library system eLibrary. Results. Usnic acid in certain doses and combinations with other components has a toxic e ect. These properties can be widely used in the treatment of infectious diseases (which is relevant due to the increasing resistance of microorganisms to drugs). Cytotoxic and genotoxic e ects can be purposefully applied in the treatment of oncological neoplasms. The positive results of experimental studies, both in vitro and in vivo, proved the prospects for the development of new original pharmaceutical substances based on usninic acid derivatives obtained from lichens. It is concluded that lichens can be considered a unique natural supplier of biologically active components, primarily usninic acid. Its use is warranted for therapeutic and prophylactic purposes and requires the search and development of new pharmacological agents.

Keywords: usnic acid, lichens, bioactivity, pharmacological activity.

For reference: Krylov IA, Sherstennikov NV, Kubasova ED. et al. Prospects for the search and development of new original pharmaceutical substances - derivatives of usninic acid extracted from lichens (review) The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 97-103. DOI: 10.20969/VSKM.2023.16(4).97-103.

References

Литература

  1. Храмченкова О.М., Новиков Р.И. Содержание усниновой кислоты в различных частях талломов Evernia Prunastri (L.) Ach., Ramalina Pollinaria (Westr.) Ach. и Cladonia Arbuscula (Wallr.) Flot // Бюллетень Брянского отделения Российского ботанического общества. – 2018. – No 3(15). – С. 49-53. [Hramchenkova OM, Novikov RI. Soderzhanie usninovoj kisloty v razlichnyh chastyah tallomov Evernia Prunastri (L.) Ach., Ramalina Pollinaria (Westr.) Ach. i Cladonia Arbuscula (Wallr.) Flo. [Usnic acid concentration in di erent thallus parts of Evernia prunastri (L.) Ach., Ramalina pollinaria (Westr.) Ach. and Cladonia arbuscula lichens (Wallr.) Flot.]. Byulleten’ Bryanskogo otdeleniya Rossijskogo botanicheskogo obshchestva [Bulletin of Bryansk dpt. of RBS]. 2018; 3(15): 49-53. (In Russ.)]. DOI:10.22281/2307-4353-2018-3-49-53

  2. Jayaprakasha GK, Rao LJ. Phenolic constituents from the lichen Parmotrema stuppeum (Nyl.) Hale and their antioxidant activity. Z Naturforsch C J Biosci. 2000; 55(11-12): 1018–1022. DOI: 10.1515/znc-2000-11-1227

  3. Sanders WB; Masumoto H. Lichen algae: The photosynthetic partners in lichen symbioses. Lichenologist. 2021; 53(5): 347–393. DOI: 10.1017/S0024282921000335

  4. Yang MX, Devkota S, Wang LS, Scheidegger C. Ethnolichenology The use of lichens in the Himalayas and southwestern parts of China. Diversity. 2021; 13(7): 330. DOI: 10.3390/d13070330

  5. Cocchietto M, Skert N, Nimis PL, Sava G. A review on usnic acid, an interesting natural compound. Naturwissenschaften. 2002; 89(4): 137–146. DOI: 10.1007/s00114-002-0305-3

  6. Okuyama E, Umeyama K, Yamazaki M, Kinoshita Y, Yamamoto Y. Usnic acid and di ractaic acid as analgesic and antipyretic components of Usnea di racta. Planta Med. 1995; 61(2): 113–115. DOI: 10.1055/s-2006-958027

  7. Mitchell P. Vectorial chemistry and the molecular mechanics of chemiosmotic coupling power transmission by proticity. Biochem Soc Trans. 1976; 4(3): 399–430. DOI: 10.1042/bst0040399

  8. Rafanelli S, Bacchilega R, Stanganelli I, Rafanelli A. Contact dermatitis from usnic acid in vaginal ovules. Contact Dermatitis. 1995; 33(4): 271–272. DOI: 10.1111/ j.1600-0536.1995.tb00484.x

  9. Frankos VH. Nomination for usnic acid and Usnea barbata herb // National Toxicology Program. Washington, DC: Food and Drug Administration. 2005; https://ntp.niehs. nih.gov/sites/default/ les/ntp/htdocs/chem_background/ exsumpdf/usnicacid_508.pdf

  10. Аньшакова В.В., Степанова А.В., Смагулова А.Ш. Разработки на основе лишайникового сырья (твердофазные биопрепараты) // Вестник спортивной науки. – 2013. – No6. – С. 28-30. [An’shakova VV, Stepanova AV, Smagulova ASh. Razrabotki na osnove lishajnikovogo syr’ya (tverdofaznye biopreparaty) [Lichen raw material based preparations (solvent-free technologies)]. Vestnik sportivnoj nauki [Bulletin of Sports Science]. 2013; 6: 28-30. (In Russ.)].

  11. Popovici V, Bucur L, Gîrd CE. Advances in the Characterization of Usnea barbata (L.) Weber ex F.H. Wigg from Călimani Mountains, Romania. Appl. Sci. 2022; 12: 4234. DOI: 10.3390/ app12094234

  12. Barton DHR, De orin AM, Edwards OE. The synthesis of usnic acid. J Chem Soc. 1956; 530-534. DOI: 10.1039/ JR9560000530

  13. Taguchi H, Sankawa U, Shibata S. Biosynthesis of natural products. VI. Biosynthesis of usnic acid in lichens. A general scheme of biosynthesis of usnic acid. Chem Pharm Bull (Tokyo). 1969; 17(10): 2054–2060. DOI: 10.1248/cpb.17.2054

  14. Toxicity studies of (+)-usnic acid administered in feed to F344/N Nctr rats and B6C3F1/Nctr mice. National Toxicology Program. Toxic Rep Ser. 2022; 104:NTP-TOX-104. DOI: 10.22427/NTP-TOX-104

  15. Venkataramana D, Krishna DR. Pharmacokinetics of d(+)-usnic acid in rabbits after intravenous administration. European Journal of Drug metabolism and Pharmacokinetics. 1993; 18(2): 161-163. DOI: 10.1007/BF03188791

  16. Durazo FA, Lassman C, Han SHB. Fulminant liver failure due to usnic acid for weight loss. Am. J. Gastroenterol. 2004; 99(5): 950–952. DOI: 10.1111/j.1572-0241.2004.04165.x

  17. Sanchez W, Maple JT, Burgart LJ, Kamath PS. Severe Hepatotoxicity Associated With Use of a Dietary Supplement Containing Usnic Acid. Mayo Clin. Proc. 2006; 81(4): 541-544. DOI: 10.4065/81.4.541

  18. Hsu LM, Huang YS, Chang FY, Lee SD. “Fat burner” herb, usnic acid, induced acute hepatitis in a family. J. Gastroenterol. Hepatol. 2005; 20(7): 1138–1139. DOI: 10.1111/j.1440-1746.2005.03855.x

  19. Ne GW, Reddy KR, Durazo FA, Meyer D, Marrero R, Kaplowitz N. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. Journal of Hepatology. 2004; 41(6): pp. 1062–1064. DOI: 10.1016/j.jhep.2004.06.028

  20. Foti RS, Dickmann LJ, Davis JA, Greene RJ. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements. Xenobiotica. 2008; 38(3): 264–280. DOI: 10.1080/00498250701802514

  21. Pramyothin P, Janthasoot W, Pongnimitprasert N, Phrukudom S, Ruangrungsi N. Hepatotoxic e ect of (+) usnic acid from Usnea siamensis Wainio in rats, isolated rat hepatocytes and isolated rat liver mitochondria. J Ethnopharmacol. 2004; 90(2-3): 381–387. DOI: 10.1016/j.jep.2003.10.019

  22. Guo L, Shi Q, Fang JL, Mei N. Review of usnic acid and Usnea barbata toxicity. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2008; 26(4): 317-338. DOI: 10.1080/10590500802533392

  23. Dailey RN, Montgomery DL, Ingram JT, Siemion R, Vasquez M, Raisbeck MF. Toxicity of the lichen secondary metabolite (+)-usnic acid in domestic sheep. Vet. Pathol. 2008; 45(1): 19–25. DOI: 10.1354/vp.45-1-19

  24. Yokouchi Y, Imaoka M, Niino N, Kiyosawa N, Sayama A, Jindo T. (+)-Usnic Acid-induced Myocardial Toxicity in Rats. Toxicologic Pathology. 2015; 43(3): 424-434. DOI: 10.1177/0192623313504308

  25. Kumar KC, Muller K. Lichen metabolites. 2. Antiproliferative and cytotoxic activity of gyrophoric, usnic, and di ractaic acid on human keratinocyte growth. J Nat Prod. 1999; 62(6): 821–823. DOI: 10.1021/ np980378z

  26. Pyrczak-Felczykowska А, Narlawar R, Pawlik A. Synthesis of Usnic Acid Derivatives and Evaluation of Their Antiproliferative Activity against Cancer Cells. J. Nat. Prod. 2019; 82(7): 1768-1778. DOI:10.1021/acs. jnatprod.8b00980

  27. Koparal AT, Tüylü BA, Türk H. In vitro cytotoxic activities of (+)-usnic acid and (-)-usnic acid on V79, A549, and human lymphocyte cells and their nongenotoxicity on human lymphocytes. Nat. Prod. Res. 2006; 20(14): 1300–1307. DOI: 10.1080/14786410601101910

  28. Рахманова М.Е., Лузина О.А., Покровский М.А. Синтез цианэтильных производных усниновой кислоты и их цитотоксическая активность // Изв. Акад. Наук. Серия Химическая. – 2016. – No2. – С. 566-569. [Rahmanova ME, Luzina OA, Pokrovskij MA. Sintez cianetil’nyh proizvodnyh usninovoj kisloty i ih citotoksicheskaya aktivnost’ [Synthesis and cytotoxic activity of usnic acid cyanoethyl derivatives]. Izv. Akad. Nauk. Seriya Himicheskaya [Russian Chemical Bulletin]. 2016; 2: 566-569. (In Russ.)].

  29. Brown JP. A review of the genetic e ects of naturally occurring avonoids, anthraquinones and related compounds. Mutat Res. 1980; 75(3): 243–277. DOI: 10.1016/0165-1110(80)90029-9

  30. Shibamoto T, Wei CI. Mutagenicity of lichen constituents. Environ Mutagen. 1984; 6(5): 757–762. DOI: 10.1002/ em.2860060512

  31. Alpsoy L, Orhan F, Nardemir G, Agar G, Gulluce M, Aslan A. Antigenotoxic potencies of a lichen species, Evernia prunastri. Toxicol Ind Health. 2015; 31(2): 153-161. DOI: 10.1177/0748233712469655

  32. Bekairi AM, Qureshi S, Chaudhry MA, Krishna DR, Shah AH. Mitodepressive, clastogenic and biochemical e ects of (+)-usnic acid in mice. J Ethnopharmacol. 1991; 33(3): 217–220. DOI: 10.1016/0378-8741(91)90079-s

  33. Zorrilla JG; D’Addabbo T; Roscetto E. Antibiotic and Nematocidal Metabolites from Two Lichen Species Collected on the Island of Lampedusa (Sicily). Int. J. Mol. Sci. 2022; 23(15): 8471. DOI: 10.3390/ijms23158471. DOI: 10.3390/ijms23158471

  34. Ghione M, Parrello D, Grasso L. Usnic acid revisited, its activity on oral ora. Chemioterapia. 1988; 7(5): 302– 305.

  35. Ingolfsdottir K, Chung GA, Skulason VG, Gissurarson SR, Vilhelmsdottir M. Antimycobacterial activity of lichen metabolites in vitro. Eur J Pharm Sci. 1998; 6(1): 141– 144. DOI: 10.1016/s0928-0987(97)00078-x

  36. Tatipamula VB, Annam SSP. Antimycobacterial activity of acetone extract and isolated metabolites from folklore medicinal lichen Usnea laevis Nyl. against drug-sensitive and multidrug-resistant tuberculosis strains. J Ethnopharmacol. 2022; 282: 114641. DOI:10.1016/j. jep.2021.114641

  37. Francolini I, Piozzi A, Donelli G. Usnic Acid: Potential Role in Management of Wound Infections. Adv Exp Med Biol. 2019; 1214: 31-41. DOI: 10.1007/5584_2018_260

  38. OhE,WangW,ParkKH,ParkC,ChoY,LeeJ,KangE, Kang H. (+)-Usnic acid and its salts, inhibitors of SARS-CoV-2, identi ed by using in silico methods and in vitro assay. Sci Rep. 2022; 12(1): 13118. DOI: 10.1038/ s41598-022-17506-3

 

UDC 616-008-056.7-02:577.125.8:616.12-008

DOI: 10.20969/VSKM.2023.16(4).104-110

PDF download HYPERTRIGLYCERIDEMIA AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASES

NURIEVA LUIZA M., ORCID ID: 0000-0002-1762-9492; cardiologist of the cardiology department No. 1 of City Clinical Hospital No. 7, Kazan, Russia, e-mail: nurievaluiza@list.ru

KIM ZULFIYA F., ORCID ID: 0000-0003-4240-3329; C. Med. Sci., Deputy Head physician on medical affairs of City Clinical Hospital No. 7, Kazan, Russia; Chief freelance cardiologist of the Ministry of Health of Republic of Tatarstan; associate professor of the Department of internal medicine No 2 of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, e-mail: profz@yandex.ru

GALYVICH ALBERT S., ORCID ID: 0000-0002-4510-6197; D. Med. Sci., professor, the Head of the Department of cardiology of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49; Chief freelance cardiologist of the Ministry of Health of the Russian Federation in the Volga Federal District, e-mail: agalyavich@mail.ru

SADYKOVA DINARA I., ORCID ID: 0000-0002-6662-3548, D. Med. Sci., professor, the Head of the Department of hospital pediatrics of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49; pediatric cardiologist; chief freelance pediatric specialist cardiologist of the Ministry of Health of the Russian Federation in the Volga Federal District and RT, e-mail: sadykovadi@mail.ru

Abstract. Introduction. Elevated triglyceride levels are associated with an increased risk of cardiovascular disease. An increase in the concentration of triglycerides indicates an elevated level of atherogenic lipoproteins, such as very low density lipoproteins, very low density lipoproteins residues and chylomicron residues. Lipoproteins rich in triglycerides increase the formation of foam cells, which is one of the key stages of the pathogenesis of atherosclerosis. Aim. To analyze the results of modern studies on elevated triglycerides and cardiovascular diseases. Material and methods.A review of medical literature and current research for the period from 1965 to 2022, published in the databases eLibrary, Google Scholar, PubMed, devoted to the analysis of hypertriglyceridemia and its e ect on atherosclerotic cardiovascular diseases by the keywords «hypertriglyceridemia», «cardiovascular diseases», «atherosclerosis».Results and discussion. According to the Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation study, an elevated level of triglyceride was found in 30.2±0.52% of men in the entire sample, which is signi cantly higher than in women (20.1±0.34%; p<0.0001). According to the largest epide miological study (Framingham Study), a TG level of more than 1.7 mmol/l means a signi cantly higher risk of developing cardiovascular complications. A prospective study by The Prospective Cardiovascular Munster (PROCAM) showed that an increase in the concentration of triglycerides from 2.3 mmol/l to 9.00 mmol/l increases the risk of cardiovascular diseases., even after correction of other risk factors. Conclusion. Triglycerides play an important role in the development of atherosclerotic diseases of the cardiovascular system, regardless of the etiology of hypertriglyceridemia. And e ective lipid-lowering therapy prescribed in time can increase the life expectancy of such patients.

Key words: lipid metabolism disorders, dyslipidemia, triglycerides, hypertriglyceridemia, cardiovascular diseases, atherosclerosis.

For reference: Nurieva LM, Kim ZF, Galyvich AS, Sadykova DI. Hypertriglyceridemia and atherosclerotic cardiovascular diseases. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 104-110. DOI: 10.20969/VSKM.2023.16(4).104-110.

References

Литература

  1. Mach F, Baigent C, Catapano AL, и др. 2019 Рекомендации ESC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска // Российский кардиологический журнал. – 2020. – No25(5). - C.3826. [Mach F, Baigent C, Catapano AL, et al. 2019 Rekomendacii ESC/EAS po lecheniyu dislipidemij: modi kaciya lipidov dlya snizheniya serdechno-sosudistogo riska [2019 ESC/ EAS Guidelines for themanagement of dyslipidaemias: lipid modi cation to reduce cardiovascular risk]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2020;25(5):3826. (In Russ.)]. DOI: 10.15829/1560-4071-2020-3826

  2. Кухарчук В.В., Ежов М.В., Сергиенко И.В., и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр // Атеросклероз и дислипидемии. – 2020. – No1(38). - C.7- 42. [Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnostika i korrekciya narushenij lipidnogo obmena s cel’yu pro laktiki i lecheniya ateroskleroza. Rossijskie rekomendacii, VII peresmotr [Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VII revision]. Ateroskleroz i dislipidemii [The Journal of Atherosclerosis and Dyslipidemias]. Moscow, 2020; 2020.1(38):7-42. (In Russ.).]. DOI: 10.34687/2219-8202.JAD.2020.01.0002

  3. Галлер Г., Ганефельд М., Яросс В. Нарушения липидного обмена. Диагностика. Клиника. Терапия. пер. с нем. // Москва: Медицина. - 1979. - 335 с. [Haller G., Ganefeld M., Yaross B. Narusheniya lipidnogo obmena. Diagnostika. Klinika. Terapiya. [Violation of lipid metabolism. Diagnostics. Clinic. Therapy]. Moskva: Medicina [Moscow: Medicine] 1979; P.335.].

  4. Климов Н.А., Никульчева Н.Г. Липиды, липопротеиды и атеросклероз // Санкт-Петербург: Питер. - 1995. С. 89-199. [Klimov NA, Nikulcheva NG. Lipidy, lipoproteidy i ateroskleroz [Lipids, lipoproteins and atherosclerosis]. St. Petersburg : Peter [Sankt-Peterburg: Piter]. 1995; p. 89-199 (In Russ.).].

  5. Титов В.Н., Рожкова Т.А., Амелюшкина В.А. Жирные кислоты, триглицериды, гипертриглицеридемия, гипергликемия и инсулин: монография // Москва: ИНФРА-М. - 2016. 197 с. [Titov VN, Rozhkova TA, Amelyushkina VA. Fatty acids, triglycerides, hypertriglyceridemia, hyperglycemia and insulin: monograph [Zhirnye kisloty, trigliceridy, gipertrigliceridemiya, giperglikemiya i insulin: monogra ya]. Moskva: INFRA-M. [Moscow: INFRA-M]. 2016;197 p. (In Russ.)].

  6. Salim S. Virani, Pamela B. Morris, Anandita Agarwala, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021;Jul 28. DOI: 10.1016/j.jacc.2021.06.011

  7. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012; 97(9): 2969-89. DOI: 10.1210/jc.2011-3213

  8. Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016 Feb 19;118(4):547-63. DOI: 10.1161/ CIRCRESAHA.115.306249

  9. Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients. 2013 Mar 22;5(3):981-1001 DOI: 10.3390/nu5030981

  10. Hegele RA, Ginsberg HN, Chapman MJ, et al. European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for de nition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014 Aug;2(8):655-66. DOI: 10.1016/S2213-8587(13)70191-8

  11. Рожкова Т. А., Амелюшкина В. А., Яровая Е. Б. и др. Клинико-лабораторное выявление фенотипических особенностей у пациентов с высокой гипертриглицеридемией // Клиническая лабораторная диагностика. – 2011. - No5. C. 10—16 [Rozhkova TA, Amelyushkina VA, Yarovaya EB, etc. Kliniko-laboratornoe vyyavlenie fenotipicheskih osobennostej u pacientov s vysokoj gipertrigliceridemiej [Clinical and laboratory identi cation of phenotypic features in patients with high hypertriglyceridemia]. Klinicheskaya laboratornaya diagnostika [Klinicheskaya Laboratornaya Diagnostika]. 2011; 5: 10-16 (In Russ.)].

  12. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011 Dec;13(6):544-52. DOI: 10.1007/s11886-011-0220-3

  13. Bozzetto L, Annuzzi G, Corte GD, et al. Ezetimibe bene cially in uences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis. 2011 Jul;217(1):142-8. DOI: 10.1016/j. atherosclerosis.2011.03.012

  14. Karpov Y, Khomitskaya Y. PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. Cardiovasc Diabetol. 2015; 14: 115. DOI: 10.1186/s12933-015-0268-2

  15. Beaumont JL, Carlson LA, Cooper GR, et al. Classi cation of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ. 1970;43(6):891-915.

  16. Fredrickson DS, Lees RS. Editorial a system for phenotyping hyperlipoproteinemia. Circulation. 1965. Vol. 31, N 3. P. 321 – 327.

  17. Hegele RA. Plasma lipoproteins: genetic in uences and clinical implications. Nat Rev Genet. 2009 Feb;10(2):109-21. DOI: 10.1038/nrg2481

  18. Кошечкин В.А., Малышев П.П., Рожкова Т.А. Медико-генетическое консультирование при дислипидемиях: руководство для врачей // Москва: ГЭОТАР. Медиа. - 2021. – 264 с. [Koshechkin VA, Malyshev PP, Rozhkova TA. Medical and genetic counseling for dyslipidemia: a guide for doctors [Medical and genetic counseling for dyslipidemia: a guide for doctors]. Moskva: GEOTAR. Media. [Moscow: GEOTAR. Media] 2021; 264 p. (In Russ.)] DOI: 10.33029/9704-6191-4-GEN-2021-1-264

  19. Wion KL, Kirchgessner TG, Lusis AJ, Schotz MC, Lawn RM. Human lipoprotein lipase complementary DNA sequence. Science. 1987 Mar 27;235(4796):1638-41. DOI: 10.1126/science.3823907

  20. Brunzell JD, Miller NE, Alaupovic P, et al. Familial chylomicronemia due to a circulating inhibitor of lipoprotein lipase activity. J Lipid Res. 1983 Jan;24(1):12-9.

  21. Cox DW, Breckenridge WC, Little JA. Inheritance of apolipoprotein C-II de ciency with hypertriglyceridemia and pancreatitis. N Engl J Med. 1978 Dec 28;299(26):1421-4. DOI: 10.1056/NEJM197812282992601

  22. Okubo M, Toromanovic A, Ebara T, Murase T. Apolipoprotein C-II Tuzla: a novel large deletion in APOC2 caused by Alu-Alu homologous recombination in an infant with apolipoprotein C-II de ciency. Clin Chim Acta. 2015 Jan 1;438:148-53. DOI: 10.1016/j. cca.2014.08.022

  23. Cefalù AB, Noto D, Arpi ML, et al. Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. J Clin Endocrinol Metab. 2009 Nov;94(11):4584-90. DOI: 10.1210/jc.2009-0594

  24. Wang J, Ban MR, Kennedy BA, et al. APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med. 2008 Nov;5(11):730-7. DOI: 10.1038/ ncpcardio1326

  25. Calandra S, Priore Oliva C, Tarugi P, Bertolini S. APOA5 and triglyceride metabolism, lesson from human APOA5 de ciency. Curr Opin Lipidol. 2006 Apr;17(2):122-7. DOI: 10.1097/01.mol.0000217892.00618.54

  26. Miyashita K, Lutz J, Hudgins LC, et al. Chylomicronemia from GPIHBP1 autoantibodies. J Lipid Res. 2020 Nov;61(11):1365-1376. DOI: 10.1194/jlr.R120001116.

  27. Fong LG, Young SG, Beigneux AP, et al. GPIHBP1 and Plasma Triglyceride Metabolism. Trends Endocrinol Metab. 2016 Jul;27(7):455-469. DOI: 10.1016/j. tem.2016.04.013

  28. Stuyt PM, Demacker PN, van ‘t Laar A. Serum lipids, lipoproteins and apolipoprotein E phenotypes in relatives of patients with type III hyperlipoproteinaemia. Eur J Clin Invest. 1984 Jun;14(3):219-26. DOI: 10.1111/j.1365-2362.1984.tb01127.x.

  29. Marais AD. Apolipoprotein E and Atherosclerosis. Curr Atheroscler Rep 23, 34 (2021). DOI: 10.1007/s11883-021-00933-4

  30. Rahalkar AR, Hegele RA. Monogenic pediatric dyslipidemias: classi cation, genetics and clinical spectrum. Mol Genet Metab. 2008 Mar;93(3):282-94. DOI: 10.1016/j.ymgme.2007.10.007

  31. Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015 Feb;36(1):131-47. DOI: 10.1210/er.2014-1062

  32. Viñals C, Zambón D, Yago G, et al. Secondary hypertriglyceridemia. Clin Investig Arterioscler. 2021 May;33 Suppl 2:29-36. English, Spanish. DOI: 10.1016/j. arteri.2021.02.006

  33. Шляхто Е. В. Кардиология: национальное руководство, 2-е издание // Москва: ГЭОТАР-Медиа. - 2019. - Глава 15. – С. 411. [Shlyakhto EV. Kardiologiya: nacional’noe rukovodstvo, 2-e izdanie [Cardiology: national guidelines, 2nd edition]. Moskva: GEOTAR-Media [Moscow: GEOTAR-Media]. 2019;chapter 15,p.411 (In Russ.)].

  34. Метельская В.А., Шальнова С.А., Деев А.Д. и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ) // Профилактическая Медицина. – 2016. – No 19(1) – С.15-23. [Metelskaya VA, Shalnova SA, Deev AD, et al. Analiz rasprostranennosti pokazatelej, harakterizuyushchih aterogennost’ spektra lipoproteinov, u zhitelej Rossijskoj Federacii (po dannym issledovaniya ESSE-RF) [Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study)]. Pro lakticheskaya Meditsina [Preventive Medicine]. 2016;19(1):15-23. (In Russ.)]. DOI: 10.17116/profmed201619115-23

  35. Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993 Apr 29;328(17):1220-5. DOI: 10.1056/ NEJM199304293281702

  36. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992;70(19):3H9H. DOI: 10.1016/0002-9149(92)91083-G

  37. Carey VJ, Bishop L, Laranjo N, et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. The American journal of cardiology. 2010. Vol. 106. No. 6. P. 757–763.

  38. Barter P, Gotto AM, LaRosa JC, et al. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New England Journal of Medicine. 2007. 357(13): 1301–1310. DOI: 10.1056/nejmoa064278

  39. Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of feno brate–statin combination therapy. Atherosclerosis Supplements. 2015. Vol. 19. P. 1–12.

  40. Cullen P, Schulte H, Assmann G. The Münster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation. 1997 Oct 7;96(7):2128-36. DOI: 10.1161/01.cir.96.7.2128

  41. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996 Apr;3(2):213-9.

  42. Guo YY, Li HX, Zhang Y, He W.H. Hypertriglyceridemiainduced acute pancreatitis: progress on disease mechanisms and treatment modalities. Discov Med. 2019 Feb; 27(147): 101-109.

  43. Kiss L, Fűr G, Mátrai P, et al. The e ect of serum triglyceride concentration on the outcome of acute pancreatitis : systematic review and meta-analysis. Sci Rep. 2018; 8(1): 14096. DOI: 10.1038/s41598-018-32337-x

  44. Lloret Linares C, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008; 37: 13–2. DOI: 10.1097/MPA.0b013e31816074a1

 

FROM PRACTICAL EXPERIENCE

UDC 616.587-007.24-08

DOI: 10.20969/VSKM.2023.16(4).111-117

PDF download CORRECTION OF FIFTH TOE DEFORMITY OF THE FOOT

LEONOVA SVETLANA N., ORCID ID: 0000-0003-3675-6355; D. Med. Sci., senior researcher of Irkutsk Science Centre of Surgery and Traumatology, Russia, 664003, Irkutsk, Bortsov Revolyucii str., 1, e-mail: svetlana. leonova.1963@mail.ru

USOLTSEV IVAN V., ORCID ID: 0000-0002-4175-8403; C. Med. Sci., researcher of Irkutsk Science Centre of Surgery and Traumatology, Russia, 664003, Irkutsk, Bortsov Revolyucii str., 1, e-mail: ivu38@mail.ru

KOSAREVA MARIYA A., ORCID ID: 0000-0003-0530-3409; junior researcher of Irkutsk Science Centre of Surgery and Traumatology, Russia, 664003, Irkutsk, Bortsov Revolyucii str., 1, e-mail: mary.good.mary@yandex.ru

Abstract. Introduction. The analysis of literature data on the surgical treatment of fth toe static deformity, as well as unsatisfactory results, was carried out. The disadvantages of the known methods were identi ed and a method for correcting the fth nger varus deviation was proposed. Aim. The purpose of this article is to present own clinical observation of the fth toe varus deviation operative correction by a proposed method with a detailed description of its methodology. Material and methods. A clinical case of successful surgical correction of isolated fth toe varus deformity of the foot is presented. Results and discussion. A 22-year-old patient with a painful fth toe varus deformity, which was diagnosed by a clinical and radiological examination and requiring surgical correction. Surgical treatment, by proposed method, included performing a diaphyseal osteotomy of the fth metatarsal bone with formation of two bone «steps» on plantar fragment along precisely marked lines, medial displacement of the plantar fragment by a predetermined distance, interlocking fragments of the metatarsal bone and xing them with one screw. The proposed method allows to shift the plantar fragment as much as possible, straighten the fth nger, restore the congruence of the articular surfaces of the fth metatarsophalangeal joint, eliminate pain, and tightly stabilize the plantar and dorsal fragments. The patient was observed for 1 year. The result of the treatment was the elimination of fth toe varus deviation. Conclusion. Surgical treatment of fth toe varus deformity by using new method with special markings and simple surgical techniques, ensures the achievement of a positive result, good xation and consolidation of osteotomized fragments of the fth metatarsal, relief of pain, restoration of the anatomical condition and statodynamic function of the foot, reducing the risk of fracture of the fth metatarsal and recurrence of varus deformity the fth toe.

Keywords: fth toe varus deformity of the foot, osteotomy of the fth metatarsal, Tailor’s Bunion

For reference: Leonova SN, Usoltsev IV, Kosareva MA. Correction of fth toe deformity of the foot. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 111-117. DOI: 10.20969/VSKM.2023.16(4).111-117.

References

Литература

  1. Weil L Jr, Consul D. Fifth Metatarsal Osteotomies. Clin Podiatr Med Surg. 2015 Jul;32(3):333-53. DOI: 10.1016/j.cpm.2015.03.001. PMID: 26117571

  2. Lui TH. Percutaneous osteotomy of the fth metatarsal for symptomatic bunionette. J Foot Ankle Surg. 2014 Nov-Dec;53(6):747-52. DOI: 10.1053/j. jfas.2014.07.016. Epub 2014 Aug 29. PMID: 25176003

  3. La enêtre O, Millet-Barbé B, Darcel V, et al. Percutaneous bunionette correction: results of a 49-case retrospective study at a mean 34 months’ follow-up. Orthop Traumatol Surg Res. 2015 Apr;101(2):179-84. DOI: 10.1016/j.otsr.2014.11.017. Epub 2015 Feb 18. PMID: 25701161

  4. Michels F, Van Der Bauwhede J, Guillo S, et al. Percutaneous bunionette correction. Foot Ankle Surg. 2013 Mar;19(1):9-14. DOI: 10.1016/j.fas.2012.06.003. Epub 2012 Jul 4. PMID: 23337269

  5. Richard Paterson, Nikiforos Pandelis Saragas, Paulo Norberto Faria Ferrao. Comparison of 2 Oblique Fifth Metatarsal Osteotomies for the Management of a Bunionette. Foot & Ankle Orthopaedics. 2021, Vol. 6(1) 1-10 a The Author(s) 2021. DOI: 10.1177/2473011421993793

  6. Waizy H, Jastifer JR, Stukenborg-Colsman C, Claassen L. The Reverse Ludlo Osteotomy for Bunionette Deformity. Foot Ankle Spec. 2016 Aug;9(4):324-9. DOI: 10.1177/1938640016640886. Epub 2016 Mar 30. PMID: 27030363

  7. Albert A, Zribi M, Christophe A, Leemrijse T. Fifth metatarsal scarf osteotomy without implant xation. Orthop Traumatol Surg Res. 2021 Oct;107(6):102960. DOI: 10.1016/j.otsr.2021.102960. Epub 2021 May 13. PMID: 33992833

  8. Загородний Н.В., Карданов А.А., Макинян Л.Г., и др. Хирургическое лечение деформации пятого плюсне-фалангового сустава // Травматология и ортопедия России. – 2009 - No 3 (53). – С. 37 – 40. [Zagorodniy NV, Kardanov AA, Makinyan LG, et al. Khirurgicheskoe lechenie deformatsii pyatogo plyusne-falangovogo sustava [Surgical treatment of deformity of the fth metatarsal-phalangeal]. Travmatologiya i ortopediya Rossii [Traumatology and orthopedics of Russia]. 2009; 3 (53): 37 – 40 (in Russ.)].

  9. Barouk LS, Barouk P. Bunionette. In: Springer Ed, editor. Reconstruction de l’avant pied. Paris: Springer Verlag - ISBN; 2005, 2287289445.

  10. Seide HW, Petersen W. Tailor’s bunion: results of a scarf osteotomy for the correction of an increased intermetatarsal IV/V angle. A report on ten cases with a 1-year follow-up. Arch Orthop Trauma Surg. 2001;121(3):166-9. DOI: 10.1007/s004020000210. PMID: 11262784

  11. Glover JP, Weil L Jr, Weil LS Sr. Scarfette osteotomy for surgical treatment of bunionette deformity. Foot Ankle Spec. 2009 Apr;2(2):73-8. DOI: 10.1177/1938640009332666. PMID: 19825755

  12. Maher AJ, Kilmartin TE. Scarf osteotomy for correction of Tailor’s bunion: mid- to long-term followup. Foot Ankle Int. 2010 Aug;31(8):676-82. DOI: 10.3113/ FAI.2010.0676. PMID: 20727315

  13. Guha AR, Mukhopadhyay S, Thomas RH. ‘Reverse’ scarf osteotomy for bunionette correction: Initial results of a new surgical technique. Foot Ankle Surg. 2012 Mar; 18(1):50-4. DOI: 10.1016/j.fas.2011.03.005. Epub 2011 Apr 13. PMID: 22326005

  14. Necas L, Hrubina M, Skotak M, et alю Bunionette deformity corrected with «shortening» scarf osteotomy of the fth metatarsal: mid-term results of a 34-cases. Foot Ankle Surg. 2020 Jul;26(5):541-546. DOI: 10.1016/j.fas.2019.06.001. Epub 2019 Jun 19. PMID: 31255576

  15. Maestro M. Scarf osteotomy without screw xation. Interact Surg 2007; 2:12–6, DOI: 10.1007/s11610-007-0014-x

  16. Leemrijse T, Maestro M, Tribak K, et al. Scarf osteotomy without internal xation to correct hallux valgus. Orthop Traumatol Surg Res. 2012 Dec;98(8):921-7. DOI: 10.1016/j.otsr.2012.07.008. Epub 2012 Nov 9. PMID: 23142299

  17. Ceccarini P, Rinonapoli G, Nardi A, et al. Foot Ankle Spec. 2017 Apr;10(2):157-161. DOI: 10.1177/1938640016679696. Epub 2016 Nov 30. PMID: 27903926

  18. Coughlin MJ. Treatment of bunionette deformity with longitudinal diaphyseal osteotomy with distal soft tissue repair. Foot Ankle. 1991 Feb;11(4):195-203. DOI: 10.1177/107110079101100402. PMID: 1855704

  19. Coughlin MJ, Saltzman L, Anderson B. Mann’s Surgery of the Foot and Ankle. 9th ed. Philadelphia, PA: Elsevier Health Sciences; 2014

  20. Shi GG, Humayun A, Whalen JL, Kitaoka HB. Management of Bunionette Deformity. J Am Acad Orthop Surg. 2018 Oct 1;26(19): e396-e404. DOI: 10.5435/JAAOS-D-17-00345. PMID: 30130354

  21. Waizy H, Jastifer JR, Stukenborg-Colsman C, Claassen L. The Reverse Ludlo Osteotomy for Bunionette Deformity. Foot Ankle Spec. 2016 Aug;9(4):324-9. DOI: 10.1177/1938640016640886. Epub 2016 Mar 30. PMID: 27030363

  22. Martijn HA, Sierevelt IN, Wassink S, Nolte PA. Fifth Metatarsal Osteotomies for Treatment of Bunionette Deformity: A Meta-Analysis of Angle Correction and Clinical Condition. J Foot Ankle Surg. 2018 Jan-Feb; 57(1):140-148. DOI: 10.1053/j.jfas.2017.08.006. PMID: 29268897

  23. Лукин М.П. Хирургическое лечение деформации пятого плюснефалангового сустава: автореф. дис. ... канд. мед. наук / Лукин Максим Прокопьевич. – М., 2009 [Lukin MP. Khirurgicheskoe lechenie deformatsii pyatogo plyusnefalangovogo sustava: avtoref. dis. ... kand. med. nauk / Lukin Maksim Prokopyevich. [Surgical treatment of deformity of the fth metatarsophalangeal joint: autoref. dis. ... Candidate of Medical Sciences / Maxim Prokopievich Lukin]. M; 2009. (in Russ.)].

  24. Okuda R, Kinoshita M, Morikawa J, et al. Proximal dome-shaped osteotomy for symptomatic bunionette. Clin Orthop Relat Res. 2002 Mar;(396):173-8. DOI: 10.1097/00003086-200203000-00026. PMID: 11859240

  25. Carlos Benavente Valdivia J, Thull DM. Minimally Invasive Distal Chevron Osteotomy for Symptomatic Bunionette: Clinical and Radiologic Results of a 31-Case Retrospective Study. Foot Ankle Orthop. 2022 May 19;7(2):24730114221099022. DOI: 10.1177/24730114221099022. PMID: 35615075; PMCID: PMC9125066

 

UDC: 616.135-053.2-06:616.831-005.1

DOI: 10.20969/VSKM.2023.16(2).118-123

PDF download A CLINICAL CASE OF AORTIC COARCTATION IN A CHILD COMPLICATED BY ISCHEMIC STROKE

SAGITOVA GULNARA R, ORCID ID:0000-0002-8377-6212; D. Med. Sci., professor, Head of Department of Pediatrics with a postgraduate course of Astrakhan State Medical University, Russia, 414000, Astrakhan, ul. Bakinskaya, 121, e-mail: sagitova-gulnara04@yandex.ru

TKACHEV IVAN V., ORCID ID: 0000-0002-4767-2088; pediatric cardiologist, Head of Department of Federal Center for Cardiovascular Surgery, Russia, 414014, Russia, Astrakhan, 4 Pokrovskaya Grove str., e-mail: john-tv@yandex.ru

ANTONOVA ALYONA A., ORCID ID: 0000-0003-2581-04084; C. Med. Sci., Associate Professor of the Department of Pediatrics with a postgraduate course of Astrakhan State Medical University, Russia, 414000, Russia, Astrakhan, ul. Bakinskaya, 121, e-mail: fduecn-2010@mail.ru

DAVYDOVA OKSANA V., ORCID ID: 0000-0001-5616-7342; C. Med. Sci., Associate Professor of the Department of Pediatrics with a postgraduate course of Astrakhan State Medical University, Russia, 414000, Russia, Astrakhan, ul. Bakinskaya, 121, e-mail: оksada2009@yandex.ru

Abstract. Introduction. Aortic coarctation is a congenital defect of the cardiovascular system characterized by narrowing in the isthmus of the aorta, in which blood ow through the narrowed area is obstructed, blood pressure in the aorta increases signi cantly above the narrowing site, arterial hypertension syndrome develops, which can lead to a stroke. Aim. To analyze a clinical case of aortic coarctation, rst detected in a 4.5-year-old child, and late- diagnosed arterial hypertension led to an ischemic stroke. Material and methods. The boy D., at the age of 4.5 years, was admitted to the hospital at the place of residence with symptoms of a stroke on the background of complete well-being. Echocardiography, electrocardiography, magnetic resonance and computed tomography of the brain, computed tomography of the chest organs with contrast, aortography, and manometry were performed. Results and discussion. The crisis course of arterial hypertension resistant to therapy was objectively noted. Echocardiography revealed coarctation of the aorta in a typical place, the defect was con rmed on computed tomography of the chest organs with contrast, on magnetic resonance imaging of the brain – extensive ischemic stroke of the right hemisphere. The early post-stroke period, post-ischemic changes in the brain made it di cult to choose cardiac surgery tactics, but given the lack of response to hypotensive therapy, it was decided to operate, resection of the narrowed aortic area with the formation of an end-to-end anastomosis was performed. Observation in the postoperative period (after 2 years) revealed hypoplasia of the distal part of the aortic arch, repeated surgery was not performed, since angiography with manometry showed a su cient pressure gradient between the ascending and descending aorta. Currently, the child is on constant hypotensive therapy, is disabled due to neurological pathology. Conclusion. The lack of alertness of doctors regarding aortic coarctation and blood pressure monitoring did not allow early suspicion of this pathology and led to the appearance of ischemic stroke in the child, irreversible changes in the nervous system, made it di cult to choose cardiac surgery tactics.

Key words: aortic coarctation, late diagnosis, arterial hypertension, ischemia, stroke.

For reference: Sagitova GR, Tkachev IV, Antonova AA, Davydova OV. A clinical case of aortic coarctation in a child complicated by ischemic stroke. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 118-123.
DOI: 10.20969/VSKM.2023.16(4).118-123.

References

1. Ильин А.С., Теплов П.В., Сакович В.А. Коарктация аорты как патология сердечно-сосудистой системы. Наши возможности в хирургии // Сибирское медицинское обозрение. – 2018. – вып.3. – С. 24-33. [Il’in AS, Teplov PV, Sakovich VA. Koarktaciya aorty kak patologiya serdechno-sosudistoj sistemy. Nashi vozmozhnosti v hirurgii [Aortic coarctation as a pathology of the cardiovascular system. Our possibilities in surgery]. Sibirskoe medicinskoe obozrenie [Siberian Medical Review]. 2018; 3:24-33. (In Russ.)]. DOI: 10.20333/2500136-2018-3-24-33

2. Петрухин А.С., Бобылова М.Ю., Михайлова С.В. Этиология инсульта у детей // Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. – 2015. – Т.115, вып.3-2. – С.64-74. [Petruhin AS, Bobylova MYu, Mihajlova SV. Etiologiya insul’ta u detej [Etiology of stroke in children]. ZHurnal nevrologii i psihiatrii im. S.S. Korsakova. Specvypuski [Journal of Neurology and Psychiatry named after S.S. Korsakov. Special issues]. 2015; 115 (3-2): 64-74. (In Russ.)]. DOI: 10.17116/jnevro20151153264-74

3. Сойнов И.А., Архипов А.Н., Кулябин Ю.Ю., и др. Ар-териальная гипертензия у детей после коррекции коарктации аорты: проблемы диагностики и лечения // Патология кровообращения и кардиохирургия. – 2018. – Т.22, вып.4. – С.21-34. [Sojnov IA, Arhipov AN, Kulyabin YuYu, et al. Arterial’naya gipertenziya u detej posle korrekcii koarktacii aorty: problemy diagnostiki i lecheniya [Arterial hypertension in children after correction of aortic coarctation: problems of diagnosis and treatment]. Patologiya krovoobrashcheniya i kardiohirurgiya [Pathology of blood circulation and cardiac surgery]. 2018; 22(4): 21-34. (In Russ.)]. DOI: 10.21688/1681 -3472-2018-4-21 -34

4. Синельников Ю.С., Гасанов Э.Н., Орехова Е.Н. Сосудистая дисфункция у пациентов с коарктацией аорты: двухлетние результаты после коррекции в раннем возрасте // Патология кровообращения и кардиохирургия. – 2017. – Т.21, вып.1. – С.62-68. [Sinel’nikov YuS, Gasanov EN, Orekhova EN. Sosudistaya disfunkciya u pacientov s koarktaciej aorty: dvuhletnie rezul’taty posle korrekcii v rannem vozraste [Vascular dysfunction in patients with aortic coarctation: two-year results after correction at an early age]. Patologiya krovoobrashcheniya i kardiohirurgiya [Pathology of blood circulation and cardiac surgery]. 2017;21 (1):62-68. (In Russ.)]. DOI: 10.21688/1681 -3472-2017-1 -62-68

5. Moore JW, Vincent RN, Beekman RH, et al. Procedural results and safety of common interventional procedures in congenital heart disease initial report from the National Cardiovascular Data Registry. J. Am. Coll. Cardiol. 2014; 64 (23): 2439–51.

6. Lee MG, Brink J, Galati JC, et al. End-to-side repair for aortic arch lesions o ers excellent chances to reach adulthood without reoperation. Ann. Thorac. Surg. 2014; 98: 1405–11.

7. Ильинов В.Н., Кривощеков Е.В., Шипулин В.М. Хирургическое лечение коарктации аорты в сочетании с гипоплазией дуги // Сибирский медицинский журнал (Томск). – 2014. – Т.29, вып 3. – С.80-86. [Il’inov VN, Krivoshhekov EV, Shipulin VM. Hirurgicheskoe lechenie koarktacii aorty v sochetanii s gipoplaziej dugi [Surgical treatment coarctation of the aorta with hypoplastic aortic arch]. Sibirskij medicinskij zhurnal (Tomsk) [Siberian Medical Journal (Tomsk)]. 2014; 29(3): 80-86. (in Russ.)] DOI.10.29001/2073-8552-2014-29-3-80-86

8. Mery CM, Guzman-Pruneda FA, Carberry KE, et. al. Aortic arch advancement for aortic coarctation and hypoplastic aortic arch in neonates and infants. Ann. Thorac. Surg. 2014; 98 (2): 625–33; disc. 633.

9. Калашникова Е.А., Никитина Н.А., Галич С.Р. Диагностика, клиника, лечение и прогноз при коарктации аорты у детей // Здоровье ребенка. – 2015. – вып.1. – С.129-132. [Kalashnikova EA, Nikitina NA, Galich SR. Diagnostika, klinika, lechenie i prognoz pri koarktacii aorty u detej [Diagnosis, clinic, treatment and prognosis of coarctation of the aorta in children]. Zdorov’e Rebenka [Child’s health]. 2015;(1):129-132 (in Russ.)] https://cyberleninka.ru/article/n/diagnostika- klinika-lechenie-i-prognoz-pri-koarktatsii-aorty-u-detey ?ysclid=ljmsx8tsvi406979981

10. Ремезова Т.С. Отдаленные результаты хирургического лечения коарктации аорты у детей грудного возраста // Детские болезни сердца и сосудов. – 2011. – вып.1. – С.31-36. [Remezova TS. Otdalennye rezul’taty hirurgicheskogo lechenija koarktacii aorty u detej grudnogo vozrasta [Long-term results of surgical treatment of coarctation of the aorta in infants]. Detskie bolezni serdca i sosudov [Heart and Vessels Diseases in Children]. 2011;(1):31-36. (in Russ.)]. http://elib. fesmu.ru/eLib/Article.aspx?id=241627&ysclid

 

HEALTH ORGANIZATION

UDC 614.2

DOI: 10.20969/VSKM.2023.16(4).124-131

PDF download STAGES OF REHABILITATION FOR WOMEN AFTER EARLY REPRODUCTIVE LOSS

ALESHKINA OKSANA S., ORCID ID: 0000-0002-0505-197X; deputy chief physician for the medical department of City Clinical Hospital No. 8, Russia, Ryazan, ul. Kashirina, 6; e-mail: aleshkinaoxana@yandex.ru

KONOVALOV OLEG E., ORCID ID: 0000-0003-1974-9882; D. Med. Sci., Professor of the Department of Public Health, Health Care and Hygiene of the Medical Institute of the Peoples’ Friendship University of Russia named after Patrice Lumumba. Russia, Moscow, st. Miklukho-Maklaya, 10, bldg. 2; e-mail: konovalov_oe@mail.ru

SHULAYEV ALEXEY V., ORCID ID: 0000-0002-2073-2538; Dr. Med. Sci., Professor, Vice-Rector, Head of the Department of General Hygiene of the Kazan State Medical University. Russia, Kazan, st. Butlerova, 49; e-mail: alexs_ shu@mail.ru

PRISTUPA EVGENIA M., ORCIDID: 0000-0002-1227-5939; C. Med. Sci., Associate Professor, Associate Professor of the Department of Obstetrics and Gynecology, Ryazan State Medical University. acad. I.P. Pavlov. Russia, Ryazan, st. High voltage, 9; e-mail: empristupa@mail.ru

BREUSOV ALEXEY V., ORCID ID: 0000-0003-2335-3338; D. Med. Sci., Professor of the Department of Public Health, Health Care and Hygiene of the Medical Institute of the Peoples’ Friendship University of Russia named after Patrice Lumumba. Russia, Moscow, st. Miklukho-Maklaya, 10, bldg. 2; head of department Public Health and Healthcare of the Institute of Continuing Education with the Lean Technologies Training Center Kursk State Medical University. Russia, Kursk, st. K. Marx, 3; e-mail: ab69@yandex.ru

Abstract. Introduction. For all early reproductive losses, the need for restorative treatment is common. Aim. The purpose of the study is to analyze the experience of the gynecological hospital in Ryazan on a 3-stage comprehensive rehabilitation of women with early reproductive losses. Material and Methods. The development of this algorithm was carried out on the basis of an analysis of the results of research and the experience of leading research centers. A sociological survey was carried out among 128 obstetrician-gynecologists working in the gynecological department of the hospital and antenatal clinics in Ryazan. Results and discussion. The results of a sociological survey among obstetricians-gynecologists con rmed the importance of rehabilitation measures after early reproductive loss, as well as assessing the health status of women, including in terms of psycho-emotional status. At the same time, 44.8 % of respondents believed that the rehabilitation of women after early pregnancy loss should be carried out in a day hospital, 23.9% in a round-the-clock hospital, 21.6% - on an outpatient basis, 9.7% of the surveyed doctors found it di cult to answer. A description is given of the content of each of the three stages (stationary, restorative and supportive) of the developed and tested scheme of complex rehabilitation. Based on the results of the third stage, the doctor gives a comprehensive assessment of the woman’s reproductive health after the loss of pregnancy, together with the patient determines her further reproductive plan: either prescribe reliable contraception or prenatal preparation. Conclusion.Implementation The three-stage rehabilitation scheme makes it possible to provide full-scale specialized medical care for the restoration of reproductive health and psycho-emotional sphere to women with early reproductive loss, as well as to form their further reproductive plans.

Keywords: early reproductive losses, rehabilitation, stages.

For reference: Aleshkina OS, Konovalov OE, Shuvalov AV, et al. Stages of rehabilitation of women after early reproductive losses. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 124-131.
DOI: 10.20969/VSKM.2023.16(4).124-131.

References

  1. Вовк И.Б., Кондратюк В.К., Трохимович О.Б., Бори О.Ю. Алгоритм обследования и лечения женщин с разными формами ранних потерь беременности // Здоровье женщины. - 2013. - No 6 (82). - С. 97. [Vovk IB, Kondratyuk VK, Trohimovich OB, Bori OYu. Algoritm obsledovaniya i lecheniya zhenshchin s raznymi formami rannih poter’ beremennosti [Algorithm for the examination and treatment of women with di erent forms of early pregnancy loss]. Zdorov’e zhenshchiny [Women’s health]. 2013; 6 (82): 97 p. (In Russ.)].

  2. Бушмелева Н.Н., Вахрушева Ю.Н. Этиопатогенетический аспект ранних репродуктивных потерь при совершенствовании организации медицинской помощи женщинам (аналитический обзор) // Социальные аспекты здоровья населения. - 2020. - Т. 66, No 5. [Bushmeleva NN, Vahrusheva YuN. Etiopatogeneticheskij aspekt rannih reproduktivnyh poter’ pri sovershenstvovanii organizacii medicinskoj pomoshchi zhenshchinam (analiticheskij obzor) [Etiopathogenetic aspect of early reproductive losses in the process of improving the organization of medical care for women (analytical review)]. Social’nye aspekty zdorov’ya naseleniya [Social aspects of public health]. 2020; 66 (5). (In Russ.)]. http://vestnik.mednet.ru/ content/view/1199/30/. DOI: 10.21045/2071-5021-2020-66-5-6

  3. Котова Е.Г., Кобякова О.С., Стародубов В.И. и др. Основные показатели здоровья матери и ребенка, деятельность службы охраны детства и родовспоможения в Российской Федерации: статистические материалы // М.: ЦНИИОИЗ Минздрава России, 2021. – 171 с. [Kotova EG, Kobyakova OS, Starodubov VI, et al. Osnovnye pokazateli zdorov’ya materi i rebenka, deyatel’nost’ sluzhby ohrany detstva i rodovspomozheniya v Rossijskoj Federacii: statisticheskie materialy [The main indicators of maternal and child health, the activities of the child protection and obstetric services in the Russian Federation: statistical materials]. M.: CNIIOIZ Minzdrava Rossii [M.: TsNIIOIZ of the Ministry of Health of Russia]. 2021: 171 p. (In Russ.)]. https://minzdrav.gov.ru/documents/6994- statisticheskaya-informatsiya

  4. Адамян Л.В., Артымук Н.В., Белокриницкая Т.Е. и др. Выкидыш в ранние сроки беременности: диагностика и тактика ведения: Клинические рекомендации (протокол лечения) - М., 2016. - 19 с. [Adamyan LV, Artymuk NV, Belokrinickaya TE. et al. Vykidysh v rannie sroki beremennosti: diagnostika i taktika vedeniya: Klinicheskie rekomendacii (protokol lecheniya) [Miscarriage in early pregnancy: diagnosis and management: Clinical guidelines (treatment protocol)]. 2016; 19 p. (In Russ.)]. https://rokb.ru/sites/default/ les/pictures/vykidysh_v_rannie_sroki_beremennosti_ diagnostika_i_taktika_vedeniya.pdf

  5. Озолиня Л.А., Овсепян Н.Р., Савченко Т.Н. Первый этап медицинской реабилитации пациенток после самопроизвольного выкидыша // Медицинский совет. - 2019. - No 7. - С. 70-75. [Ozolinya LA, Ovsepyan NR, Savchenko TN. Pervyj etap medicinskoj reabilitacii pacientok posle samoproizvol’nogo vykidysha [The rst stage of medical rehabilitation of patients after spontaneous miscarriage]. Medicinskij sovet [Medical advice]. 2019; 7: 70-75 (In Russ.)]. https://cyberleninka. ru/article/n/pervyy-etap-meditsinskoy-reabilitatsii-patsientok-posle-samoproizvolnogo-vykidysha

  6. Мицкевич Е.А., Дивакова Т.С. Реабилитация репродуктивной функции у пациентов с самопроизвольным выкидышем при истмико-цервикальной недостаточности в анамнезе // Репродуктивное здоровье. Восточная Европа. - 2022. - Т. 12, No 5. - С. 567-581. [Mickevich EA, Divakova TS. Reabilitaciya reproduktivnoj funkcii u pacientov s samoproizvol’nym vykidyshem pri istmiko-cervikal’noj nedostatochnosti v anamneze [Rehabilitation of reproductive function in patients with spontaneous miscarriage with a history of isthmic-cervical insu ciency]. Reproduktivnoe zdorov’e. Vostochnaya Evropa [Reproductive health. Eastern Europe]. 2022; 12 (5): 567-581 (In Russ.)].

  7. Серова О.Ф., Мельник Т.Н. Реабилитация после медицинского аборта – путь к сохранению репродуктивного здоровья женщин // Русский медицинский журнал.- 2007.-17.- 1266. [Serova OF, Mel’nik TN. Reabilitaciya posle medicinskogo aborta – put’ k sohraneniyu reproduktivnogo zdorov’ya zhenshchin [Rehabilitation after medical abortion - a way to preserve the reproductive health of women]. Russkij medicinskij zhurnal [Russian medical journal]. 2007; 17: 1266 p. (In Russ.)]. https://www.rmj.ru/articles/pediatriya/ Reabilitaciya _posle_medicinskogo_aborta__puty_k_ sohraneniyu_reproduktivnogo_zdorovyya_ghenschin/

  8. Вартанян Э.А., Заргарова А.Э., Шестаков Г.С., Нечаев В.С. Разработка структурно-функциональной модели мониторинга состояния репродуктивного здоровья женщин с диагнозом привычное невынашивание // Социальные аспекты здоровья населения. - 2018. - No6. [Vartanyan EA, Zargarova AE, Shestakov GS, Nechaev VS. Razrabotka strukturno-funkcional’noj modeli monitoringa sostoyaniya reproduktivnogo zdorov’ya zhenshchin s diagnozom privychnoe nevynashivanie [Development of a structural and functional model for monitoring the reproductive health of women with a diagnosis of recurrent miscarriage]. Social’nye aspekty zdorov’ya naseleniya [Social aspects of public health]. 2018; 6 (In Russ.)]. DOI: 10.21045/2071-5021-2018-64-6-10

  9. Грудницкая Е.Н., Воскресенский С.Л. Привычная потеря беременности: современный взгляд на проблему (обзор литературы) // Репродуктивное здоровье. Восточная Европа. - 2020. - Т. 10, No 3. - С. 330-339. [Grudnickaya EN, Voskresenskij SL. Privychnaya poterya beremennosti: sovremennyj vzglyad na problemu (obzor literatury) [Habitual pregnancy loss: a modern view of the problem (literature review)]. Reproduktivnoe zdorov’e. Vostochnaya Evropa [Reproductive health. Eastern Europe.]. 2020; 10 (3): 330-339 (In Russ.)]. DOI: 10.34883/PI.2020.10.3.011

  10. Приказ Минздрава России от 01.11.2012 года No 572н «Об утверждении Порядка оказания медицинской помощи по профилю «акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)». [Prikaz Minzdrava Rossii ot 01.11.2012 goda No 572n «Ob utverzhdenii Poryadka okazaniya medicinskoj pomoshchi po pro lyu «akusherstvo i ginekologiya (za isklyucheniem ispol’zovaniya vspomogatel’nyh reproduktivnyh tekhnologij)». [Order of the Ministry of Health of Russia dated November 1, 2012 No. 572n “On approval of the Procedure for providing medical care in the eld of obstetrics and gynecology (with the exception of the use of assisted reproductive technologies)”] (In Russ.)]. https://base.garant.ru/70352632/

  11. Приказ Минздрава России от 07.11.2012 года No 590н «Об утверждении стандарта специализированной медицинской помощи при самопроизвольном прерывании беременности». [Prikaz Minzdrava Rossii ot 07.11.2012 goda No 590n «Ob utverzhdenii standarta specializirovannoj medicinskoj pomoshchi pri samoproizvol’nom preryvanii beremennosti». [Order of the Ministry of Health of Russia dated November 7, 2012 No. 590n “On approval of the standard for specialized medical care in case of spontaneous abortion”.] (In Russ.)]. https://minzdrav.gov.ru/documents/8907-prikaz- ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-7-noyabrya-2012-g-590n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-samoproizvolnom-preryvanii-beremennosti

  12. Аполихина И.А., Горбунова Е.А., Кубицкая Ю.В. и др. Реабилитация женщин после хирургического прерывания беременности в первом триместре: чья ответственность? // Медицинский совет. – 2015. – No11 – С. 84-89. [Apolihina IA, Gorbunova EA, Kubickayai YuV et al. Reabilitaciya zhenshchin posle hirurgicheskogo preryvaniya beremennosti v pervom trimestre: ch’ya otvetstvennost’? [Rehabilitation of women after surgical termination of pregnancy in the rst trimester: whose responsibility?] // Medicinskij sovet [Medical advice]. 2015; 11: 84-89 p. (In Russ.)]. https://cyberleninka.ru/ article/n/reabilitatsiya-zhenschin-posle-hirurgicheskogo-preryvaniya-beremennosti-v-pervom-trimestre-chya-otvetstvennost

  13. Радзинский В.Е., Алеев И.А., Бриль Ю.А., и др. Неразвивающаяся беременность. Методические рекомендации МАРС (Междисциплинарной ассоциации специалистов репродуктивной медицины) // М.: Status Praesens, 2015. — 48 с. [Radzinskij VE, Aleev IA, Bril’ YuA, et al. Nerazvivayushchayasya beremennost’. Metodicheskie rekomendacii MARS (Mezhdisciplinarnoj associacii specialistov reproduktivnoj mediciny) [Non-developing pregnancy. MARS (Interdisciplinary Association of Reproductive Medicine) Guidelines] // M.: StatusPraesens, 2015: 48 p. (In Russ.)]. https:// praesens.ru/ les/2021/web/nerazber.pdf

 

UDC 614.253.1/.2:614.254:331.101.32

DOI: 10.20969/VSKM.2023.16(4).132-137

PDF download SATISFACTION WITH THE WORK OF GENERAL PRACTITIONERS AND SURGEONS IN PUBLIC AND PRIVATE MEDICAL ORGANIZATIONS

SHUKUROV MURAT R., ORCID ID: 0009-0008-9784-9292; postgraduate student of the Department of Public Health, Health Care and Hygiene of the Medical Institute of the Peoples’ Friendship University of Russia (RUDN University), Moscow, Russian Federation. Russia, Moscow, st. Miklukho-Maklaya, 10, bldg. 2, e-mail: 1042215247@rudn.ru

KONOVALOV OLEG E., ORCID ID: 0000-0003-1974-9882; Scopus Author ID 7006781195; SPIN: 5181-8547, Author ID: 250753, Dr. Med. Sci., Professor of the Department of Public Health, Health Care and Hygiene of the Medical Institute of the Peoples’ Friendship University of Russia (RUDN University), Russia, Moscow, st. Miklukho-Maklaya, 10, bldg. 2, e-mail: konovalov_oe@mail.ru

SHULAEV ALEXEY V., ORCID ID: 0000-0002-2073-2538; Scopus Author ID 57204471176, SPIN: 3229-1913, AuthorID: 210271, Dr. Med. Sci., Professor, Vice-Rector, Head of the Department of General Hygiene, Kazan State Medical University, Russia, Kazan, st. Butlerova, 49, e mail: alexs_shu@mail.ru

Abstract. Introduction. Job satisfaction has a signi cant impact on the commitment of the sta of a medical organization and their motivation to work. Aim. To study satisfaction with the work of therapeutic and surgical doctors in medical organizations of various forms of ownership. Material and methods. With the help of a specially designed questionnaire, a sociological survey of 404 therapeutic and surgical doctors working in public and private medical organizations in the city of Voronezh was conducted. Results and discussion. According to the results of the survey, 78.0% of the doctors who participated in the study were completely or partially satis ed with their work, 4.7% were not satis ed at all, and 5.8% of the respondents found it di cult to answer. Doctors of public and private polyclinics are more often dissatis ed with their work than those working in hospitals. In addition, doctors of private medical organizations, both inpatient and outpatient, more often gave an overall positive assessment of satisfaction. In most cases, the reasons for job dissatisfaction were insu cient wages, somewhat less often an uncomfortable work schedule, low equipment of a medical organization and the level of work organization. Conclusion. The revealed features of satisfaction with the work of various gender and age groups of therapeutic and surgical doctors in medical organizations of various forms of ownership should be taken into account by management in the formation of personnel policy and corporate culture.

Keywords: doctors, specialty, type of medical organization, work, satisfaction.

For reference: Shukurov MR, Konovalov OE, Shulaev AV. Satisfaction with the work of general practitioners and surgeons in public and private medical organizations. The Bulletin of Contemporary Clinical Medicine. 2023; 16(4): 132-137. DOI: 10.20969/VSKM.2023.16(4).132-137.

References

Литература

  1. Андреева Т.В., Кудрина В.Г., Трущелев С.А. Социально-гигиеническая характеристика жизненных ценностей медицинских работников // Человек и лекарство. Тезисы докладов. Серия: «Библиотека Российского национального конгресса «Человек и лекарство». М., 2017. - С. 116. [Andreeva TV, Kudrina VG, Trushchelev SA. Social’no-gigienicheskaya harakteristika zhiznennyh cennostej medicinskih rabotnikov [Social and hygienic characteristics of life values of medical workers]. Chelovek i lekarstvo. Tezisy dokladov. Seriya: «Biblioteka Rossijskogo nacional’nogo kongressa «Chelovek i lekarstvo» [Man and medicine. Abstracts of reports. Series: «Library of the Russian National Congress «Man and medicine»]. M., 2017: 116. (In Russ.)]. URL: https://www.elibrary.ru/item. asp?id=29391071
  2. Гераськин Д.В. Коммуникативные игры сотрудников сферы здравоохранения // Вся жизнь - делу врачевания и просвещения. Материалы Всероссийской научно-практической конференции с международным участием. Омск, 2020. - С. 58-61. [Geras’kin DV. Kommunikativnye igry sotrudnikov sfery zdravoohraneniya [Communication games for healthcare professionals]. Vsya zhizn’ - delu vrachevaniya i prosveshcheniya. Materialy Vserossijskoj nauchno-prakticheskoj konferencii s mezhdunarodnym uchastiem [All life is the cause of healing and education. Materials of the All-Russian scienti c and practical conference with international participation]. Omsk, 2020: 58-61 (In Russ.)].
  3. Кудрина В.Г., Садыкова Т.И., Липатова Е.Л., и др. Информационные технологии в современном дополнительном профессиональном образовании медицинских работников // Врач и информационные технологии. - 2022. - No 3. - С. 36-43. [Kudrina VG, Sadykova TI, Lipatova EL, et al. Informacionnye tekhnologii v sovremennom dopolnitel’nom professional’nom obrazovanii medicinskih rabotnikov [Information technologies in modern additional professional education of medical workers]. Vrach i informacionnye tekhnologii [Doctor and information technology]. 2022; 3: 36-43 (In Russ.)]. DOI: 10.25881/18110193_2022_3_36
  4. Черкасов С.Н., Костикова А.Ю. Удовлетворенность врачей государственных медицинских учреждений // Международный научно-исследовательский журнал. - 2017. - No 4–3. - С. 198–200. [Cherkasov SN, Kostikova AYu. Udovletvorennost’ vrachej gosudarstvennyh medicinskih uchrezhdenij [Satisfaction of doctors of state medical institutions]. Mezhdunarodnyj nauchno-issledovatel’skij zhurnal [International research journal]. 2017; 4–3: 198–200. (In Russ.)]. URL: https:// cyberleninka.ru/article/n/udovletvorennost-vrachey-gosudarstvennyh-meditsinskih-uchrezhdeniy
  5. Канева Д.А. Развитие мотивационных механизмов в управлении персоналом медицинских органи-заций различных форм собственности / Д.А. Канева: автореф. дис. ... канд. мед. наук. М.: РУДН, 2019. - 25 с. [Kaneva DA. Razvitie motivacionnyh mekhanizmov v upravlenii personalom medicinskih organizacij razlichnyh form sobstvennosti [Development of motivational mechanisms in personnel management of medical organizations of various forms of ownership]. D.A. Kaneva: avtoref. dis. ... kand. med. nauk. M.: RUDN, 2019: 25 (In Russ.)]. URL: https://cyberleninka. ru/article/n/razvitie-motivatsionnyh-mehanizmov-v-upravlenii-personalom-meditsinskih-organizatsiy-razlichnyh-form-sobstvennosti-obzor-literatury
  6. Богдан И.В. Новые подходы к позиционированию образа медицинского работника в диалоге с молодыми специалистами системы здравоохранения // Социология здоровья: уроки пандемии и контуры будущего здравоохранения. Труды III Форума с международным участием. М., 2021. – С. 45-47. [Bogdan IV. Novye podhody k pozicionirovaniyu obraza medicinskogo rabotnika v dialoge s molodymi specialistami sistemy zdravoohraneniya [New approaches to positioning the image of a medical worker in a dialogue with young healthcare professionals]. Sociologiya zdorov’ya: uroki pandemii i kontury budushchego zdravoohraneniya. Trudy III Foruma s mezhdunarodnym uchastiem [Sociology of health: lessons from the pandemic and the contours of the future of healthcare. Proceedings of the III Forum with international participation]. M., 2021: 45-47 (In Russ.)]. URL: https://www.elibrary.ru/item. asp?edn=aqvvla
  7. Hjalmarsson A, Östlund G, Asp M, et al. Matter of participation? A critical incident study of municipal care personnel in situations involving care-dependent older persons and emergency medical services. Int J Qual Stud Health Well-being. 2022; 17 (1): 2082062.
  8. Stokar YN, Pat-Horenczyk R. E ects of end-of-life care on medical health professionals: A dialectical approach // Palliat Support Care. 2022; 20 (1): 76-83.
  9. Волнухин А.В. Удовлетворенность медицинского персонала сети негосударственных поликлиник условиями труда // European Research. – 2017. - No1. – С. 91–93. [Volnuhin AV. Udovletvorennost’ medicinskogo personala seti negosudarstvennyh poliklinik usloviyami truda [Satisfaction of medical personnel of the network of non-state polyclinics with working conditions] European Research [European Research]. 2017; 1: 91–93 (In Russ.)] URL: https://cyberleninka.ru/article/n/ udovletvorennost-meditsinskogo-personala-seti-negosudarstvennyh-poliklinik-usloviyami-truda
  10. Орел В.И. Актуальные проблемы оплаты труда в медицинских организациях, оказывающих первичную медико-санитарную помощь. Медицина и организация здравоохранения. - 2022. Т. 7, No 3. – С. 12-19. [Orel VI. Aktual’nye problemy oplaty truda v medicinskih organizaciyah, okazyvayushchih pervichnuyu mediko-sanitarnuyu pomoshch’ [Actual problems of remuneration in medical organizations providing primary health care]. Medicina i organizaciya zdravoohraneniya [Medicine and healthcare organization]. 2022; 7 (3): 12-19.] URL: https://cyberleninka.ru/article/n/aktualnye- problemy-oplaty-truda-v-meditsinskih-organizatsiyah-okazyvayuschih-pervichnuyu-mediko-sanitarnuyu-pomosch
  11. Paniotto VI, Maksimenko V.S. Statistical analysis of sociological data. Kiev: Publishing House «KM Academy», 2004: 270.
  12. Грудницкая Е.Н., Воскресенский С.Л. Привычная потеря беременности: современный взгляд на проблему (обзор литературы) // Репродуктивное здоровье. Восточная Европа. - 2020. - Т. 10, No 3. - С. 330-339. [Grudnickaya EN, Voskresenskij SL. Privychnaya poterya beremennosti: sovremennyj vzglyad na problemu (obzor literatury) [Habitual pregnancy loss: a modern view of the problem (literature review)]. Reproduktivnoe zdorov’e. Vostochnaya Evropa [Reproductive health. Eastern Europe.]. 2020; 10 (3): 330-339 (In Russ.)]. DOI: 10.34883/PI.2020.10.3.011
  13. Приказ Минздрава России от 01.11.2012 года No 572н «Об утверждении Порядка оказания медицинской помощи по профилю «акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)». [Prikaz Minzdrava Rossii ot 01.11.2012 goda No 572n «Ob utverzhdenii Poryadka okazaniya medicinskoj pomoshchi po pro lyu «akusherstvo i ginekologiya (za isklyucheniem ispol’zovaniya vspomogatel’nyh reproduktivnyh tekhnologij)». [Order of the Ministry of Health of Russia dated November 1, 2012 No. 572n “On approval of the Procedure for providing medical care in the eld of obstetrics and gynecology (with the exception of the use of assisted reproductive technologies)”] (In Russ.)]. https://base.garant.ru/70352632/
  14. Приказ Минздрава России от 07.11.2012 года No 590н «Об утверждении стандарта специализированной медицинской помощи при самопроизвольном прерывании беременности». [Prikaz Minzdrava Rossii ot 07.11.2012 goda No 590n «Ob utverzhdenii standarta specializirovannoj medicinskoj pomoshchi pri samoproizvol’nom preryvanii beremennosti». [Order of the Ministry of Health of Russia dated November 7, 2012 No. 590n “On approval of the standard for specialized medical care in case of spontaneous abortion”.] (In Russ.)]. https://minzdrav.gov.ru/documents/8907-prikaz- ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-7-noyabrya-2012-g-590n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-samoproizvolnom-preryvanii-beremennosti
  15. Аполихина И.А., Горбунова Е.А., Кубицкая Ю.В. и др. Реабилитация женщин после хирургического прерывания беременности в первом триместре: чья ответственность? // Медицинский совет. – 2015. – No11 – С. 84-89. [Apolihina IA, Gorbunova EA, Kubickayai YuV et al. Reabilitaciya zhenshchin posle hirurgicheskogo preryvaniya beremennosti v pervom trimestre: ch’ya otvetstvennost’? [Rehabilitation of women after surgical termination of pregnancy in the rst trimester: whose responsibility?] // Medicinskij sovet [Medical advice]. 2015; 11: 84-89 p. (In Russ.)]. https://cyberleninka.ru/ article/n/reabilitatsiya-zhenschin-posle-hirurgicheskogo-preryvaniya-beremennosti-v-pervom-trimestre-chya-otvetstvennost

  16. Радзинский В.Е., Алеев И.А., Бриль Ю.А., и др. Неразвивающаяся беременность. Методические рекомендации МАРС (Междисциплинарной ассоциации специалистов репродуктивной медицины) // М.: Status Praesens, 2015. — 48 с. [Radzinskij VE, Aleev IA, Bril’ YuA, et al. Nerazvivayushchayasya beremennost’. Metodicheskie rekomendacii MARS (Mezhdisciplinarnoj associacii specialistov reproduktivnoj mediciny) [Non-developing pregnancy. MARS (Interdisciplinary Association of Reproductive Medicine) Guidelines] // M.: StatusPraesens, 2015: 48 p. (In Russ.)]. https:// praesens.ru/ les/2021/web/nerazber.pdf

 

HISTORY OF MEDICINE

UDC 61(091)

DOI: 10.20969/VSKM.2023.16(4).138-143

PDF download TO THE 225TH ANNIVERSARY OF THE PROMINENT RUSSIAN INTERNIST KARL KARLOVICH SEIDLITZ

EGORYSHEVA IRINA V., ORCID ID: 0000-0001-5936-8254, C. Hist. Sci., leading researcher of the Department of history of medicine and public health of N.A. Semashko National Scientific Research Institute of Public Health, 12, bld. 1, Vorontsovo Pole, Moscow, 105064, Russian Federation, е-mail: egorysheva@rambler.ru

MOROZOV ALEXEY V., ORCID ID: 0000-0001-7724-2735, Scopus - Author ID: 8455076900, Web of Science - Researcher ID: AAI-7096–2021; Deputy Head of the Medical Department of the FCS of Russia, Federal Customs Service, Russia, 107842, Moscow. Novozavodskaya str., 11/5; C. Med. Sci., Associate Professor, Peoples’ Friendship University of Russia (RUDN University), Department of History of Medicine, Address: 6, Miklukho-Maklaya Str., 117198 Moscow, Russian Federation, е-mail: a0067138@yandex.ru

Abstract. Introduction. 2023 marks the 225th anniversary of the birth of Karl Karlovich Seidlitz, a prominent Russian scientist, internal medicine doctor, professor of the Medical and Surgical Academy, one of the reformers of medical education and the founder of the clinical and anatomical method in Russian medicine, the founder of the department of the Faculty academic therapeutic Clinic, a close friend and biographer of the poet V.A. Zhukovsky. Аim. Is to show the role of K.K. Seidlitz in the development of clinical medicine and education in the Russian Empire. The appeal to his memory in the jubilee year allows us to preserve the continuity of generations. Material and methods. The study uses general methodological approaches for historical and medical research. The analysis of literary sources on the history of medicine is carried out, articles and materials revealing the priority and importance of the works of K.K. Seidlitz for medical science and the history of culture of Russia are studied. Results and discussion. The contribution of K.K. Seidlitz to the ght against infectious diseases in the Russian Empire is analyzed. K.K. Seidlitz was one of the rst to describe the clinic and epidemiology of leptospirosis. Having headed the therapeutic clinic of the St. Petersburg Medical and Surgical (now Military Medical) Academy, he was one of the rst in Russia to introduce di erential diagnostics, methods of physical research, created an outpatient clinic and a laboratory at the clinic for conducting research using microscopes discharged from Paris, introduced pathoanatomical studies of deceased patients, etc. Conclusion. In modern literature, the name of K.K. Seidlitz is primarily associated with the rst detailed in modern literature, the name of K.K. Seidlitz is primarily associated with the rst detailed systematized biography of the poet V.A. Zhukovsky written by him. However, K.K. Seidlitz has great merits in the eld of the development of clinical medicine in Russia and its teaching, which the reader should be reminded of.

Keywords: K.K. Seidlitz, clinical medicine, Imperial Medical and Surgical Academy, Temporary Medical Committee, Charter of the University of St. Vladimir (Kiev).

For reference: Yegorysheva IV, Morozov AV, To the 225th anniversary of the prominent Russian internist Karl Karlovich Seidlitz. The Вulletin of Contemporary Clinical Medicine. 2023. 16(4): 138-143. DOI: 10.20969/VSKM.2023.16(4).138-143.

References

1. Бородулин В.И. Клиника внутренних болезней в Российской империи. История в лицах // Москва: Лакуэр, 2020. – С. 36-38. [Borodulin VI. Klinika vnutrennih boleznej v Rossijskoj imperii. Istoriya v licah [Clinic of internal diseases in the Russian Empire. History in persons]. Moskva: Lakuer [Moscow: Lacouer]. 2020; 36-38 (In Russ.)].

2. Пупкевич – Диамант Я.С., Кузнецов И.А. Карл Карлович Зейдлиц и его время // СПб.: ЭЛБИ-СПб, 2003. – 220 с. [Pupkevich – Diamant YaS, Kuznecov IA. Karl Karlovich Zejdlic i ego vremya [Karl Karlovich Seidlitz and his time]. SPb. 2003; 220 p. (In Russ.)].

3. Зейдлиц Карл Карлович // Энциклопедический словарь Брокгауза и Эфрона: [в 86 т.] / под ред. К.К. Арсеньева СПб.: типо-литография И.А. Эфрона. Т. XXII: Жилы-Земпахъ 1894. - C. 380. [Zejdlic Karl Karlovich [Seydlitz Karl Karlovich]. Enciklopedicheskij slovar’ Brokgauza i Efrona: [v 86 t.] / pod red. K.K. Arsen’eva SPb.: tipo-litografiya I.A. Efrona. T. XXII: Zhily-Zempah [Encyclopedic dictionary of Brockhaus and Efron: [in 86 volumes] / edited by K.K. Arsenyev St. Petersburg: typolithography of I.A. Efron. Vol. XXII: Veins-Zempakh]. 1894: 380. (In Russ.)].

4. Зейдлиц Карл Карлович // Сборник Императорского Русского Исторического Общества. Азбучный указатель имен русских деятелей для Русского Биографического Словаря [в 148 т.] / Печ. под набл. Г.Ф. Штендмана СПб.: Императорская Академия наук. Т. 60: Ч.1 (А-Л) 1887. - С. 273. [Zejdlic Karl Karlovich [Seydlitz Karl Karlovich]. Sbornik Imperatorskogo Russkogo Istoricheskogo Obshchestva. Azbuchnyj ukazatel’ imen russkih deyatelej dlya Russkogo Biograficheskogo Slovarya [v 148 t.] / Pech. pod nabl. G.F. Shtendmana SPb.: Imperatorskoj Akademii nauk. T. 60: Ch.1 (AL) [The Collection of the Imperial Russian Historical Society. Russian Biographical Dictionary Alphabetical index of names of Russian figures [in 148 t.] / Oven. under the name of G.F. Shtendman St. Petersburg: Imperial Academy of Sciences. Vol. 60: Part 1 (A-L)]. 1887: 273. (In Russ.)].

5. Воспоминания доктора Зейдлица о турецком походе 1829 г. в письмах к друзьям // Русcкий Архив. - 1878. вып. 5 - С.88-113. [Vospominaniya doktora Zejdlica o tureckom pohode 1829 g. v pis’mah k druz’yam [Memoirs of Dr. Seidlitz about the Turkish campaign of 1829 in letters to friends]. Rusckij Arhiv [Russian Archive Books]. 1878; (5): 88-113. (In Russ.)]. 

6. Фарбер В.Б. К.К. Зейдлиц как клиницист // Клиническая медицина. - 1958. - Т. 36, вып. 1 - С. 154-158. [Farber VB. K.K. Zejdlic kak klinicist [K.K. Seidlitz as a clinician]. Klinicheskaya medicina [Clinical medicine]. 1958; 36(1): 154-158. (In Russ.)].

7. Здекауер Н.Ф. Русская старина // Императорская Санкт-Петербургская Медико-хирургическая академия, 1891. № 4. - С. 37, 117- 132. [Zdekauer N.F. Russkaya starina [Zdekauer N.F. Russian antiquity]. Imperatorskaya Sankt-Peterburgskaya Medikohirurgicheskaya akademiya [Imperial St. Petersburg Medical and Surgical Academy]. 1891; 4: 37, 117- 132. (In Russ.)].

8. Зейдлиц К.К. Отчет о занятиях в терапевтической клинике Медико-хирургической академии в течение 1839 - 1840 учебного года. Записки по части врачебных наук // Императорская Санкт-Петербургская Медико-хирургическая академия, 1841. Кн. 2. - С.110-142, Кн.3. - С. 1-136, Кн. 4. - С. 1-100. [Zejdlic K.K. Otchet o zanyatiyah v terapevticheskoj klinike Mediko-hirurgicheskoj akademii v techenie 1839-1840 uchebnogo goda. Zapiski po chasti vrachebnyh nauk [Report on classes at the therapeutic clinic of the Medical and Surgical Academy during the 1839-1840 academic year. Notes on the part of medical sciences]. Imperatorskaya Sankt-Peterburgskaya Medikohirurgicheskaya akademiya [Imperial St. Petersburg Medical and Surgical Academy]. 1841; Book 2:110-142, Book 3:1-136, Book 4: 1-100. (In Russ.)].

9. Кириков Н.Н. Материалы к истории русской клиники: Ученая и учебная деятельность проф. К. Зейдлица (Каф. Акад. тарапевт. клиники, С.-Петербург, 1836-1846 гг.) // Саратов: Типография Союза печатного дела, 1916. - 65 с. [Kirikov NN. Materialy k istorii russkoj kliniki: Uchenaya i uchebnaya deyatel’nost’ prof. K. Zejdlica (Kaf. Akad. tarapevt. kliniki, S.-Peterburg, 1836-1846 gg.) [Materials for the History of the Russian clinic: Scientific and educational activities of Prof. K.Seidlitz (Faculty of the Academy of Sciences. therapist. clinics, St. Petersburg, 1836-1846]. Saratov: Tipografiya Soyuza pechatnogo dela [Saratov: Printing House of the Union of Printing]. 1916; 65 p. (In Russ.)].

10. Профессора Военно-медицинской (Медико-хирургической) академии (1798-1998) / гл. ред. Ю.Л. Шевченко. СПб.: Наука, 1998. - С.117. [Professora Voenno-medicinskoj (Mediko-hirurgicheskoj) akademii (1798-1998) / gl. red. YuL Shevchenko [Professors of the Military Medical (Medico-Surgical) Academy (1798-1998) / Editor-in-chief Yu.L. Shevchenko]. SPb.: Nauka [SPb: Science]. 1998; 117 (In Russ.)].

11. Павловский Е.Н. Академик К.М. Бэр и Медико-хирургическая академия // Ленинград: Изд-ва Акад. наук СССР, 1948. - 216 с. [Pavlovskij EN. Akademik K.M. Ber i Mediko-hirurgicheskaya akademiya [Academician K.M. Behr and the Medical and Surgical Academy]. Leningrad: Izd-va Akad. nauk SSSR [Leningrad: Publishing House of the Academy of Sciences of the USSR]. 1948; 216 p. (In Russ.)].

12. Севастопольские письма Н.И. Пирогов 1854-1855 / под ред. Ю.Г. Малиса, СПб.: типография М. Мреркушева, 1907. – С. 177. [Sevastopol’skie pis’ma N.I. Pirogov 1854-1855 [Sevastopol letters of N.I. Pirogov 1854-1855]. Pod red. Yu.G. Malisa. SPb.: tipografiya M. Mrerkusheva [edited by Yu.G. Malis. SPb house of M. Merkushev]. 1907: 177 (In Russ.)].

13. Горелова Л.Е. Организация медицинского факультета при университете Св. Владимира в Киеве - этап единой реформы медицинского образования в российской империи // Российская академия медицинских наук. Бюллетень национального научно-исследовательского института общественного здоровья. - 2013. № S1 - С. 50-52. [Gorelova LE. Organizaciya medicinskogo fakul’teta pri universitete Sv. Vladimira v Kieve - etap edinoj reformy medicinskogo obrazovaniya v rossijskoj imperii [Organization of the Medical Faculty at the University of St. Vladimir in Kiev - the stage of the unified reform of medical education in the Russian Empire]. Rossijskaya akademiya medicinskih nauk. Byulleten’ nacional’nogo nauchno-issledovatel’skogo instituta obshchestvennogo zdorov’ya [Russian Academy of Medical Sciences. Bulletin of the National Research Institute of Public Health]. 2013;(S1): 50-52. (In Russ.)].

14. Сточик А.М., Затравкин С.Н., Горелова Л.Е., Игнатьев В.Г. Подготовка и введение в действие Устава Университета Святого Владимира (Киев), 1842. 2. Проект К.К. Зейдлица и его практическая реализация // Проблемы социальной гигиены и история медицины. – 2002. № 3. - С. 54-57. [Stochik AM, Zatravkin SN, Gorelova LE, Ignat’ev VG. Podgotovka i vvedenie v dejstvie Ustava Universiteta Svyatogo Vladimira (Kiev), 1842. 2. Proekt K.K. Zejdlica i ego prakticheskaya realizaciya [Preparation and enactment of the Charter of the University of St. Vladimir (Kiev), 1842. 2. The project of K.K. Seidlitz and its practical implementation]. Problemy social’noj gigieny i istoriya mediciny [Problems of social hygiene and the history of medicine]. 2002; (3): 54-57. (In Russ.)].

15. Назаров А.Г., Цуцкин Е.В. Карл Максимович Бэр, 1792-1876 / отв. ред. В. В. Бабков. М.: Наука 2008. - С. 359. [Nazarov AG, Cuckin EV. Karl Maksimovich Ber, 1792-1876 / otv. red. VV. Babkov [Karl Maksimovich Ber, 1792-1876 / red. VV. Babkov]. M.: Nauka [M.: Science]. 2008; 359 (In Russ.)].

16. Самойлов В.О. История российской медицины // Москва: Эпидавр, 1997. - С. 98. [Samojlov VO. Istoriya rossijskoj mediciny [History of Russian medicine]. Moskva: Epidavr [Moscow: Epidaur]. 1997; 98. (In Russ.)].

17. Зейдлиц К.К. Жизнь и поэзия В.А.Жуковского 1783-1852: По неизданным источникам и личным воспоминаниям К.К. Зейдлица // Издание редакции Вестник Европы.- Санкт-Петербург. Типография М.М. Стасюлевича, 1883. - 259 с. [Zejdlic KK. Zhizn’ i poeziya V.A.Zhukovskogo 1783-1852: Po neizdannym istochnikam i lichnym vospominaniyam K.K. Zejdlica [The Life and Poetry of V.A.Zhukovsky 1783-1852: According to unpublished sources and personal memoirs of K.K. Seidlitz]. SPb.: Izdanie redakcii Vestnik Evropy [St. Petersburg: Edition of the editorial office of the Bulletin of Europe]. 1883; 259 p. (In Russ.)].